/*! For license information please see main.89eb8bce.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function p(e){return e.length}function f(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,b=0,y=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function k(){return g=y>0?c(_,--y):0,v--,10===g&&(v=1,h--),g}function T(){return g=y<b?c(_,y++):0,v++,10===g&&(v=1,h++),g}function C(){return c(_,y)}function P(){return y}function x(e,t){return d(_,e,t)}function E(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function F(e){return h=v=1,b=p(_=e),y=0,[]}function N(e){return _="",e}function A(e){return s(x(y-1,M(91===e?e+2:40===e?e+1:e)))}function R(e){for(;(g=C())&&g<33;)T();return E(e)>2||E(g)>3?"":" "}function O(e,t){for(;--t&&T()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return x(e,P()+(t<6&&32==C()&&32==T()))}function M(e){for(;T();)switch(g){case e:return y;case 34:case 39:34!==e&&39!==e&&M(g);break;case 40:41===e&&M(e);break;case 92:T()}return y}function D(e,t){for(;T()&&e+g!==57&&(e+g!==84||47!==C()););return"/*"+x(t,y-1)+"*"+o(47===e?e:T())}function z(e){for(;!E(C());)T();return x(e,y)}var W="-ms-",L="-moz-",I="-webkit-",B="comm",j="rule",Z="decl",H="@keyframes";function V(e,t){for(var n="",r=f(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function U(e,t,n,r){switch(e.type){case"@import":case Z:return e.return=e.return||e.value;case B:return"";case H:return e.return=e.value+"{"+V(e.children,r)+"}";case j:e.value=e.props.join(",")}return p(n=V(e.children,r))?e.return=e.value+"{"+n+"}":""}function J(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return I+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return I+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return I+e+L+e+W+e+e;case 6828:case 4268:return I+e+W+e+e;case 6165:return I+e+W+"flex-"+e+e;case 5187:return I+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return I+e+W+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return I+e+W+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return I+e+W+l(e,"shrink","negative")+e;case 5292:return I+e+W+l(e,"basis","preferred-size")+e;case 6060:return I+"box-"+l(e,"-grow","")+I+e+W+l(e,"grow","positive")+e;case 4554:return I+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,I+"$1"),/(image-set)/,I+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,I+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+I+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,I+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(p(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?J(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,p(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+I)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+I+(45===c(e,14)?"inline-":"")+"box$3$1"+I+"$2$3$1"+W+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return I+e+W+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return I+e+W+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return I+e+W+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return I+e+W+e+e}return e}function $(e){return N(G("",null,null,null,[""],e=F(e),0,[0],e))}function G(e,t,n,r,a,i,s,c,d){for(var f=0,h=0,v=s,b=0,y=0,g=0,_=1,w=1,S=1,x=0,E="",F=a,N=i,M=r,W=E;w;)switch(g=x,x=T()){case 40:if(108!=g&&58==W.charCodeAt(v-1)){-1!=u(W+=l(A(x),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:W+=A(x);break;case 9:case 10:case 13:case 32:W+=R(g);break;case 92:W+=O(P()-1,7);continue;case 47:switch(C()){case 42:case 47:m(K(D(T(),P()),t,n),d);break;default:W+="/"}break;case 123*_:c[f++]=p(W)*S;case 125*_:case 59:case 0:switch(x){case 0:case 125:w=0;case 59+h:y>0&&p(W)-v&&m(y>32?Q(W+";",r,n,v-1):Q(l(W," ","")+";",r,n,v-2),d);break;case 59:W+=";";default:if(m(M=q(W,t,n,f,h,a,c,E,F=[],N=[],v),i),123===x)if(0===h)G(W,t,M,M,F,i,v,c,N);else switch(b){case 100:case 109:case 115:G(e,M,M,r&&m(q(e,M,M,0,0,a,c,E,a,F=[],v),N),a,N,v,c,r?F:N);break;default:G(W,M,M,M,[""],N,0,c,N)}}f=h=y=0,_=S=1,E=W="",v=s;break;case 58:v=1+p(W),y=g;default:if(_<1)if(123==x)--_;else if(125==x&&0==_++&&125==k())continue;switch(W+=o(x),x*_){case 38:S=h>0?1:(W+="\f",-1);break;case 44:c[f++]=(p(W)-1)*S,S=1;break;case 64:45===C()&&(W+=A(T())),b=C(),h=v=p(E=W+=z(P())),x++;break;case 45:45===g&&2==p(W)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,p,m,h){for(var v=o-1,b=0===o?i:[""],y=f(b),g=0,_=0,S=0;g<r;++g)for(var k=0,T=d(e,v+1,v=a(_=u[g])),C=e;k<y;++k)(C=s(_>0?b[k]+" "+T:l(T,/&\f/g,b[k])))&&(p[S++]=C);return w(e,t,n,0===o?j:c,p,m,h)}function K(e,t,n){return w(e,t,n,B,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,Z,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=C(),38===r&&12===a&&(t[n]=1),!E(a);)T();return x(e,y)},X=function(e,t){return N(function(e,t){var n=-1,r=44;do{switch(E(r)){case 0:38===r&&12===C()&&(t[n]=1),e[n]+=Y(y-1,t,n);break;case 2:e[n]+=A(r);break;case 4:if(44===r){e[++n]=58===C()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=T());return e}(F(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case Z:e.return=J(e.value,e.length);break;case H:return V([S(e,{value:l(e.value,"@","@"+I)})],r);case j:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return V([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return V([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,W+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[U,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],p=function(e){var t=f(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,V($(e?e+"{"+t.styles+"}":t.styles),p),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return f={name:t,styles:n,next:f},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function p(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return f={name:n.name,styles:n.styles,next:f},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)f={name:r.name,styles:r.styles,next:f},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=p(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=p(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=f,o=n(e);return f=a,p(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var f,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";f=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=p(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=p(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:f}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return I}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},p={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},f={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},b={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},y={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function k(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,k=void 0===u?.2:u,T=(0,a.Z)(e,g),C=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),P=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:f[200],light:f[50],dark:f[400]}:{main:f[500],light:f[300],dark:f[700]}}(n),x=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),E=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[700],light:b[500],dark:b[900]}}(n),F=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[800],light:y[500],dark:y[900]}}(n),N=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function A(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var R=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,k),S(t,"dark",c,k),t.contrastText||(t.contrastText=A(t.main)),t},O={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:R({color:C,name:"primary"}),secondary:R({color:P,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:R({color:x,name:"error"}),warning:R({color:N,name:"warning"}),info:R({color:E,name:"info"}),success:R({color:F,name:"success"}),grey:p,contrastThreshold:l,getContrastText:A,augmentColor:R,tonalOffset:k},O[n]),T)}var T=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var C={textTransform:"uppercase"},P='"Roboto", "Helvetica", "Arial", sans-serif';function x(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?P:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,p=n.fontWeightRegular,f=void 0===p?400:p,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,b=void 0===v?700:v,y=n.htmlFontSize,g=void 0===y?16:y,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,T);var k=u/14,x=w||function(e){return"".concat(e/g*k,"rem")},E=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:x(t),lineHeight:n},s===P?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},F={h1:E(d,96,1.167,-1.5),h2:E(d,60,1.2,-.5),h3:E(f,48,1.167,0),h4:E(f,34,1.235,.25),h5:E(f,24,1.334,0),h6:E(h,20,1.6,.15),subtitle1:E(f,16,1.75,.15),subtitle2:E(h,14,1.57,.1),body1:E(f,16,1.5,.15),body2:E(f,14,1.43,.15),button:E(h,14,1.75,.4,C),caption:E(f,12,1.66,.4),overline:E(f,12,2.66,1,C)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:x,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:f,fontWeightMedium:h,fontWeightBold:b},F),S,{clone:!1})}function E(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var F=["none",E(0,2,1,-1,0,1,1,0,0,1,3,0),E(0,3,1,-2,0,2,2,0,0,1,5,0),E(0,3,3,-2,0,3,4,0,0,1,8,0),E(0,2,4,-1,0,4,5,0,0,1,10,0),E(0,3,5,-1,0,5,8,0,0,1,14,0),E(0,3,5,-1,0,6,10,0,0,1,18,0),E(0,4,5,-2,0,7,10,1,0,2,16,1),E(0,5,5,-3,0,8,10,1,0,3,14,2),E(0,5,6,-3,0,9,12,1,0,3,16,2),E(0,6,6,-3,0,10,14,1,0,4,18,3),E(0,6,7,-4,0,11,15,1,0,4,20,3),E(0,7,8,-4,0,12,17,2,0,5,22,4),E(0,7,8,-4,0,13,19,2,0,5,24,4),E(0,7,9,-4,0,14,21,2,0,5,26,4),E(0,8,9,-5,0,15,22,2,0,6,28,5),E(0,8,10,-5,0,16,24,2,0,6,30,5),E(0,8,11,-5,0,17,26,2,0,6,32,5),E(0,9,11,-5,0,18,28,2,0,7,34,6),E(0,9,12,-6,0,19,29,2,0,7,36,6),E(0,10,13,-6,0,20,31,3,0,8,38,7),E(0,10,13,-6,0,21,33,3,0,8,40,7),E(0,10,14,-6,0,22,35,3,0,8,42,7),E(0,11,14,-7,0,23,36,3,0,9,44,8),E(0,11,15,-7,0,24,38,3,0,9,46,8)],N=["duration","easing","delay"],A={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},R={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function O(e){return"".concat(Math.round(e),"ms")}function M(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function D(e){var t=(0,r.Z)({},A,e.easing),n=(0,r.Z)({},R,e.duration);return(0,r.Z)({getAutoHeightDuration:M,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,N);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:O(i)," ").concat(l," ").concat("string"===typeof c?c:O(c))})).join(",")}},e,{easing:t,duration:n})}var z={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},W=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,p=void 0===d?{}:d,f=e.typography,m=void 0===f?{}:f,h=(0,a.Z)(e,W);if(e.vars)throw new Error((0,o.Z)(18));var v=k(c),b=(0,s.Z)(e),y=(0,i.Z)(b,{mixins:u(b.breakpoints,n),palette:v,shadows:F.slice(),typography:x(v,m),transitions:D(p),zIndex:(0,r.Z)({},z)});y=(0,i.Z)(y,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,i.Z)(e,t)}),y)}var I=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return k},isMuiElement:function(){return T},ownerDocument:function(){return P},ownerWindow:function(){return x},requirePropFactory:function(){return E},setRef:function(){return F},unstable_ClassNameGenerator:function(){return B},unstable_useEnhancedEffect:function(){return N},unstable_useId:function(){return M},unsupportedProp:function(){return D},useControlled:function(){return z},useEventCallback:function(){return W.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return I.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),p=n(5513),f=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),b=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],y=(0,f.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,p,f,m,h,v,b,y=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=y.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=y.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=y.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=y.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=y.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(p=(y.vars||y).palette)||null==(f=p[g.color])?void 0:f.main)?d:{action:null==(m=(y.vars||y).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(y.vars||y).palette)||null==(b=v.action)?void 0:b.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,p.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,f=n.component,m=void 0===f?"svg":f,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,k=void 0!==S&&S,T=n.titleAccess,C=n.viewBox,P=void 0===C?"0 0 24 24":C,x=(0,u.Z)(n,b),E=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:k,viewBox:P}),F={};k||(F.viewBox=P);var N=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(E);return(0,v.jsxs)(y,(0,i.Z)({as:m,className:(0,c.Z)(N.root,o),focusable:"false",color:w,"aria-hidden":!T||void 0,role:T?"img":void 0,ref:t},F,x,{ownerState:E,children:[r,T?(0,v.jsx)("title",{children:T}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var k=function(e,t){return function(){return null}};var T=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function C(e){return e&&e.ownerDocument||document}var P=C;var x=function(e){return C(e).defaultView||window};var E=function(e,t){return function(){return null}},F=n(2971).Z,N=n(5721).Z,A=n(885),R=0;var O=l.useId;var M=function(e){if(void 0!==O){var t=O();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,A.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(R+=1))}),[r]),o}(e)};var D=function(e,t,n,r,a){return null};var z=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,A.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},W=n(6702),L=n(792),I=n(2763),B={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var p=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),p=s,f=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?p:f},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},b=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var p=h(t,n,s),f=p||m(d),b=!f("as");return function(){var y=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==y[0]||void 0===y[0].raw)g.push.apply(g,y);else{0,g.push(y[0][0]);for(var _=y.length,w=1;w<_;w++)g.push(y[w],y[0][w])}var S=(0,l.w)((function(e,t,n){var a=b&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var y in h={},e)h[y]=e[y];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=b&&void 0===p?m(a):f,S={};for(var k in e)b&&"as"===k||w(k)&&(S[k]=e[k]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=p,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},y=b.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){y[e]=y(e)}));var g=y;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return T},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function p(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var f=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function b(e){return 0===Object.keys(e).length}function y(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=p(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[p(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var k=(0,l.Z)();function T(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?k:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,p=e.styleFunctionSx,T=void 0===p?f.Z:p,C=function(e){var t=b(e.theme)?n:e.theme;return T((0,i.Z)({},e,{theme:t}))};return C.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,p=t.slot,f=t.skipVariantsResolver,k=t.skipSx,T=t.overridesResolver,P=(0,o.Z)(t,m),x=void 0!==f?f:p&&"Root"!==p||!1,E=k||!1;var F=S;"Root"===p?F=u:p?F=d:y(e)&&(F=void 0);var N=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:F,label:l},P)),A=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:b(r)?n:r},a))}:e})):[],d=e;c&&T&&u.push((function(e){var t=b(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),T(e,o)}return null})),c&&!x&&u.push((function(e){var t=b(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),E||u.push(C);var p=u.length-s.length;if(Array.isArray(e)&&p>0){var f=new Array(p).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(f))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(f))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:b(r)?n:r},a))});var m=N.apply(void 0,[d].concat((0,r.Z)(u)));return m};return N.withConfig&&(A.withConfig=N.withConfig),A}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),p=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),f=Object.keys(p);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=f.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[f[r]]?n[f[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:f,values:p,up:m,down:h,between:v,only:function(e){return f.indexOf(e)+1<f.length?v(e,f[f.indexOf(e)+1]):m(e)},not:function(e){var t=f.indexOf(e);return 0===t?m(f[1]):t===f.length-1?h(f[t]):v(e,f[f.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var p=["breakpoints","palette","spacing","shape"];var f=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,f=e.shape,m=void 0===f?{}:f,h=(0,a.Z)(e,p),v=l(n),b=d(c),y=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:b,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return y=_.reduce((function(e,t){return(0,o.Z)(e,t)}),y)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return G}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,p,f,m,h,v,b,y,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),k=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["gap"];var T=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["columnGap"];var C=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["rowGap"];var P=o(k,T,C,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),x=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),E=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),F=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function N(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var A=(0,r.Z)({prop:"width",transform:N}),R=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||N(t)}}))}return null};R.filterProps=["maxWidth"];var O=(0,r.Z)({prop:"minWidth",transform:N}),M=(0,r.Z)({prop:"height",transform:N}),D=(0,r.Z)({prop:"maxHeight",transform:N}),z=(0,r.Z)({prop:"minHeight",transform:N}),W=((0,r.Z)({prop:"size",cssProperty:"width",transform:N}),(0,r.Z)({prop:"size",cssProperty:"height",transform:N}),o(A,R,O,M,D,z,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),I=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),B=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),j=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),Z=(0,r.Z)({prop:"letterSpacing"}),H=(0,r.Z)({prop:"textTransform"}),V=(0,r.Z)({prop:"lineHeight"}),U=(0,r.Z)({prop:"textAlign"}),J=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,I,B,j,Z,V,U,H),$={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:P.filterProps,positions:x.filterProps,palette:E.filterProps,shadows:F.filterProps,sizing:W.filterProps,spacing:i.ZP.filterProps,typography:J.filterProps},G={borders:_,display:w,flexbox:S,grid:P,positions:x,palette:E,shadows:F,sizing:W,spacing:i.ZP,typography:J},q=Object.keys($).reduce((function(e,t){return $[t].forEach((function(n){e[n]=G[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],p=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],f=[].concat(d,p);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function b(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function y(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return b(e,t,r,n)})).reduce(i.Z,{})}function g(e){return y(e,d)}function _(e){return y(e,p)}function w(e){return y(e,f)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=p,w.propTypes={},w.filterProps=f;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,p=void 0===d?{}:d;if(!c)return null;function f(e){var o=e;if("function"===typeof e)o=e(p);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(p.breakpoints),d=Object.keys(c),f=c;return Object.keys(o).forEach((function(e){var c=l(o[e],p);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])f=(0,a.Z)(f,n(e,c,p));else{var d=(0,i.k9)({theme:p},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?f[e]=u({sx:c,theme:p}):f=(0,a.Z)(f,d)}else f=(0,a.Z)(f,n(e,c,p))})),(0,i.L7)(d,f)}return Array.isArray(c)?c.map(f):f(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var p=t[i-1];return i>1&&"string"===typeof p.value&&(p.added||p.removed)&&e.equals("",p.value)&&(t[i-2].value+=p.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,p=[{newPos:-1,components:[]}],f=this.extractCommon(p[0],t,e,0);if(p[0].newPos+1>=l&&f+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=p[a-1],f=p[a+1],m=(f?f.newPos:0)-a;d&&(p[a-1]=void 0);var h=d&&d.newPos+1<l,v=f&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<f.newPos?(o=r(f),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));p[a]=o}else p[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var p=new t;function f(e,t,n){return p.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return p.diff(e,t,r)}p.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var b=new t;function y(e,t,n){return b.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||k()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function k(){throw new TypeError("Invalid attempt to spread non-iterable instance")}b.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var T=Object.prototype.toString,C=new t;function P(e,t,n){return C.diff(e,t,n)}function x(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===T.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=x(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=x(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}C.useLongestToken=!0,C.tokenize=p.tokenize,C.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(x(e,null,null,a),a,"  ")},C.equals=function(e,n){return t.prototype.equals.call(C,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var E=new t;function F(e,t,n){return E.diff(e,t,n)}function N(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function A(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function R(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=N(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,p=0;function f(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,b=0,y=p+h.oldStart-1,g=A(y,d,v);void 0!==b;b=g())if(f(h,y+b)){h.offset=p+=b;break}if(void 0===b)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],k=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,k<0&&(k=0);for(var T=0;T<S.lines.length;T++){var C=S.lines[T],P=C.length>0?C[0]:" ",x=C.length>0?C.substr(1):C,E=S.linedelimiters[T];if(" "===P)k++;else if("-"===P)o.splice(k,1),i.splice(k,1);else if("+"===P)o.splice(k,0,x),i.splice(k,0,E),k++;else if("\\"===P){var F=S.lines[T-1]?S.lines[T-1][0]:null;"+"===F?r=!0:"-"===F&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var R=0;R<o.length-1;R++)o[R]=o[R]+i[R];return o.join("")}function O(e,t){"string"===typeof e&&(e=N(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=R(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function M(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=f(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,p=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var f=s[e-1];c=m,d=h,f&&(p=i.context>0?l(f.lines.slice(-i.context)):[],c-=p.length,d-=p.length)}(o=p).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=p).push.apply(v,_(l(a)))}else{var b,y=Math.min(a.length,i.context);(b=p).push.apply(b,_(l(a.slice(0,y))));var g={oldStart:c,oldLines:m-c+y,newStart:d,newLines:h-d+y,lines:p};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),k=0==a.length&&p.length>g.oldLines;!w&&k&&p.splice(g.oldLines,0,"\\ No newline at end of file"),(w||k)&&S||p.push("\\ No newline at end of file")}u.push(g),c=0,d=0,p=[]}m+=a.length,h+=a.length}},b=0;b<s.length;b++)v(b);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function D(e,t,n,r,a,o,i){var s=M(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function z(e,t,n,r,a,o){return D(e,e,t,n,r,a,o)}function W(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function I(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function B(e,t,n){e=j(e,n),t=j(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(Z(e)?Z(t)?(r.oldFileName=H(r,e.oldFileName,t.oldFileName),r.newFileName=H(r,e.newFileName,t.newFileName),r.oldHeader=H(r,e.oldHeader,t.oldHeader),r.newHeader=H(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(V(l,u))r.hunks.push(U(l,i)),a++,s+=l.newLines-l.oldLines;else if(V(u,l))r.hunks.push(U(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};J(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function j(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return N(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return M(void 0,void 0,t,e)}return e}function Z(e){return e.newFileName&&e.newFileName!==e.oldFileName}function H(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function V(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function U(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function J(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(Y(i)))}else"-"===s[0]&&" "===l[0]?G(e,o,i):"-"===l[0]&&" "===s[0]?G(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else $(e,o,i)}Q(e,o),Q(e,i),I(e)}function $(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(W(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function G(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}E.tokenize=function(e){return e.slice()},E.join=E.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=f,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=y,e.diffJson=P,e.diffArrays=F,e.structuredPatch=M,e.createTwoFilesPatch=D,e.createPatch=z,e.applyPatch=R,e.applyPatches=O,e.parsePatch=N,e.merge=B,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=x,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return I},css:function(){return W},cx:function(){return R},flush:function(){return N},getRegisteredStyles:function(){return M},hydrate:function(){return A},injectGlobal:function(){return D},keyframes:function(){return z},merge:function(){return O},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,p){for(var f,m,h,v,_,S=0,k=0,T=0,C=0,P=0,R=0,M=h=f=0,z=0,W=0,L=0,I=0,B=l.length,j=B-1,Z="",H="",V="",U="";z<B;){if(m=l.charCodeAt(z),z===j&&0!==k+C+T+S&&(0!==k&&(m=47===k?10:47),C=T=S=0,B++,j++),0===k+C+T+S){if(z===j&&(0<W&&(Z=Z.replace(d,"")),0<Z.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:Z+=l.charAt(z)}m=59}switch(m){case 123:for(f=(Z=Z.trim()).charCodeAt(0),h=1,I=++z;z<B;){switch(m=l.charCodeAt(z)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(z+1)){case 42:case 47:e:{for(M=z+1;M<j;++M)switch(l.charCodeAt(M)){case 47:if(42===m&&42===l.charCodeAt(M-1)&&z+2!==M){z=M+1;break e}break;case 10:if(47===m){z=M+1;break e}}z=M}}break;case 91:m++;case 40:m++;case 34:case 39:for(;z++<j&&l.charCodeAt(z)!==m;);}if(0===h)break;z++}if(h=l.substring(I,z),0===f&&(f=(Z=Z.replace(c,"").trim()).charCodeAt(0)),64===f){switch(0<W&&(Z=Z.replace(d,"")),m=Z.charCodeAt(1)){case 100:case 109:case 115:case 45:W=r;break;default:W=A}if(I=(h=t(r,W,h,m,p+1)).length,0<O&&(_=s(3,h,W=n(A,Z,L),r,E,x,I,m,p,u),Z=W.join(""),void 0!==_&&0===(I=(h=_.trim()).length)&&(m=0,h="")),0<I)switch(m){case 115:Z=Z.replace(w,i);case 100:case 109:case 45:h=Z+"{"+h+"}";break;case 107:h=(Z=Z.replace(b,"$1 $2"))+"{"+h+"}",h=1===N||2===N&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=Z+h,112===u&&(H+=h,h="")}else h=""}else h=t(r,n(r,Z,L),h,u,p+1);V+=h,h=L=W=M=f=0,Z="",m=l.charCodeAt(++z);break;case 125:case 59:if(1<(I=(Z=(0<W?Z.replace(d,""):Z).trim()).length))switch(0===M&&(f=Z.charCodeAt(0),45===f||96<f&&123>f)&&(I=(Z=Z.replace(" ",":")).length),0<O&&void 0!==(_=s(1,Z,r,e,E,x,H.length,u,p,u))&&0===(I=(Z=_.trim()).length)&&(Z="\0\0"),f=Z.charCodeAt(0),m=Z.charCodeAt(1),f){case 0:break;case 64:if(105===m||99===m){U+=Z+l.charAt(z);break}default:58!==Z.charCodeAt(I-1)&&(H+=a(Z,f,m,Z.charCodeAt(2)))}L=W=M=f=0,Z="",m=l.charCodeAt(++z)}}switch(m){case 13:case 10:47===k?k=0:0===1+f&&107!==u&&0<Z.length&&(W=1,Z+="\0"),0<O*D&&s(0,Z,r,e,E,x,H.length,u,p,u),x=1,E++;break;case 59:case 125:if(0===k+C+T+S){x++;break}default:switch(x++,v=l.charAt(z),m){case 9:case 32:if(0===C+S+k)switch(P){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===C+k+S&&(W=L=1,v="\f"+v);break;case 108:if(0===C+k+S+F&&0<M)switch(z-M){case 2:112===P&&58===l.charCodeAt(z-3)&&(F=P);case 8:111===R&&(F=R)}break;case 58:0===C+k+S&&(M=z);break;case 44:0===k+T+C+S&&(W=1,v+="\r");break;case 34:case 39:0===k&&(C=C===m?0:0===C?m:C);break;case 91:0===C+k+T&&S++;break;case 93:0===C+k+T&&S--;break;case 41:0===C+k+S&&T--;break;case 40:if(0===C+k+S){if(0===f)if(2*P+3*R===533);else f=1;T++}break;case 64:0===k+T+C+S+M+h&&(h=1);break;case 42:case 47:if(!(0<C+S+T))switch(k){case 0:switch(2*m+3*l.charCodeAt(z+1)){case 235:k=47;break;case 220:I=z,k=42}break;case 42:47===m&&42===P&&I+2!==z&&(33===l.charCodeAt(I+2)&&(H+=l.substring(I,z+1)),v="",k=0)}}0===k&&(Z+=v)}R=P,P=m,z++}if(0<(I=H.length)){if(W=r,0<O&&(void 0!==(_=s(2,H,W,e,E,x,I,u,p,u))&&0===(H=_).length))return U+H+V;if(H=W.join(",")+"{"+H+"}",0!==N*F){switch(2!==N||o(H,2)||(F=0),F){case 111:H=H.replace(g,":-moz-$1")+H;break;case 112:H=H.replace(y,"::-webkit-input-$1")+H.replace(y,"::-moz-$1")+H.replace(y,":-ms-input-$1")+H}F=0}}return U+H+V}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===N||2===N&&o(l,1)?"-webkit-"+l+l:l}if(0===N||2===N&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(P,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return f.test(i)?i.replace(p,":-webkit-")+i.replace(p,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(k,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(k,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===C.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),M(2!==t?r:r.replace(T,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,p=0,f=t;p<O;++p)switch(d=R[p].call(u,e,f,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:f=d}if(f!==t)return f}function l(e){return void 0!==(e=e.prefix)&&(M=null,e?"function"!==typeof e?N=1:(N=2,M=e):N=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<O){var a=s(-1,n,r,r,E,x,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(A,r,n,0,0);return 0<O&&(void 0!==(a=s(-2,o,r,r,E,x,o.length,0,0,0))&&(o=a)),"",F=0,x=E=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,p=/: */g,f=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,b=/@(k\w+)\s*(\S*)\s*/,y=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,k=/-self|flex-/g,T=/[^]*?(:[rp][el]a[\w-]+)[^]*/,C=/stretch|:\s*\w+\-(?:conte|avail)/,P=/([^-])(image-set\()/,x=1,E=1,F=0,N=1,A=[],R=[],O=0,M=null,D=0;return u.use=function e(t){switch(t){case void 0:case null:O=R.length=0;break;default:if("function"===typeof t)R[O++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else D=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,p){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===p?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(p.inserted[a]=!0)};var p={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return p};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var p=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},f=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},b=p((function(e){return h(e)?e:e.replace(f,"-$&").toLowerCase()})),y=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=b(o)+":"+y(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=b(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=b(o)+":"+y(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function k(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var T=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function C(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function P(e,t,n){var r=[],a=k(e,r,n);return r.length<2?n:a+t(r)}var x=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},E=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return T(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return P(t.registered,n,x(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);C(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return C(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:k.bind(null,t.registered),merge:P.bind(null,t.registered,n)}},F=E(),N=F.flush,A=F.hydrate,R=F.cx,O=F.merge,M=F.getRegisteredStyles,D=F.injectGlobal,z=F.keyframes,W=F.css,L=F.sheet,I=F.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=f(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var b=i[v];if(!o[b]&&(!r||!r[b])&&(!h||!h[b])&&(!s||!s[b])){var y=p(n,b);try{u(t,b,y)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,p=n?Symbol.for("react.forward_ref"):60112,f=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,b=n?Symbol.for("react.block"):60121,y=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case f:return e;default:switch(e=e&&e.$$typeof){case u:case p:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=p,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=f,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===p},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===f},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===f||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===p||e.$$typeof===y||e.$$typeof===g||e.$$typeof===_||e.$$typeof===b)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),p="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:p,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},p=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},f=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return f(e,t,n,r);if(i(e))return p(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),p=c,f=c,m=[],h=0,v=[],b=[],y=function e(t,a,s,c,m){return u(t).map((function(t,y){var g={},_={};if(!(b.includes(a+"-"+y)||m&&0!==y)){if(s||c)if(v.includes(h)||v.push(h),c){f+=1,g.lineNumber=f,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[y]){var S=e(w.value,a,!0,!1,!0)[0].right,k=S.value,T=S.lineNumber,C=S.type;if(b.push(a+1+"-"+y),_.lineNumber=T,_.type=C,n)_.value=k;else{var P=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,k,r);_.value=P.right,g.value=P.left}}}else p+=1,_.lineNumber=p,_.type=o.ADDED,_.value=t;else f+=1,p+=1,g.lineNumber=f,g.type=o.DEFAULT,g.value=t,_.lineNumber=p,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,y(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var p=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,p,f,m,h=r+"-"+e,v=u+"-"+l,b=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),y=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=y,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=b,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=y,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=b,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=y,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=b,p))},a.createElement("pre",null,y&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=y,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=b,f))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),p=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),f=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=f,s))}),f?a.createElement(a.Fragment,null,a.createElement("td",null),p):a.createElement(a.Fragment,null,p,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,p=c.diffLines,f=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=p[0],i=r-t;if(n.props.showDiffOnly&&(i===-f&&(m=[],p.shift()),e.left.type===s.DiffType.DEFAULT&&(i>f||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===f&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var p=n.renderDiff(),f=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?f:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:f,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,p))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=p},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var p=e.variables,f=void 0===p?{}:p,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},f.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},f.dark||{})},v=t?h.dark:h.light,b=o.css({width:"100%",label:"content"}),y=o.css(((n={})["."+b]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),k=o.css({color:v.gutterColor,label:"line-number"}),T=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+k]={color:v.removedGutterColor},s.label="diff-removed",s)),C=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+k]={color:v.addedGutterColor},l.label="diff-added",l)),P=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),x=o.css({background:v.wordAddedBackground,label:"word-added"}),E=o.css({background:v.wordRemovedBackground,label:"word-removed"}),F=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),N=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),A=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),R=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+C]={pre:{color:v.addedColor}},u["&."+T]={pre:{color:v.removedColor}},u)),O=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+x+", ."+E]={backgroundColor:"initial"},c)),M=o.css({label:"highlighted-gutter"}),D=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+C]={background:v.addedGutterBackground},d["&."+T]={background:v.removedGutterBackground},d["&."+M]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),z=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),W={diffContainer:g,diffRemoved:T,diffAdded:C,splitView:y,marker:R,highlightedGutter:M,highlightedLine:O,gutter:D,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:P,wordAdded:x,wordRemoved:E,codeFoldGutter:F,codeFold:N,emptyGutter:z,emptyLine:A,lineNumber:k,contentText:w,content:b,codeFoldContent:_,titleBlock:S},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(W).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(W[t],L[t]):W[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,p=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,f={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var b=/[\-:]([a-z])/g;function y(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(f,e)&&(p.test(e)?m[e]=!0:(f[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(b,y);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),k=Symbol.for("react.fragment"),T=Symbol.for("react.strict_mode"),C=Symbol.for("react.profiler"),P=Symbol.for("react.provider"),x=Symbol.for("react.context"),E=Symbol.for("react.forward_ref"),F=Symbol.for("react.suspense"),N=Symbol.for("react.suspense_list"),A=Symbol.for("react.memo"),R=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var O=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var M=Symbol.iterator;function D(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=M&&e[M]||e["@@iterator"])?e:null}var z,W=Object.assign;function L(e){if(void 0===z)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);z=t&&t[1]||""}return"\n"+z+e}var I=!1;function B(e,t){if(!e||I)return"";I=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{I=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function j(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=B(e.type,!1);case 11:return e=B(e.type.render,!1);case 1:return e=B(e.type,!0);default:return""}}function Z(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case k:return"Fragment";case S:return"Portal";case C:return"Profiler";case T:return"StrictMode";case F:return"Suspense";case N:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case x:return(e.displayName||"Context")+".Consumer";case P:return(e._context.displayName||"Context")+".Provider";case E:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case A:return null!==(t=e.displayName||null)?t:Z(e.type)||"Memo";case R:t=e._payload,e=e._init;try{return Z(e(t))}catch(n){}}return null}function H(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return Z(t);case 8:return t===T?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function V(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function U(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function J(e){e._valueTracker||(e._valueTracker=function(e){var t=U(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function $(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=U(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function G(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return W({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=V(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=V(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,V(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&G(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+V(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return W({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:V(n)}}function oe(e,t){var n=V(t.value),r=V(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function pe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var fe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||fe.hasOwnProperty(e)&&fe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(fe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),fe[t]=fe[e]}))}));var be=W({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function ye(e,t){if(t){if(be[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,ke=null,Te=null;function Ce(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function Pe(e){ke?Te?Te.push(e):Te=[e]:ke=e}function xe(){if(ke){var e=ke,t=Te;if(Te=ke=null,Ce(e),t)for(e=0;e<t.length;e++)Ce(t[e])}}function Ee(e,t){return e(t)}function Fe(){}var Ne=!1;function Ae(e,t,n){if(Ne)return e(t,n);Ne=!0;try{return Ee(e,t,n)}finally{Ne=!1,(null!==ke||null!==Te)&&(Fe(),xe())}}function Re(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Oe=!1;if(c)try{var Me={};Object.defineProperty(Me,"passive",{get:function(){Oe=!0}}),window.addEventListener("test",Me,Me),window.removeEventListener("test",Me,Me)}catch(ce){Oe=!1}function De(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var ze=!1,We=null,Le=!1,Ie=null,Be={onError:function(e){ze=!0,We=e}};function je(e,t,n,r,a,o,i,s,l){ze=!1,We=null,De.apply(Be,arguments)}function Ze(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function He(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ve(e){if(Ze(e)!==e)throw Error(o(188))}function Ue(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=Ze(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ve(a),e;if(i===r)return Ve(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?Je(e):null}function Je(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=Je(e);if(null!==t)return t;e=e.sibling}return null}var $e=a.unstable_scheduleCallback,Ge=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function pt(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function ft(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function bt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function yt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,kt,Tt,Ct,Pt=!1,xt=[],Et=null,Ft=null,Nt=null,At=new Map,Rt=new Map,Ot=[],Mt="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Dt(e,t){switch(e){case"focusin":case"focusout":Et=null;break;case"dragenter":case"dragleave":Ft=null;break;case"mouseover":case"mouseout":Nt=null;break;case"pointerover":case"pointerout":At.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Rt.delete(t.pointerId)}}function zt(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function Wt(e){var t=ya(e.target);if(null!==t){var n=Ze(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=He(n)))return e.blockedOn=t,void Ct(e.priority,(function(){kt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function It(e,t,n){Lt(e)&&n.delete(t)}function Bt(){Pt=!1,null!==Et&&Lt(Et)&&(Et=null),null!==Ft&&Lt(Ft)&&(Ft=null),null!==Nt&&Lt(Nt)&&(Nt=null),At.forEach(It),Rt.forEach(It)}function jt(e,t){e.blockedOn===t&&(e.blockedOn=null,Pt||(Pt=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,Bt)))}function Zt(e){function t(t){return jt(t,e)}if(0<xt.length){jt(xt[0],e);for(var n=1;n<xt.length;n++){var r=xt[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Et&&jt(Et,e),null!==Ft&&jt(Ft,e),null!==Nt&&jt(Nt,e),At.forEach(t),Rt.forEach(t),n=0;n<Ot.length;n++)(r=Ot[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Ot.length&&null===(n=Ot[0]).blockedOn;)Wt(n),null===n.blockedOn&&Ot.shift()}var Ht=_.ReactCurrentBatchConfig,Vt=!0;function Ut(e,t,n,r){var a=gt,o=Ht.transition;Ht.transition=null;try{gt=1,$t(e,t,n,r)}finally{gt=a,Ht.transition=o}}function Jt(e,t,n,r){var a=gt,o=Ht.transition;Ht.transition=null;try{gt=4,$t(e,t,n,r)}finally{gt=a,Ht.transition=o}}function $t(e,t,n,r){if(Vt){var a=qt(e,t,n,r);if(null===a)Vr(e,t,r,Gt,n),Dt(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Et=zt(Et,e,t,n,r,a),!0;case"dragenter":return Ft=zt(Ft,e,t,n,r,a),!0;case"mouseover":return Nt=zt(Nt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return At.set(o,zt(At.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Rt.set(o,zt(Rt.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Dt(e,r),4&t&&-1<Mt.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Vr(e,t,r,Gt,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Vr(e,t,r,null,n)}}var Gt=null;function qt(e,t,n,r){if(Gt=null,null!==(e=ya(e=we(r))))if(null===(t=Ze(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=He(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Gt=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return W(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=W({},un,{view:0,detail:0}),pn=an(dn),fn=W({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Cn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(fn),hn=an(W({},fn,{dataTransfer:0})),vn=an(W({},dn,{relatedTarget:0})),bn=an(W({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),yn=W({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(yn),_n=an(W({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},kn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Tn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=kn[e])&&!!t[e]}function Cn(){return Tn}var Pn=W({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Cn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),xn=an(Pn),En=an(W({},fn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),Fn=an(W({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Cn})),Nn=an(W({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),An=W({},fn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),Rn=an(An),On=[9,13,27,32],Mn=c&&"CompositionEvent"in window,Dn=null;c&&"documentMode"in document&&(Dn=document.documentMode);var zn=c&&"TextEvent"in window&&!Dn,Wn=c&&(!Mn||Dn&&8<Dn&&11>=Dn),Ln=String.fromCharCode(32),In=!1;function Bn(e,t){switch(e){case"keyup":return-1!==On.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function jn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Zn=!1;var Hn={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Vn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Hn[e.type]:"textarea"===t}function Un(e,t,n,r){Pe(r),0<(t=Jr(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var Jn=null,$n=null;function Gn(e){Lr(e,0)}function qn(e){if($(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Yn;if(c){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){Jn&&(Jn.detachEvent("onpropertychange",nr),$n=Jn=null)}function nr(e){if("value"===e.propertyName&&qn($n)){var t=[];Un(t,$n,e,we(e)),Ae(Gn,t)}}function rr(e,t,n){"focusin"===e?(tr(),$n=n,(Jn=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn($n)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function pr(){for(var e=window,t=G();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=G((e=t.contentWindow).document)}return t}function fr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=pr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&fr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,br=null,yr=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==G(r)||("selectionStart"in(r=vr)&&fr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},yr&&lr(yr,r)||(yr=r,0<(r=Jr(br,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},kr={},Tr={};function Cr(e){if(kr[e])return kr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Tr)return kr[e]=n[t];return e}c&&(Tr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var Pr=Cr("animationend"),xr=Cr("animationiteration"),Er=Cr("animationstart"),Fr=Cr("transitionend"),Nr=new Map,Ar="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Rr(e,t){Nr.set(e,t),l(t,[e])}for(var Or=0;Or<Ar.length;Or++){var Mr=Ar[Or];Rr(Mr.toLowerCase(),"on"+(Mr[0].toUpperCase()+Mr.slice(1)))}Rr(Pr,"onAnimationEnd"),Rr(xr,"onAnimationIteration"),Rr(Er,"onAnimationStart"),Rr("dblclick","onDoubleClick"),Rr("focusin","onFocus"),Rr("focusout","onBlur"),Rr(Fr,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Dr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),zr=new Set("cancel close invalid load scroll toggle".split(" ").concat(Dr));function Wr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(je.apply(this,arguments),ze){if(!ze)throw Error(o(198));var c=We;ze=!1,We=null,Le||(Le=!0,Ie=c)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;Wr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;Wr(a,s,u),o=l}}}if(Le)throw e=Ie,Le=!1,Ie=null,e}function Ir(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Hr(t,e,2,!1),n.add(r))}function Br(e,t,n){var r=0;t&&(r|=4),Hr(n,e,r,t)}var jr="_reactListening"+Math.random().toString(36).slice(2);function Zr(e){if(!e[jr]){e[jr]=!0,i.forEach((function(t){"selectionchange"!==t&&(zr.has(t)||Br(t,!1,e),Br(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[jr]||(t[jr]=!0,Br("selectionchange",!1,t))}}function Hr(e,t,n,r){switch(Kt(t)){case 1:var a=Ut;break;case 4:a=Jt;break;default:a=$t}n=a.bind(null,t,n,e),a=void 0,!Oe||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Vr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ya(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Ae((function(){var r=o,a=we(n),i=[];e:{var s=Nr.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=xn;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=Fn;break;case Pr:case xr:case Er:l=bn;break;case Fr:l=Nn;break;case"scroll":l=pn;break;case"wheel":l=Rn;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=En}var c=0!==(4&t),d=!c&&"scroll"===e,p=c?null!==s?s+"Capture":null:s;c=[];for(var f,m=r;null!==m;){var h=(f=m).stateNode;if(5===f.tag&&null!==h&&(f=h,null!==p&&(null!=(h=Re(m,p))&&c.push(Ur(m,h,f)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ya(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ya(u):null)&&(u!==(d=Ze(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",p="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=En,h="onPointerLeave",p="onPointerEnter",m="pointer"),d=null==l?s:_a(l),f=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=f,h=null,ya(a)===r&&((c=new c(p,m+"enter",u,n,a)).target=f,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(p=u,m=0,f=c=l;f;f=$r(f))m++;for(f=0,h=p;h;h=$r(h))f++;for(;0<m-f;)c=$r(c),m--;for(;0<f-m;)p=$r(p),f--;for(;m--;){if(c===p||null!==p&&c===p.alternate)break e;c=$r(c),p=$r(p)}c=null}else c=null;null!==l&&Gr(i,s,l,c,!1),null!==u&&null!==d&&Gr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Vn(s))if(Qn)v=ir;else{v=ar;var b=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Un(i,v,n,a):(b&&b(e,s,r),"focusout"===e&&(b=s._wrapperState)&&b.controlled&&"number"===s.type&&ee(s,"number",s.value)),b=r?_a(r):window,e){case"focusin":(Vn(b)||"true"===b.contentEditable)&&(vr=b,br=r,yr=null);break;case"focusout":yr=br=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var y;if(Mn)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Zn?Bn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(Wn&&"ko"!==n.locale&&(Zn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Zn&&(y=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Zn=!0)),0<(b=Jr(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:b}),y?g.data=y:null!==(y=jn(n))&&(g.data=y))),(y=zn?function(e,t){switch(e){case"compositionend":return jn(t);case"keypress":return 32!==t.which?null:(In=!0,Ln);case"textInput":return(e=t.data)===Ln&&In?null:e;default:return null}}(e,n):function(e,t){if(Zn)return"compositionend"===e||!Mn&&Bn(e,t)?(e=en(),Xt=Yt=Qt=null,Zn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return Wn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=Jr(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=y))}Lr(i,t)}))}function Ur(e,t,n){return{instance:e,listener:t,currentTarget:n}}function Jr(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Re(e,n))&&r.unshift(Ur(e,o,a)),null!=(o=Re(e,t))&&r.push(Ur(e,o,a))),e=e.return}return r}function $r(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Gr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Re(n,o))&&i.unshift(Ur(n,l,s)):a||null!=(l=Re(n,o))&&i.push(Ur(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Zt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Zt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),pa="__reactFiber$"+da,fa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ba="__reactHandles$"+da;function ya(e){var t=e[pa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[pa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[pa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[pa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[fa]||null}var Sa=[],ka=-1;function Ta(e){return{current:e}}function Ca(e){0>ka||(e.current=Sa[ka],Sa[ka]=null,ka--)}function Pa(e,t){ka++,Sa[ka]=e.current,e.current=t}var xa={},Ea=Ta(xa),Fa=Ta(!1),Na=xa;function Aa(e,t){var n=e.type.contextTypes;if(!n)return xa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Ra(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Oa(){Ca(Fa),Ca(Ea)}function Ma(e,t,n){if(Ea.current!==xa)throw Error(o(168));Pa(Ea,t),Pa(Fa,n)}function Da(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,H(e)||"Unknown",a));return W({},n,r)}function za(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||xa,Na=Ea.current,Pa(Ea,e),Pa(Fa,Fa.current),!0}function Wa(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Da(e,t,Na),r.__reactInternalMemoizedMergedChildContext=e,Ca(Fa),Ca(Ea),Pa(Ea,e)):Ca(Fa),Pa(Fa,n)}var La=null,Ia=!1,Ba=!1;function ja(e){null===La?La=[e]:La.push(e)}function Za(){if(!Ba&&null!==La){Ba=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Ia=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),$e(Xe,Za),a}finally{gt=t,Ba=!1}}return null}var Ha=[],Va=0,Ua=null,Ja=0,$a=[],Ga=0,qa=null,Ka=1,Qa="";function Ya(e,t){Ha[Va++]=Ja,Ha[Va++]=Ua,Ua=e,Ja=t}function Xa(e,t,n){$a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Ua;)Ua=Ha[--Va],Ha[Va]=null,Ja=Ha[--Va],Ha[Va]=null;for(;e===qa;)qa=$a[--Ga],$a[Ga]=null,Qa=$a[--Ga],$a[Ga]=null,Ka=$a[--Ga],$a[Ga]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Au(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Au(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function po(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw fo(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function fo(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function bo(e,t){if(e&&e.defaultProps){for(var n in t=W({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var yo=Ta(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function ko(e){var t=yo.current;Ca(yo),e._currentValue=t}function To(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function Co(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function Po(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var xo=null;function Eo(e){null===xo?xo=[e]:xo.push(e)}function Fo(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Eo(t)):(n.next=a.next,a.next=n),t.interleaved=n,No(e,r)}function No(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Ao=!1;function Ro(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Oo(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Mo(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Do(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&El)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,No(e,n)}return null===(a=r.interleaved)?(t.next=t,Eo(r)):(t.next=a.next,a.next=t),r.interleaved=t,No(e,n)}function zo(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}function Wo(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;Ao=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var p=s.lane,f=s.eventTime;if((r&p)===p){null!==c&&(c=c.next={eventTime:f,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(p=t,f=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(f,d,p);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(p="function"===typeof(m=h.payload)?m.call(f,d,p):m)||void 0===p)break e;d=W({},d,p);break e;case 2:Ao=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(p=a.effects)?a.effects=[s]:p.push(s))}else f={eventTime:f,lane:p,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=f,l=d):c=c.next=f,i|=p;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(p=s).next,p.next=null,a.lastBaseUpdate=p,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);zl|=i,e.lanes=i,e.memoizedState=d}}function Io(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var Bo=(new r.Component).refs;function jo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:W({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Zo={isMounted:function(e){return!!(e=e._reactInternals)&&Ze(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Mo(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Do(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Mo(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Do(e,o,a))&&(nu(t,e,a,r),zo(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Mo(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Do(e,a,r))&&(nu(t,e,r,n),zo(t,e,r))}};function Ho(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Vo(e,t,n){var r=!1,a=xa,o=t.contextType;return"object"===typeof o&&null!==o?o=Po(o):(a=Ra(t)?Na:Ea.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Aa(e,a):xa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Zo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Uo(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Zo.enqueueReplaceState(t,t.state,null)}function Jo(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=Bo,Ro(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=Po(o):(o=Ra(t)?Na:Ea.current,a.context=Aa(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(jo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Zo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function $o(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===Bo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Go(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Ou(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=Wu(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===k?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===R&&qo(o)===t.type)?((r=a(t,n.props)).ref=$o(e,t,n),r.return=e,r):((r=Mu(n.type,n.key,n.props,null,e.mode,r)).ref=$o(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lu(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Du(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function p(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=Wu(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Mu(t.type,t.key,t.props,null,e.mode,n)).ref=$o(e,null,t),n.return=e,n;case S:return(t=Lu(t,e.mode,n)).return=e,t;case R:return p(e,(0,t._init)(t._payload),n)}if(te(t)||D(t))return(t=Du(t,e.mode,n,null)).return=e,t;Go(e,t)}return null}function f(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case R:return f(e,t,(a=n._init)(n._payload),r)}if(te(n)||D(n))return null!==a?null:d(e,t,n,r,null);Go(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case R:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||D(r))return d(t,e=e.get(n)||null,r,a,null);Go(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var b=f(a,d,s[h],l);if(null===b){null===d&&(d=v);break}e&&d&&null===b.alternate&&t(a,d),o=i(b,o,h),null===c?u=b:c.sibling=b,c=b,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=p(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Ya(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),u}function v(a,s,l,u){var c=D(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,b=null,y=l.next();null!==h&&!y.done;v++,y=l.next()){h.index>v?(b=h,h=null):b=h.sibling;var g=f(a,h,y.value,u);if(null===g){null===h&&(h=b);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=b}if(y.done)return n(a,h),ao&&Ya(a,v),c;if(null===h){for(;!y.done;v++,y=l.next())null!==(y=p(a,y.value,u))&&(s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return ao&&Ya(a,v),c}for(h=r(a,h);!y.done;v++,y=l.next())null!==(y=m(h,a,v,y.value,u))&&(e&&null!==y.alternate&&h.delete(null===y.key?v:y.key),s=i(y,s,v),null===d?c=y:d.sibling=y,d=y);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===k&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===k){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===R&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=$o(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===k?((o=Du(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Mu(i.type,i.key,i.props,null,r.mode,l)).ref=$o(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lu(i,r.mode,l)).return=r,r=o}return s(r);case R:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(D(i))return v(r,o,i,l);Go(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=Wu(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=Ta(Xo),ti=Ta(Xo),ni=Ta(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(Pa(ni,t),Pa(ti,e),Pa(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Ca(ei),Pa(ei,t)}function oi(){Ca(ei),Ca(ti),Ca(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(Pa(ti,e),Pa(ei,n))}function si(e){ti.current===e&&(Ca(ei),Ca(ti))}var li=Ta(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var pi=_.ReactCurrentDispatcher,fi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,bi=null,yi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function ki(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ti(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,pi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,bi=vi=null,t.updateQueue=null,pi.current=us,e=n(r,a)}while(gi)}if(pi.current=is,t=null!==vi&&null!==vi.next,mi=0,bi=vi=hi=null,yi=!1,t)throw Error(o(300));return e}function Ci(){var e=0!==_i;return _i=0,e}function Pi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===bi?hi.memoizedState=bi=e:bi=bi.next=e,bi}function xi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===bi?hi.memoizedState:bi.next;if(null!==t)bi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===bi?hi.memoizedState=bi=e:bi=bi.next=e}return bi}function Ei(e,t){return"function"===typeof t?t(e):t}function Fi(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var p={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=p,s=r):u=u.next=p,hi.lanes|=d,zl|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,zl|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ni(e){var t=xi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Ai(){}function Ri(e,t){var n=hi,r=xi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Vi(Di.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==bi&&1&bi.memoizedState.tag){if(n.flags|=2048,Ii(9,Mi.bind(null,n,r,a,t),void 0,null),null===Fl)throw Error(o(349));0!==(30&mi)||Oi(n,t,a)}return a}function Oi(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Mi(e,t,n,r){t.value=n,t.getSnapshot=r,zi(t)&&Wi(e)}function Di(e,t,n){return n((function(){zi(t)&&Wi(e)}))}function zi(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function Wi(e){var t=No(e,1);null!==t&&nu(t,e,1,-1)}function Li(e){var t=Pi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Ei,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Ii(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function Bi(){return xi().memoizedState}function ji(e,t,n,r){var a=Pi();hi.flags|=e,a.memoizedState=Ii(1|t,n,void 0,void 0===r?null:r)}function Zi(e,t,n,r){var a=xi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&ki(r,i.deps))return void(a.memoizedState=Ii(t,n,o,r))}hi.flags|=e,a.memoizedState=Ii(1|t,n,o,r)}function Hi(e,t){return ji(8390656,8,e,t)}function Vi(e,t){return Zi(2048,8,e,t)}function Ui(e,t){return Zi(4,2,e,t)}function Ji(e,t){return Zi(4,4,e,t)}function $i(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Gi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Zi(4,4,$i.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=xi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,zl|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=fi.transition;fi.transition={};try{e(!1),t()}finally{gt=n,fi.transition=r}}function es(){return xi().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Fo(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Eo(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Fo(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=yi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,yt(e,n)}}var is={readContext:Po,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:Po,useCallback:function(e,t){return Pi().memoizedState=[e,void 0===t?null:t],e},useContext:Po,useEffect:Hi,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,ji(4194308,4,$i.bind(null,t,e),n)},useLayoutEffect:function(e,t){return ji(4194308,4,e,t)},useInsertionEffect:function(e,t){return ji(4,2,e,t)},useMemo:function(e,t){var n=Pi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=Pi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},Pi().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return Pi().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Xi.bind(null,e[1]),Pi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=Pi();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Fl)throw Error(o(349));0!==(30&mi)||Oi(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Hi(Di.bind(null,r,i,e),[e]),r.flags|=2048,Ii(9,Mi.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=Pi(),t=Fl.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:Po,useCallback:Ki,useContext:Po,useEffect:Vi,useImperativeHandle:Gi,useInsertionEffect:Ui,useLayoutEffect:Ji,useMemo:Qi,useReducer:Fi,useRef:Bi,useState:function(){return Fi(Ei)},useDebugValue:qi,useDeferredValue:function(e){return Yi(xi(),vi.memoizedState,e)},useTransition:function(){return[Fi(Ei)[0],xi().memoizedState]},useMutableSource:Ai,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1},us={readContext:Po,useCallback:Ki,useContext:Po,useEffect:Vi,useImperativeHandle:Gi,useInsertionEffect:Ui,useLayoutEffect:Ji,useMemo:Qi,useReducer:Ni,useRef:Bi,useState:function(){return Ni(Ei)},useDebugValue:qi,useDeferredValue:function(e){var t=xi();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ni(Ei)[0],xi().memoizedState]},useMutableSource:Ai,useSyncExternalStore:Ri,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=j(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function ps(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var fs="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Mo(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Vl||(Vl=!0,Ul=r),ps(0,t)},n}function hs(e,t,n){(n=Mo(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){ps(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){ps(0,t),"function"!==typeof r&&(null===Jl?Jl=new Set([this]):Jl.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new fs;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Cu.bind(null,e,t,n),t.then(e,e))}function bs(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function ys(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Mo(-1,1)).tag=2,Do(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return Co(t,a),r=Ti(e,t,n,r,o,a),n=Ci(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function ks(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ru(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Mu(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Ts(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Vs(e,t,a)}return t.flags|=1,(e=Ou(o,r)).ref=t.ref,e.return=t,t.child=e}function Ts(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Vs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return xs(e,t,n,r,a)}function Cs(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},Pa(Ol,Rl),Rl|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,Pa(Ol,Rl),Rl|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,Pa(Ol,Rl),Rl|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,Pa(Ol,Rl),Rl|=r;return ws(e,t,a,n),t.child}function Ps(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function xs(e,t,n,r,a){var o=Ra(n)?Na:Ea.current;return o=Aa(t,o),Co(t,a),n=Ti(e,t,n,r,o,a),r=Ci(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function Es(e,t,n,r,a){if(Ra(n)){var o=!0;za(t)}else o=!1;if(Co(t,a),null===t.stateNode)Hs(e,t),Vo(t,n,r),Jo(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=Po(u):u=Aa(t,u=Ra(n)?Na:Ea.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Uo(t,i,r,u),Ao=!1;var p=t.memoizedState;i.state=p,Lo(t,r,i,a),l=t.memoizedState,s!==r||p!==l||Fa.current||Ao?("function"===typeof c&&(jo(t,n,c,r),l=t.memoizedState),(s=Ao||Ho(t,n,s,r,p,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Oo(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:bo(t.type,s),i.props=u,d=t.pendingProps,p=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=Po(l):l=Aa(t,l=Ra(n)?Na:Ea.current);var f=n.getDerivedStateFromProps;(c="function"===typeof f||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||p!==l)&&Uo(t,i,r,l),Ao=!1,p=t.memoizedState,i.state=p,Lo(t,r,i,a);var m=t.memoizedState;s!==d||p!==m||Fa.current||Ao?("function"===typeof f&&(jo(t,n,f,r),m=t.memoizedState),(u=Ao||Ho(t,n,u,r,p,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),r=!1)}return Fs(e,t,n,r,o,a)}function Fs(e,t,n,r,a,o){Ps(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&Wa(t,n,!1),Vs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&Wa(t,n,!0),t.child}function Ns(e){var t=e.stateNode;t.pendingContext?Ma(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Ma(0,t.context,!1),ai(e,t.containerInfo)}function As(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Rs,Os,Ms,Ds={dehydrated:null,treeContext:null,retryLane:0};function zs(e){return{baseLanes:e,cachePool:null,transitions:null}}function Ws(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),Pa(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=zu(l,a,0,null),e=Du(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=zs(n),t.memoizedState=Ds,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Is(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=zu({mode:"visible",children:r.children},a,0,null),(i=Du(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=zs(s),t.memoizedState=Ds,i);if(0===(1&t.mode))return Is(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Is(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Fl)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,No(e,a),nu(r,e,a,-1))}return hu(),Is(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=xu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&($a[Ga++]=Ka,$a[Ga++]=Qa,$a[Ga++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Ou(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Ou(r,s):(s=Du(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?zs(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Ds,a}return e=(s=e.child).sibling,a=Ou(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=zu({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Is(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function Bs(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),To(e.return,t,n)}function js(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Zs(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&Bs(e,n,t);else if(19===e.tag)Bs(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(Pa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),js(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}js(t,!0,n,null,o);break;case"together":js(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Hs(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Vs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),zl|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Ou(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Ou(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Us(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function Js(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function $s(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return Js(t),null;case 1:case 17:return Ra(t.type)&&Oa(),Js(t),null;case 3:return r=t.stateNode,oi(),Ca(Fa),Ca(Ea),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(po(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),Js(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Os(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return Js(t),null}if(e=ri(ei.current),po(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[pa]=t,r[fa]=i,e=0!==(1&t.mode),n){case"dialog":Ir("cancel",r),Ir("close",r);break;case"iframe":case"object":case"embed":Ir("load",r);break;case"video":case"audio":for(a=0;a<Dr.length;a++)Ir(Dr[a],r);break;case"source":Ir("error",r);break;case"img":case"image":case"link":Ir("error",r),Ir("load",r);break;case"details":Ir("toggle",r);break;case"input":K(r,i),Ir("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Ir("invalid",r);break;case"textarea":ae(r,i),Ir("invalid",r)}for(var l in ye(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&Ir("scroll",r)}switch(n){case"input":J(r),X(r,i,!0);break;case"textarea":J(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[pa]=t,e[fa]=r,Rs(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Ir("cancel",e),Ir("close",e),a=r;break;case"iframe":case"object":case"embed":Ir("load",e),a=r;break;case"video":case"audio":for(a=0;a<Dr.length;a++)Ir(Dr[a],e);a=r;break;case"source":Ir("error",e),a=r;break;case"img":case"image":case"link":Ir("error",e),Ir("load",e),a=r;break;case"details":Ir("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Ir("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=W({},r,{value:void 0}),Ir("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Ir("invalid",e)}for(i in ye(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&pe(e,c):"number"===typeof c&&pe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&Ir("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":J(e),X(e,r,!1);break;case"textarea":J(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+V(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return Js(t),null;case 6:if(e&&null!=t.stateNode)Ms(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),po(t)){if(r=t.stateNode,n=t.memoizedProps,r[pa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[pa]=t,t.stateNode=r}return Js(t),null;case 13:if(Ca(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))fo(),mo(),t.flags|=98560,i=!1;else if(i=po(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[pa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;Js(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Ml&&(Ml=3):hu())),null!==t.updateQueue&&(t.flags|=4),Js(t),null);case 4:return oi(),null===e&&Zr(t.stateNode.containerInfo),Js(t),null;case 10:return ko(t.type._context),Js(t),null;case 19:if(Ca(li),null===(i=t.memoizedState))return Js(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Us(i,!1);else{if(0!==Ml||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Us(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return Pa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Zl&&(t.flags|=128,r=!0,Us(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Us(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return Js(t),null}else 2*Qe()-i.renderingStartTime>Zl&&1073741824!==n&&(t.flags|=128,r=!0,Us(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,Pa(li,r?1&n|2:1&n),t):(Js(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Rl)&&(Js(t),6&t.subtreeFlags&&(t.flags|=8192)):Js(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Gs(e,t){switch(to(t),t.tag){case 1:return Ra(t.type)&&Oa(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Ca(Fa),Ca(Ea),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Ca(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Ca(li),null;case 4:return oi(),null;case 10:return ko(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Rs=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Os=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=W({},a,{value:void 0}),r=W({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(c in ye(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&Ir("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Ms=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Tu(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Tu(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[pa],delete t[fa],delete t[ha],delete t[va],delete t[ba])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function pl(e,t,n){for(n=n.child;null!==n;)fl(e,t,n),n=n.sibling}function fl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=cl,a=dl;cl=null,pl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Zt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,pl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}pl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Tu(n,t,s)}pl(e,t,n);break;case 21:pl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,pl(e,t,n),Ks=r):pl(e,t,n);break;default:pl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Eu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));fl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){Tu(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),bl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Tu(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Tu(e,e.return,v)}}break;case 1:hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),bl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{pe(a,"")}catch(v){Tu(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],p=u[s+1];"style"===d?ve(a,p):"dangerouslySetInnerHTML"===d?de(a,p):"children"===d?pe(a,p):g(a,d,p,c)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var f=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):f!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[fa]=i}catch(v){Tu(e,e.return,v)}}break;case 6:if(hl(t,e),bl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Tu(e,e.return,v)}}break;case 3:if(hl(t,e),bl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Zt(t.containerInfo)}catch(v){Tu(e,e.return,v)}break;case 4:default:hl(t,e),bl(e);break;case 13:hl(t,e),bl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(jl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),bl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(p=Ys=d;null!==Ys;){switch(m=(f=Ys).child,f.tag){case 0:case 11:case 14:case 15:nl(4,f,f.return);break;case 1:Xs(f,f.return);var h=f.stateNode;if("function"===typeof h.componentWillUnmount){r=f,n=f.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Tu(r,n,v)}}break;case 5:Xs(f,f.return);break;case 22:if(null!==f.memoizedState){wl(p);continue}}null!==m?(m.return=f,Ys=m):wl(p)}d=d.sibling}e:for(d=null,p=e;;){if(5===p.tag){if(null===d){d=p;try{a=p.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=p.stateNode,s=void 0!==(u=p.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){Tu(e,e.return,v)}}}else if(6===p.tag){if(null===d)try{p.stateNode.nodeValue=c?"":p.memoizedProps}catch(v){Tu(e,e.return,v)}}else if((22!==p.tag&&23!==p.tag||null===p.memoizedState||p===e)&&null!==p.child){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;null===p.sibling;){if(null===p.return||p.return===e)break e;d===p&&(d=null),p=p.return}d===p&&(d=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:hl(t,e),bl(e),4&r&&ml(e);case 21:}}function bl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(pe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Tu(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function yl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Ys=l):Sl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:bo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Io(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Io(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var p=d.dehydrated;null!==p&&Zt(p)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(f){Tu(t,t.return,f)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Sl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Tu(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Tu(t,a,l)}}var o=t.return;try{al(t)}catch(l){Tu(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Tu(t,i,l)}}}catch(l){Tu(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var kl,Tl=Math.ceil,Cl=_.ReactCurrentDispatcher,Pl=_.ReactCurrentOwner,xl=_.ReactCurrentBatchConfig,El=0,Fl=null,Nl=null,Al=0,Rl=0,Ol=Ta(0),Ml=0,Dl=null,zl=0,Wl=0,Ll=0,Il=null,Bl=null,jl=0,Zl=1/0,Hl=null,Vl=!1,Ul=null,Jl=null,$l=!1,Gl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function eu(){return 0!==(6&El)?Qe():-1!==Yl?Yl:Yl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&El)&&0!==Al?Al&-Al:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));bt(e,n,r),0!==(2&El)&&e===Fl||(e===Fl&&(0===(2&El)&&(Wl|=n),4===Ml&&su(e,Al)),ru(e,r),1===n&&0===El&&0===(1&t.mode)&&(Zl=Qe()+500,Ia&&Za()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=ft(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=pt(e,e===Fl?Al:0);if(0===r)null!==n&&Ge(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&Ge(n),1===t)0===e.tag?function(e){Ia=!0,ja(e)}(lu.bind(null,e)):ja(lu.bind(null,e)),ia((function(){0===(6&El)&&Za()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Fu(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Yl=-1,Xl=0,0!==(6&El))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=pt(e,e===Fl?Al:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=El;El|=2;var i=mu();for(Fl===e&&Al===t||(Hl=null,Zl=Qe()+500,pu(e,t));;)try{yu();break}catch(l){fu(e,l)}So(),Cl.current=i,El=a,null!==Nl?t=0:(Fl=null,Al=0,t=Ml)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Dl,pu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Dl,pu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,Bl,Hl);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=jl+500-Qe())){if(0!==pt(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,Bl,Hl),t);break}wu(e,Bl,Hl);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Tl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,Bl,Hl),r);break}wu(e,Bl,Hl);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=Il;return e.current.memoizedState.isDehydrated&&(pu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=Bl,Bl=n,null!==t&&iu(t)),e}function iu(e){null===Bl?Bl=e:Bl.push.apply(Bl,e)}function su(e,t){for(t&=~Ll,t&=~Wl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&El))throw Error(o(327));Su();var t=pt(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Dl,pu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,Bl,Hl),ru(e,Qe()),null}function uu(e,t){var n=El;El|=1;try{return e(t)}finally{0===(El=n)&&(Zl=Qe()+500,Ia&&Za())}}function cu(e){null!==Gl&&0===Gl.tag&&0===(6&El)&&Su();var t=El;El|=1;var n=xl.transition,r=gt;try{if(xl.transition=null,gt=1,e)return e()}finally{gt=r,xl.transition=n,0===(6&(El=t))&&Za()}}function du(){Rl=Ol.current,Ca(Ol)}function pu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Nl)for(n=Nl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Oa();break;case 3:oi(),Ca(Fa),Ca(Ea),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Ca(li);break;case 10:ko(r.type._context);break;case 22:case 23:du()}n=n.return}if(Fl=e,Nl=e=Ou(e.current,null),Al=Rl=t,Ml=0,Dl=null,Ll=Wl=zl=0,Bl=Il=null,null!==xo){for(t=0;t<xo.length;t++)if(null!==(r=(n=xo[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}xo=null}return e}function fu(e,t){for(;;){var n=Nl;try{if(So(),pi.current=is,yi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}yi=!1}if(mi=0,bi=vi=hi=null,gi=!1,_i=0,Pl.current=null,null===n||null===n.return){Ml=1,Dl=t,Nl=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=Al,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,p=d.tag;if(0===(1&d.mode)&&(0===p||11===p||15===p)){var f=d.alternate;f?(d.updateQueue=f.updateQueue,d.memoizedState=f.memoizedState,d.lanes=f.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=bs(s);if(null!==m){m.flags&=-257,ys(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var b=bs(s);if(null!==b){0===(65536&b.flags)&&(b.flags|=256),ys(b,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Ml&&(Ml=2),null===Il?Il=[i]:Il.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,Wo(i,ms(0,u,t));break e;case 1:l=u;var y=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof y.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===Jl||!Jl.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,Wo(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,Nl===n&&null!==n&&(Nl=n=n.return);continue}break}}function mu(){var e=Cl.current;return Cl.current=is,null===e?is:e}function hu(){0!==Ml&&3!==Ml&&2!==Ml||(Ml=4),null===Fl||0===(268435455&zl)&&0===(268435455&Wl)||su(Fl,Al)}function vu(e,t){var n=El;El|=2;var r=mu();for(Fl===e&&Al===t||(Hl=null,pu(e,t));;)try{bu();break}catch(a){fu(e,a)}if(So(),El=n,Cl.current=r,null!==Nl)throw Error(o(261));return Fl=null,Al=0,Ml}function bu(){for(;null!==Nl;)gu(Nl)}function yu(){for(;null!==Nl&&!qe();)gu(Nl)}function gu(e){var t=kl(e.alternate,e,Rl);e.memoizedProps=e.pendingProps,null===t?_u(e):Nl=t,Pl.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=$s(n,t,Rl)))return void(Nl=n)}else{if(null!==(n=Gs(n,t)))return n.flags&=32767,void(Nl=n);if(null===e)return Ml=6,void(Nl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Nl=t);Nl=t=e}while(null!==t);0===Ml&&(Ml=5)}function wu(e,t,n){var r=gt,a=xl.transition;try{xl.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Gl);if(0!==(6&El))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Fl&&(Nl=Fl=null,Al=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||$l||($l=!0,Fu(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=xl.transition,xl.transition=null;var s=gt;gt=1;var l=El;El|=4,Pl.current=null,function(e,t){if(ea=Vt,fr(e=pr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,p=e,f=null;t:for(;;){for(var m;p!==n||0!==a&&3!==p.nodeType||(l=s+a),p!==i||0!==r&&3!==p.nodeType||(u=s+r),3===p.nodeType&&(s+=p.nodeValue.length),null!==(m=p.firstChild);)f=p,p=m;for(;;){if(p===e)break t;if(f===n&&++c===a&&(l=s),f===i&&++d===r&&(u=s),null!==(m=p.nextSibling))break;f=(p=f).parentNode}p=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Vt=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,b=h.memoizedState,y=t.stateNode,g=y.getSnapshotBeforeUpdate(t.elementType===t.type?v:bo(t.type,v),b);y.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Tu(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Vt=!!ea,ta=ea=null,e.current=n,yl(n,e,a),Ke(),El=l,gt=s,xl.transition=i}else e.current=n;if($l&&($l=!1,Gl=e,ql=a),0===(i=e.pendingLanes)&&(Jl=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Vl)throw Vl=!1,e=Ul,Ul=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Za()}(e,t,n,r)}finally{xl.transition=a,gt=r}return null}function Su(){if(null!==Gl){var e=_t(ql),t=xl.transition,n=gt;try{if(xl.transition=null,gt=16>e?16:e,null===Gl)var r=!1;else{if(e=Gl,Gl=null,ql=0,0!==(6&El))throw Error(o(331));var a=El;for(El|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Ys=c;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var p=d.child;if(null!==p)p.return=d,Ys=p;else for(;null!==Ys;){var f=(d=Ys).sibling,m=d.return;if(ol(d),d===c){Ys=null;break}if(null!==f){f.return=m,Ys=f;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var b=v.sibling;v.sibling=null,v=b}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var y=i.sibling;if(null!==y){y.return=i.return,Ys=y;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Tu(l,l.return,S)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(El=a,Za(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,xl.transition=t}}return!1}function ku(e,t,n){e=Do(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(bt(e,1,t),ru(e,t))}function Tu(e,t,n){if(3===e.tag)ku(e,e,n);else for(;null!==t;){if(3===t.tag){ku(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===Jl||!Jl.has(r))){t=Do(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(bt(t,1,e),ru(t,e));break}}t=t.return}}function Cu(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Fl===e&&(Al&n)===n&&(4===Ml||3===Ml&&(130023424&Al)===Al&&500>Qe()-jl?pu(e,0):Ll|=n),ru(e,t)}function Pu(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=No(e,t))&&(bt(e,t,n),ru(e,n))}function xu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),Pu(e,n)}function Eu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),Pu(e,n)}function Fu(e,t){return $e(e,t)}function Nu(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Au(e,t,n,r){return new Nu(e,t,n,r)}function Ru(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Ou(e,t){var n=e.alternate;return null===n?((n=Au(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Mu(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ru(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case k:return Du(n.children,a,i,t);case T:s=8,a|=8;break;case C:return(e=Au(12,n,t,2|a)).elementType=C,e.lanes=i,e;case F:return(e=Au(13,n,t,a)).elementType=F,e.lanes=i,e;case N:return(e=Au(19,n,t,a)).elementType=N,e.lanes=i,e;case O:return zu(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case P:s=10;break e;case x:s=9;break e;case E:s=11;break e;case A:s=14;break e;case R:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Au(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Du(e,t,n,r){return(e=Au(7,e,r,t)).lanes=n,e}function zu(e,t,n,r){return(e=Au(22,e,r,t)).elementType=O,e.lanes=n,e.stateNode={isHidden:!1},e}function Wu(e,t,n){return(e=Au(6,e,null,t)).lanes=n,e}function Lu(e,t,n){return(t=Au(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Iu(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function Bu(e,t,n,r,a,o,i,s,l){return e=new Iu(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Au(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Ro(o),e}function ju(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Zu(e){if(!e)return xa;e:{if(Ze(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Ra(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Ra(n))return Da(e,n,t)}return t}function Hu(e,t,n,r,a,o,i,s,l){return(e=Bu(n,r,!0,e,0,o,0,s,l)).context=Zu(null),n=e.current,(o=Mo(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Do(n,o,a),e.current.lanes=a,bt(e,a,r),ru(e,r),e}function Vu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Zu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Mo(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Do(a,t,i))&&(nu(e,a,i,o),zo(e,a,i)),i}function Uu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function Ju(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function $u(e,t){Ju(e,t),(e=e.alternate)&&Ju(e,t)}kl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Fa.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Ns(t),mo();break;case 5:ii(t);break;case 1:Ra(t.type)&&za(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;Pa(yo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(Pa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?Ws(e,t,n):(Pa(li,1&li.current),null!==(e=Vs(e,t,n))?e.sibling:null);Pa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Zs(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),Pa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Cs(e,t,n)}return Vs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,Ja,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Hs(e,t),e=t.pendingProps;var a=Aa(t,Ea.current);Co(t,n),a=Ti(null,t,r,e,a,n);var i=Ci();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Ra(r)?(i=!0,za(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Ro(t),a.updater=Zo,t.stateNode=a,a._reactInternals=t,Jo(t,r,e,n),t=Fs(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Hs(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ru(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===E)return 11;if(e===A)return 14}return 2}(r),e=bo(r,e),a){case 0:t=xs(null,t,r,e,n);break e;case 1:t=Es(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=ks(null,t,r,bo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,xs(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Es(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 3:e:{if(Ns(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Oo(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=As(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=As(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Vs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),Ps(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return Ws(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:bo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,Pa(yo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Fa.current){t=Vs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Mo(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),To(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),To(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,Co(t,n),r=r(a=Po(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=bo(r=t.type,t.pendingProps),ks(e,t,r,a=bo(r.type,a),n);case 15:return Ts(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:bo(r,a),Hs(e,t),t.tag=1,Ra(r)?(e=!0,za(t)):e=!1,Co(t,n),Vo(t,r,a),Jo(t,r,a,n),Fs(null,t,r,!0,e,n);case 19:return Zs(e,t,n);case 22:return Cs(e,t,n)}throw Error(o(156,t.tag))};var Gu="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Uu(i);s.call(e)}}Vu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Uu(i);o.call(e)}}var i=Hu(t,r,e,0,null,!1,0,"",Xu);return e._reactRootContainer=i,e[ma]=i.current,Zr(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Uu(l);s.call(e)}}var l=Bu(e,0,!1,null,0,!1,0,"",Xu);return e._reactRootContainer=l,e[ma]=l.current,Zr(8===e.nodeType?e.parentNode:e),cu((function(){Vu(t,l,n,r)})),l}(n,t,e,a,r);return Uu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Vu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Vu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=Tt();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Ot.length&&0!==t&&t<Ot[n].priority;n++);Ot.splice(n,0,e),0===n&&Wt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(yt(t,1|n),ru(t,Qe()),0===(6&El)&&(Zl=Qe()+500,Za()))}break;case 13:cu((function(){var t=No(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),$u(e,1)}},St=function(e){if(13===e.tag){var t=No(e,134217728);if(null!==t)nu(t,e,134217728,eu());$u(e,134217728)}},kt=function(e){if(13===e.tag){var t=tu(e),n=No(e,t);if(null!==n)nu(n,e,t,eu());$u(e,t)}},Tt=function(){return gt},Ct=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));$(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Ee=uu,Fe=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,Pe,xe,uu]},nc={findFiberByHostInstance:ya,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ue(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return ju(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Gu;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=Bu(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Zr(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ue(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Gu;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Hu(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Zr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),p=Symbol.for("react.lazy"),f=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function b(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function y(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}b.prototype.isReactComponent={},b.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},b.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},y.prototype=b.prototype;var _=g.prototype=new y;_.constructor=g,h(_,b.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,k={current:null},T={key:!0,ref:!0,__self:!0,__source:!0};function C(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!T.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:k.current}}function P(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var x=/\/+/g;function E(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function F(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+E(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(x,"$&/")+"/"),F(i,t,a,"",(function(e){return e}))):null!=i&&(P(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(x,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+E(s=e[u],u);l+=F(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=f&&e[f]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=F(s=s.value,t,a,c=o+E(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function N(e,t,n){if(null==e)return e;var r=[],a=0;return F(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function A(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var R={current:null},O={transition:null},M={ReactCurrentDispatcher:R,ReactCurrentBatchConfig:O,ReactCurrentOwner:k};t.Children={map:N,forEach:function(e,t,n){N(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return N(e,(function(){t++})),t},toArray:function(e){return N(e,(function(e){return e}))||[]},only:function(e){if(!P(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=b,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=M,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=k.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!T.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=C,t.createFactory=function(e){var t=C.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=P,t.lazy=function(e){return{$$typeof:p,_payload:{_status:-1,_result:e},_init:A}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=O.transition;O.transition={};try{e()}finally{O.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return R.current.useCallback(e,t)},t.useContext=function(e){return R.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return R.current.useDeferredValue(e)},t.useEffect=function(e,t){return R.current.useEffect(e,t)},t.useId=function(){return R.current.useId()},t.useImperativeHandle=function(e,t,n){return R.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return R.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return R.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return R.current.useMemo(e,t)},t.useReducer=function(e,t,n){return R.current.useReducer(e,t,n)},t.useRef=function(e){return R.current.useRef(e)},t.useState=function(e){return R.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return R.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return R.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,p=null,f=3,m=!1,h=!1,v=!1,b="function"===typeof setTimeout?setTimeout:null,y="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,O(S);else{var t=r(c);null!==t&&M(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,y(P),P=-1),m=!0;var o=f;try{for(_(n),p=r(u);null!==p&&(!(p.expirationTime>n)||e&&!F());){var i=p.callback;if("function"===typeof i){p.callback=null,f=p.priorityLevel;var s=i(p.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?p.callback=s:p===r(u)&&a(u),_(n)}else a(u);p=r(u)}if(null!==p)var l=!0;else{var d=r(c);null!==d&&M(w,d.startTime-n),l=!1}return l}finally{p=null,f=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var k,T=!1,C=null,P=-1,x=5,E=-1;function F(){return!(t.unstable_now()-E<x)}function N(){if(null!==C){var e=t.unstable_now();E=e;var n=!0;try{n=C(!0,e)}finally{n?k():(T=!1,C=null)}}else T=!1}if("function"===typeof g)k=function(){g(N)};else if("undefined"!==typeof MessageChannel){var A=new MessageChannel,R=A.port2;A.port1.onmessage=N,k=function(){R.postMessage(null)}}else k=function(){b(N,0)};function O(e){C=e,T||(T=!0,k())}function M(e,n){P=b((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,O(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):x=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return f},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(f){case 1:case 2:case 3:var t=3;break;default:t=f}var n=f;f=t;try{return e()}finally{f=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=f;f=e;try{return t()}finally{f=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(y(P),P=-1):v=!0,M(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,O(S))),e},t.unstable_shouldYield=F,t.unstable_wrapCallback=function(e){var t=f;return function(){var n=f;f=t;try{return e.apply(this,arguments)}finally{f=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var p=n(184);function f(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,p.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,p.jsx)(f,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},b=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var y=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},b(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),k=n(7312),T=n(1217),C=n(4419),P=n(8691),x=(0,n(4046).ZP)(),E=n(5080),F=["className","component","disableGutters","fixed","maxWidth","classes"],N=(0,E.Z)(),A=x("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,k.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),R=function(e){return(0,P.Z)({props:e,name:"MuiContainer",defaultTheme:N})},O=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,k.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,C.Z)(i,(function(e){return(0,T.Z)(t,e)}),n)};var M=n(9853),D=n(277),z=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?A:n,o=t.useThemeProps,i=void 0===o?R:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,f=n.fixed,m=void 0!==f&&f,h=n.maxWidth,v=void 0===h?"lg":h,b=(0,w.Z)(n,F),y=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=O(y,l);return(0,p.jsx)(u,(0,r.Z)({as:s,ownerState:y,className:(0,S.Z)(g.root,a),ref:t},b))}));return c}({createStyledComponent:(0,D.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,M.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),W=z,L=n(2421),I=n(104),B=n(2982),j=n(2466),Z=n(114),H=["sx"];function V(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){Z.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,H)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,B.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,j.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var U=n(886),J=["className","component"];var $=n(5902),G=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?I.Z:s,u=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,U.Z)(n),s=V(e),l=s.className,c=s.component,d=void 0===c?"div":c,f=(0,w.Z)(s,J);return(0,p.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},f))}));return c}({defaultTheme:(0,G.Z)(),defaultClassName:"MuiBox-root",generateClassName:$.Z.generate}),K=q,Q=JSON.parse('{"e":13,"C":[{"nctid":"NCT03362177","version_a":3,"version_b":4,"version_a_date":"2018-02-15","version_b_date":"2018-04-09","pom_a":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction by[ Time Frame: 17 weeks ]The primary endpoint is the subject incidence of either a chemotherapy dose delay by\u2265 4 days or a chemotherapy dose reduction by \u2265 15% due to thrombocytopenia in any 2 planned cycles of chemotherapy (chemotherapy cycles can be 14-, 21-, or 28-days long) during the treatment period."}],"pom_b":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]A thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Dose modifications are defined as a dose delay by \u2265 4 days or dose reduction by\u2265 15%, or discontinuation of the agent"}],"start_date":"September 30, 2019","primary_completion_date":"August 29, 2023","completion_date":"July 30, 2024","first_posted":"December 5, 2017","last_update_posted":"September 9, 2022"},{"nctid":"NCT03362177","version_a":10,"version_b":11,"version_a_date":"2018-10-29","version_b_date":"2018-11-20","pom_a":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]A thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Dose modifications are defined as a dose delay by \u2265 4 days or dose reduction by\u2265 15%, or discontinuation of the agent"}],"pom_b":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen."}],"start_date":"September 30, 2019","primary_completion_date":"August 29, 2023","completion_date":"July 30, 2024","first_posted":"December 5, 2017","last_update_posted":"September 9, 2022"},{"nctid":"NCT03362177","version_a":14,"version_b":15,"version_a_date":"2019-03-04","version_b_date":"2019-04-30","pom_a":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen."}],"pom_b":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 10 9/L"}],"start_date":"September 30, 2019","primary_completion_date":"August 29, 2023","completion_date":"July 30, 2024","first_posted":"December 5, 2017","last_update_posted":"September 9, 2022"},{"nctid":"NCT03362177","version_a":19,"version_b":20,"version_a_date":"2019-10-21","version_b_date":"2019-12-05","pom_a":[{"label":"1.","content":"Incidence of either a chemotherapy dose delay or reduction[ Time Frame: 48 days ]No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 10 9/L"}],"pom_b":[{"label":"1.","content":"Incidence of a Thrombocytopenia-induced chemotherapy dose modification during the second or third on study chemotherapy cycles.[ Time Frame: 48 days ]No thrombocytopenia-induced modification of any myelosuppressive treatment agent in the second and third cycles of the planned on-study chemotherapy regimen. Thrombocytopenia-induced modifications include chemotherapy dose reduction, delay, omission, or chemotherapy treatment discontinuation due to platelet counts below 100 x 10 9/L"}],"start_date":"September 30, 2019","primary_completion_date":"August 29, 2023","completion_date":"July 30, 2024","first_posted":"December 5, 2017","last_update_posted":"September 9, 2022"},{"nctid":"NCT01582061","version_a":2,"version_b":3,"version_a_date":"2012-08-20","version_b_date":"2012-11-07","pom_a":[],"pom_b":[{"label":"1.","content":"Proportion of patients having a drug-related adverse event that is recorded as grade 3 or 4 or as a serious adverse event[ Time Frame: Week 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36, 48 ]"}],"start_date":"August 16, 2011","primary_completion_date":"January 26, 2017","completion_date":"January 26, 2017","first_posted":"April 20, 2012","results_first_posted":"June 19, 2018","last_update_posted":"June 19, 2018"},{"nctid":"NCT01582061","version_a":35,"version_b":36,"version_a_date":"2018-01-11","version_b_date":"2018-05-24","pom_a":[{"label":"1.","content":"Proportion of patients having a drug-related adverse event that is recorded as grade 3 or 4 or as a serious adverse event[ Time Frame: Week 0, 1, 2, 3, 4, 8, 12, 16, 20, 24, 36, 48 ]"}],"pom_b":[{"label":"1.","content":"Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE)[ Time Frame: Baseline up to approximately 256 weeks ]Only AEs occurring on or after the start of study treatment and no more than 28 days after the discontinuation of study treatment. A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category for that treatment. A patient with multiple severity grades for an AE while on a treatment, is only counted under the maximum grade."}],"start_date":"August 16, 2011","primary_completion_date":"January 26, 2017","completion_date":"January 26, 2017","first_posted":"April 20, 2012","results_first_posted":"June 19, 2018","last_update_posted":"June 19, 2018"},{"nctid":"NCT02349412","version_a":11,"version_b":12,"version_a_date":"2018-08-10","version_b_date":"2019-02-26","pom_a":[{"label":"1.","content":"Change in FACT-G scores from baseline to 12 weeks between study arms[ Time Frame: Up to 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G)[ Time Frame: Up to 12 weeks ]Quality of Life (QOL) was measured using the Functional Assessment of Cancer Therapy-General (FACT-G) on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. Change from baseline to week-12 was calculated by subtracting the baseline scores from the scores at week-12. Higher scores on FACT-G indicate better QOL."}],"start_date":"April 2015","primary_completion_date":"July 3, 2017","completion_date":"July 15, 2019","first_posted":"January 28, 2015","results_first_posted":"February 28, 2019","last_update_posted":"July 26, 2021"},{"nctid":"NCT02135419","version_a":37,"version_b":38,"version_a_date":"2021-10-15","version_b_date":"2022-05-31","pom_a":[{"label":"1.","content":"Time to anal cancer[ Time Frame: Time from randomization to diagnosis of anal cancer, assessed up to 5 years ]The log-rank test will be used to compare the treatment and control arms with respect to time to detection of anal cancer. For each arm, the hazard rate and its 95% confidence interval will be estimated. The proportional hazards model will be used to assess the association of study site, lesion size, lesion location, nadir CD4 level and gender with time to detection of anal cancer."}],"pom_b":[{"label":"1.","content":"Time to anal cancer[ Time Frame: Time from randomization to diagnosis of anal cancer, assessed up to 5 years after randomization of the last participant ]The log-rank test will be used to compare the treatment and control arms with respect to time to detection of anal cancer. For each arm, the hazard rate and its 95% confidence interval will be estimated. The proportional hazards model will be used to assess the association of study site, lesion size, lesion location, nadir CD4 level and gender with time to detection of anal cancer."}],"start_date":"September 24, 2014","primary_completion_date":"August 6, 2021","completion_date":"September 30, 2024","first_posted":"May 12, 2014","last_update_posted":"June 21, 2022"},{"nctid":"NCT00961415","version_a":77,"version_b":78,"version_a_date":"2015-10-01","version_b_date":"2016-01-24","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: tumour assessment before cycle 3, at 2nd cycle of maintenance therapy and every 9 weeks thereafter ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival During Maintenance Treatment Phase[ Time Frame: Up to 21 months ]Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter."}],"start_date":"August 2009","primary_completion_date":"May 2011","completion_date":"May 2011","first_posted":"August 19, 2009","results_first_posted":"February 22, 2016","last_update_posted":"February 22, 2016"},{"nctid":"NCT00644787","version_a":8,"version_b":9,"version_a_date":"2008-09-25","version_b_date":"2008-09-26","pom_a":[{"label":"1.","content":"Period 1: Dose titration success rate Period 2: The mean VAS score for the last 3 days before the completion (or discontinuation) of Period 2"}],"pom_b":[{"label":"1.","content":"Period 1: Dose titration success rate Period 2: The mean VAS score for the last 3 days before the completion (or discontinuation) of Period 2[ Time Frame: The primary outcome measure of Period I is from the first system application (Period 1-Day 1) until the dose is fixed (Up to Period 1-Day14). The primary outcome measure of Period II is from the end of Period I to Period 2- Day 10. ]"}],"start_date":"December 2007","primary_completion_date":"October 2008","completion_date":"October 2008","first_posted":"March 27, 2008","results_first_posted":"May 21, 2013","last_update_posted":"June 13, 2013"},{"nctid":"NCT00644787","version_a":12,"version_b":13,"version_a_date":"2010-04-26","version_b_date":"2013-04-01","pom_a":[{"label":"1.","content":"Period 1: Dose titration success rate Period 2: The mean VAS score for the last 3 days before the completion (or discontinuation) of Period 2[ Time Frame: The primary outcome measure of Period I is from the first system application (Period 1-Day 1) until the dose is fixed (Up to Period 1-Day14). The primary outcome measure of Period II is from the end of Period I to Period 2- Day 10. ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Achieving Dose Titration Success[ Time Frame: Day 14 or early discontinuation (ED) ]Participants achieving dose titration success included all participants who had a mean Visual Analog Scale (VAS) score of less than or equal to 34 millimeter (mm) and received not more than 2 rescue doses during the last 3 days before the completion or discontinuation of dose titration phase. Pain Intensity VAS measured severity of pain on a 100 mm scale ranging from 0 mm (no pain) to 100 mm (severest pain conceivable) and rescue dose was defined as dose of a fast-acting oral morphine hydrochloride solution or morphine in water solution used in the case of breakthrough pain."},{"label":"2.","content":"Change From Dose Titration Phase in the Mean Visual Analog Scale (VAS) Score at Double Blind Phase[ Time Frame: Dose Titration Phase (Day 12 to Day 14) and Double Blind Phase (Day 8 to Day 10) ]The mean VAS score for the last 3 days before the completion or discontinuation of Double Blind Phase was compared with that for the last 3 days before the completion or discontinuation of Dose Titration Phase and the change from Dose Titration Phase in the mean VAS Score at Double Blind Phase was reported. Pain Intensity VAS measured severity of pain on a 100 mm scale ranging from 0 mm (no pain) to 100 mm (severest pain conceivable)."}],"start_date":"December 2007","primary_completion_date":"October 2008","completion_date":"October 2008","first_posted":"March 27, 2008","results_first_posted":"May 21, 2013","last_update_posted":"June 13, 2013"},{"nctid":"NCT01165281","version_a":36,"version_b":37,"version_a_date":"2013-04-08","version_b_date":"2013-12-13","pom_a":[{"label":"1.","content":"The average pain intensity score using an 11 point numerical rating scale (NRS)[ Time Frame: Change from baseline to the last 3 days of study drug administration ]"}],"pom_b":[{"label":"1.","content":"Change From Baseline to the Last 3 Days of Study Drug Administration (Last Observation Carried Forward) in the Score for Average Pain Intensity on an 11-point Numerical Rating Scale[ Time Frame: Baseline, Last 3 Days of Study Drug Administration (4 weeks) ]The patients recorded their average pain intensity over the past 24 hours once daily in the evening and at the same time as much as possible (eg, 10:00 PM) throughout the study in response to the following question: \\"What has your average pain level been for the past 24 hours, where 0=no pain and 10=pain as bad as you can imagine.\\" The score at 3 days before the completion of study drug administration was defined as the average pain intensity score averaged over the last 3 days before completion of study drug administration."}],"start_date":"August 2010","primary_completion_date":"August 2012","completion_date":"August 2012","first_posted":"July 19, 2010","results_first_posted":"January 15, 2014","last_update_posted":"July 21, 2017"},{"nctid":"NCT02604342","version_a":13,"version_b":14,"version_a_date":"2016-11-01","version_b_date":"2017-03-14","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS)[ Time Frame: Baseline until disease progression or death (up to 24 months) ]"}],"pom_b":[{"label":"1.","content":"PFS Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator[ Time Frame: Baseline until disease progression or death (assessed at every 6 weeks, up to 24 months) ]"}],"start_date":"November 3, 2015","primary_completion_date":"January 26, 2017","completion_date":"August 13, 2018","first_posted":"November 13, 2015","results_first_posted":"February 26, 2018","last_update_posted":"October 29, 2019"},{"nctid":"NCT02604342","version_a":18,"version_b":19,"version_a_date":"2017-12-12","version_b_date":"2018-01-24","pom_a":[{"label":"1.","content":"PFS Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator[ Time Frame: Baseline until disease progression or death (assessed at every 6 weeks, up to 24 months) ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator[ Time Frame: Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD) ]PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions."}],"start_date":"November 3, 2015","primary_completion_date":"January 26, 2017","completion_date":"August 13, 2018","first_posted":"November 13, 2015","results_first_posted":"February 26, 2018","last_update_posted":"October 29, 2019"},{"nctid":"NCT02604342","version_a":22,"version_b":23,"version_a_date":"2018-10-22","version_b_date":"2019-10-07","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator[ Time Frame: Approximately 15 months (Tumor assessments at baseline, every 6 weeks until progressive disease (PD), death or withdrawal from study prior to PD) ]PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator[ Time Frame: Randomization to first documented disease progression, death from any cause, or study end (up to 33 months) ]PFS was defined as the time from randomization to the first documented disease progression, as determined using RECIST v1.1, or death from any cause, whichever occurred first. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions."}],"start_date":"November 3, 2015","primary_completion_date":"January 26, 2017","completion_date":"August 13, 2018","first_posted":"November 13, 2015","results_first_posted":"February 26, 2018","last_update_posted":"October 29, 2019"},{"nctid":"NCT00676650","version_a":90,"version_b":91,"version_a_date":"2012-01-13","version_b_date":"2013-02-05","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: 18 months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Baseline up to 32 months ]OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4."}],"start_date":"July 2008","primary_completion_date":"December 2011","completion_date":"December 2011","first_posted":"May 13, 2008","results_first_posted":"March 8, 2013","last_update_posted":"March 8, 2013"},{"nctid":"NCT04162210","version_a":24,"version_b":25,"version_a_date":"2022-01-14","version_b_date":"2022-02-25","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 20 months ]PFS, defined as the time from the date of randomization until the earliest date of documented disease progression (according to International Myeloma Working Group [IMWG] Response Criteria) or death due to any cause"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 20 months ]PFS is defined as the time from the date of randomization until the earliest date of documented disease progression (according to International Myeloma Working Group [IMWG] Response Criteria) or death due to any cause."}],"start_date":"April 2, 2020","primary_completion_date":"August 22, 2022","completion_date":"March 28, 2025","first_posted":"November 14, 2019","last_update_posted":"August 24, 2022"},{"nctid":"NCT04162210","version_a":25,"version_b":26,"version_a_date":"2022-02-25","version_b_date":"2022-08-21","pom_a":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 20 months ]PFS is defined as the time from the date of randomization until the earliest date of documented disease progression (according to International Myeloma Working Group [IMWG] Response Criteria) or death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS)[ Time Frame: Up to 25 months ]PFS is defined as the time from the date of randomization until the earliest date of documented disease progression (according to International Myeloma Working Group [IMWG] Response Criteria) or death due to any cause."}],"start_date":"April 2, 2020","primary_completion_date":"August 22, 2022","completion_date":"March 28, 2025","first_posted":"November 14, 2019","last_update_posted":"August 24, 2022"},{"nctid":"NCT00948428","version_a":3,"version_b":4,"version_a_date":"2019-07-02","version_b_date":"2020-09-02","pom_a":[{"label":"1.","content":"Primary - Proportion of subjects in each treatment group with Complete Clearance of AK lesions.[ Time Frame: 8-weeks post-treatment (Week 24, Test-of-Cure/TOC) visit. ]"}],"pom_b":[{"label":"1.","content":"Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24)[ Time Frame: Week 24 ]"}],"start_date":"May 2008","primary_completion_date":"March 2009","completion_date":"April 2009","first_posted":"July 29, 2009","results_first_posted":"September 4, 2020","last_update_posted":"September 4, 2020"},{"nctid":"NCT00528424","version_a":5,"version_b":6,"version_a_date":"2009-05-27","version_b_date":"2010-09-24","pom_a":[{"label":"1.","content":"Clinical success of each treated joint[ Time Frame: Within 30 days after the last injection ]"}],"pom_b":[{"label":"1.","content":"Reduction in Contracture to 5\xb0 or Less[ Time Frame: Within 30 days after the last injection ]The Primary Outcome Measure is the percentage of 320 joints that were successfully treated where \\"successfully treated\\" was defined as reduction in contracture to 5\xb0 or less."}],"start_date":"December 2007","primary_completion_date":"November 2008","completion_date":"November 2008","first_posted":"September 12, 2007","results_first_posted":"October 22, 2010","last_update_posted":"December 2, 2017"},{"nctid":"NCT00528424","version_a":12,"version_b":13,"version_a_date":"2017-09-07","version_b_date":"2017-10-26","pom_a":[{"label":"1.","content":"Reduction in Contracture to 5\xb0 or Less[ Time Frame: Within 30 days after the last injection ]The Primary Outcome Measure is the percentage of 320 joints that were successfully treated where \\"successfully treated\\" was defined as reduction in contracture to 5\xb0 or less."}],"pom_b":[{"label":"1.","content":"Reduction in Contracture to 5\xb0 or Less[ Time Frame: Within 30 days after last injection ]Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5\xb0 of normal within 30 days of injection."}],"start_date":"December 2007","primary_completion_date":"November 2008","completion_date":"November 2008","first_posted":"September 12, 2007","results_first_posted":"October 22, 2010","last_update_posted":"December 2, 2017"},{"nctid":"NCT00950001","version_a":16,"version_b":17,"version_a_date":"2015-01-12","version_b_date":"2015-07-14","pom_a":[{"label":"1.","content":"Time to Local Recurrence (TTLR)[ Time Frame: Differences in TTLR will be monitored at 3 timepoints and will take place: 1) after a total of 39 events occur; 2) after 77 events occur; and 3) after at least 115 events occur. ]"}],"pom_b":[{"label":"1.","content":"Time to Local Recurrence (TTLR)[ Time Frame: MRI of brain 5-8 weeks after surgery, every 6-9 weeks for a year and then every 3-4 months for a year, then every 6 months till recurrance ]Primary analysis for TTLR is intent to treat analysis that A) will include all randomized patients; B) preserve the original treatment assignment; and C) is based on the stratified log-rank test."}],"start_date":"August 13, 2009","primary_completion_date":"August 31, 2020","completion_date":"August 31, 2020","first_posted":"July 31, 2009","last_update_posted":"January 2, 2020"},{"nctid":"NCT00950001","version_a":17,"version_b":18,"version_a_date":"2015-07-14","version_b_date":"2016-01-14","pom_a":[{"label":"1.","content":"Time to Local Recurrence (TTLR)[ Time Frame: MRI of brain 5-8 weeks after surgery, every 6-9 weeks for a year and then every 3-4 months for a year, then every 6 months till recurrance ]Primary analysis for TTLR is intent to treat analysis that A) will include all randomized patients; B) preserve the original treatment assignment; and C) is based on the stratified log-rank test."}],"pom_b":[{"label":"1.","content":"Time to Local Recurrence (TTLR)[ Time Frame: MRI of brain 5-8 weeks after surgery, every 6-9 weeks for a year and then every 3-4 months for a year, then every 6 months till recurrence ]Primary analysis for TTLR is intent to treat analysis that A) will include all randomized patients; B) preserve the original treatment assignment; and C) is based on the stratified log-rank test."}],"start_date":"August 13, 2009","primary_completion_date":"August 31, 2020","completion_date":"August 31, 2020","first_posted":"July 31, 2009","last_update_posted":"January 2, 2020"},{"nctid":"NCT00950001","version_a":22,"version_b":23,"version_a_date":"2018-02-26","version_b_date":"2019-05-29","pom_a":[{"label":"1.","content":"Time to Local Recurrence (TTLR)[ Time Frame: MRI of brain 5-8 weeks after surgery, every 6-9 weeks for a year and then every 3-4 months for a year, then every 6 months till recurrence ]Primary analysis for TTLR is intent to treat analysis that A) will include all randomized patients; B) preserve the original treatment assignment; and C) is based on the stratified log-rank test."}],"pom_b":[{"label":"1.","content":"Time to local recurrence[ Time Frame: 6 months ]A univariate test between groups will be conducted using a log rank test of Kaplan-Meier survival estimates and multivariate analyses will be conducted via the Cox proportional hazards model. The hazard ratio comparing each arm will be computed for each endpoint with and without adjustment for other covariates. Confidence intervals (95%) will be computed for the hazard ratio estimates. The proportion of patients experiencing neurological complications will be computed via univariate and multivariate logistic regression analysis."}],"start_date":"August 13, 2009","primary_completion_date":"August 31, 2020","completion_date":"August 31, 2020","first_posted":"July 31, 2009","last_update_posted":"January 2, 2020"},{"nctid":"NCT04161885","version_a":1,"version_b":2,"version_a_date":"2019-11-11","version_b_date":"2020-01-16","pom_a":[{"label":"1.","content":"Relapse-Free Survival (RFS)[ Time Frame: Up to 39 months after the first participant is randomized ]RFS is defined as the number of days from randomization to the date of relapse or the date of death from any cause, whichever comes first."}],"pom_b":[{"label":"1.","content":"Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)[ Time Frame: Upto the first treatment cycle (28 days) ]DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax and AZA as described in the protocol and evaluated by the Investigator and the sponsor."},{"label":"2.","content":"Relapse-Free Survival (RFS) (Part 2)[ Time Frame: Up to 39 months after the first participant is randomized ]RFS is defined as the number of days from randomization to the date of relapse or the date of death from any cause, whichever comes first."}],"start_date":"February 26, 2020","primary_completion_date":"September 3, 2025","completion_date":"December 11, 2025","first_posted":"November 13, 2019","last_update_posted":"September 2, 2022"},{"nctid":"NCT00331773","version_a":17,"version_b":18,"version_a_date":"2006-10-25","version_b_date":"2006-11-09","pom_a":[],"pom_b":[{"label":"1.","content":"Disease-free survival at 5 years as measured by Kaplan-Meier"}],"start_date":"April 2006","primary_completion_date":"July 2015","first_posted":"May 31, 2006","results_first_posted":"April 13, 2017","last_update_posted":"May 13, 2022"},{"nctid":"NCT00331773","version_a":341,"version_b":342,"version_a_date":"2012-08-03","version_b_date":"2014-05-16","pom_a":[{"label":"1.","content":"Disease-free survival at 5 years as measured by Kaplan-Meier"}],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: From randomization to date of disease-free failure event, defined as local progression, distant progression, or biochemical failure, or last follow-up. ]"}],"start_date":"April 2006","primary_completion_date":"July 2015","first_posted":"May 31, 2006","results_first_posted":"April 13, 2017","last_update_posted":"May 13, 2022"},{"nctid":"NCT00331773","version_a":346,"version_b":347,"version_a_date":"2016-03-03","version_b_date":"2017-02-28","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: From randomization to date of disease-free failure event, defined as local progression, distant progression, or biochemical failure, or last follow-up. ]"}],"pom_b":[{"label":"1.","content":"Five-year Disease-free Survival (DFS) Rate[ Time Frame: Analysis occurs after all patients have been followed for five years. ]Five-year rates are estimated by the Kaplan-Meier method. DFS events included local progression, distant metastatic progression, biochemical recurrence as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, or death from any cause. Patients who experienced second primary cancers remained under observation for DFS events."}],"start_date":"April 2006","primary_completion_date":"July 2015","first_posted":"May 31, 2006","results_first_posted":"April 13, 2017","last_update_posted":"May 13, 2022"},{"nctid":"NCT00788697","version_a":11,"version_b":12,"version_a_date":"2014-08-19","version_b_date":"2017-05-17","pom_a":[{"label":"1.","content":"To demonstrate the Sensitivity and Specificity of SonoVue-enhanced US is superior to unenhanced US for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging clinical data as truth standard.[ Time Frame: 6 months ]"}],"pom_b":[{"label":"1.","content":"Sensitivity[ Time Frame: 24 hours to 6 months ]Sensitivity of SonoVue-enhanced versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Truth standard: contrast-enhanced (CE) CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100."},{"label":"2.","content":"Specificity[ Time Frame: 24 hours to 6 months ]Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100."}],"start_date":"September 2009","primary_completion_date":"July 2013","completion_date":"July 2013","first_posted":"November 11, 2008","results_first_posted":"June 14, 2017","last_update_posted":"December 12, 2017"},{"nctid":"NCT00788697","version_a":12,"version_b":13,"version_a_date":"2017-05-17","version_b_date":"2017-09-20","pom_a":[{"label":"1.","content":"Sensitivity[ Time Frame: 24 hours to 6 months ]Sensitivity of SonoVue-enhanced versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Truth standard: contrast-enhanced (CE) CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100."},{"label":"2.","content":"Specificity[ Time Frame: 24 hours to 6 months ]Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized. Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100."}],"pom_b":[{"label":"1.","content":"Sensitivity[ Time Frame: 24 hours to 6 months ]Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.Among the 240 ITD participants, only 124 participants (lesions) were malignant based on the truth standard.Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100."},{"label":"2.","content":"Specificity[ Time Frame: 24 hours to 6 months ]Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.Among the 240 ITD participants, only 116 participants (lesions) were benign based on the truth standard.Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100."}],"start_date":"September 2009","primary_completion_date":"July 2013","completion_date":"July 2013","first_posted":"November 11, 2008","results_first_posted":"June 14, 2017","last_update_posted":"December 12, 2017"},{"nctid":"NCT00788697","version_a":13,"version_b":14,"version_a_date":"2017-09-20","version_b_date":"2017-11-13","pom_a":[{"label":"1.","content":"Sensitivity[ Time Frame: 24 hours to 6 months ]Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.Among the 240 ITD participants, only 124 participants (lesions) were malignant based on the truth standard.Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100."},{"label":"2.","content":"Specificity[ Time Frame: 24 hours to 6 months ]Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.Among the 240 ITD participants, only 116 participants (lesions) were benign based on the truth standard.Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100."}],"pom_b":[{"label":"1.","content":"Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard[ Time Frame: 24 hours to 6 months ]Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs), using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-Diagnose (ITD) population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.Truth standard: contrast-enhanced computed tomography (CE CT) and /or contrast-enhanced magnetic resonance imaging (CE-MRI) examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100."},{"label":"2.","content":"Specificity: Percentage of True Negative Lesions Among All Malignant Lesions Per Truth Standard[ Time Frame: 24 hours to 6 months ]Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.True negative: subject with a target lesion characterized as benign by both ultrasonography and the truth standard.Truth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100."}],"start_date":"September 2009","primary_completion_date":"July 2013","completion_date":"July 2013","first_posted":"November 11, 2008","results_first_posted":"June 14, 2017","last_update_posted":"December 12, 2017"},{"nctid":"NCT00402779","version_a":3,"version_b":4,"version_a_date":"2007-06-27","version_b_date":"2007-12-26","pom_a":[{"label":"1.","content":"This study will test the ability of an EGFR inhibitor (erlotinib) to reduce the incidence of oral cancer in the high-risk setting of oral leukoplakia with LOH in two cohorts, oral IEN (Intraepithelial neoplasia) pts."}],"pom_b":[{"label":"1.","content":"This study will test the ability of an EGFR inhibitor (erlotinib) to reduce the incidence of oral cancer in the high-risk setting of oral leukoplakia with LOH in two cohorts, oral IEN (Intraepithelial neoplasia) pts.[ Time Frame: Study period will be 4.5 years. Interim analyses will be conducted at the ends of year 2.5 and year 3.5, and the final analysis will be done at the end of year 4.5. ]"}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":7,"version_b":8,"version_a_date":"2008-10-08","version_b_date":"2008-10-24","pom_a":[{"label":"1.","content":"This study will test the ability of an EGFR inhibitor (erlotinib) to reduce the incidence of oral cancer in the high-risk setting of oral leukoplakia with LOH in two cohorts, oral IEN (Intraepithelial neoplasia) pts.[ Time Frame: Study period will be 4.5 years. Interim analyses will be conducted at the ends of year 2.5 and year 3.5, and the final analysis will be done at the end of year 4.5. ]"}],"pom_b":[{"label":"1.","content":"To learn if erlotinib hydrochloride (Tarceva/OSI-774) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth.[ Time Frame: 3 years ]"}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":9,"version_b":10,"version_a_date":"2009-05-01","version_b_date":"2009-07-14","pom_a":[{"label":"1.","content":"To learn if erlotinib hydrochloride (Tarceva/OSI-774) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth.[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Months 1, 3, 6, 9, and 12 ]"}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":11,"version_b":12,"version_a_date":"2009-12-28","version_b_date":"2010-06-03","pom_a":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Months 1, 3, 6, 9, and 12 ]"}],"pom_b":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Every 3 Months ]"}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":24,"version_b":25,"version_a_date":"2013-10-14","version_b_date":"2014-10-14","pom_a":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Every 3 Months ]"}],"pom_b":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Every 3 Months ]Cancer-free survival defined as time from randomization to the development of histologically confirmed oral cancer."}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":26,"version_b":27,"version_a_date":"2014-11-03","version_b_date":"2015-03-10","pom_a":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: Every 3 Months ]Cancer-free survival defined as time from randomization to the development of histologically confirmed oral cancer."}],"pom_b":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: 3 Months ]Cancer-free survival defined as time from randomization to the development of histologically confirmed oral cancer."}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT00402779","version_a":32,"version_b":33,"version_a_date":"2019-01-10","version_b_date":"2020-04-13","pom_a":[{"label":"1.","content":"Oral cancer-free survival[ Time Frame: 3 Months ]Cancer-free survival defined as time from randomization to the development of histologically confirmed oral cancer."}],"pom_b":[{"label":"1.","content":"Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group.[ Time Frame: 3 years ]Cancer-free survival defined as time from randomization to the development of histologically confirmed oral cancer."}],"start_date":"November 3, 2006","primary_completion_date":"June 4, 2018","completion_date":"June 4, 2018","first_posted":"November 22, 2006","results_first_posted":"April 21, 2020","last_update_posted":"April 21, 2020"},{"nctid":"NCT01243944","version_a":22,"version_b":23,"version_a_date":"2012-03-13","version_b_date":"2012-04-05","pom_a":[{"label":"1.","content":"Proportion of subjects achieving a response at Week 32. \'Response\' is defined as having achieved both: (1) the absence of protocol-defined phlebotomy eligibility and (2) a \u2265 35% reduction from baseline in spleen volume as determined by imaging[ Time Frame: 32 weeks ]"}],"pom_b":[{"label":"1.","content":"Compare efficacy of INC424 to best available therapy as measured by spleen volume.[ Time Frame: Baseline through Week 24. ]"},{"label":"2.","content":"Compare efficacy of INC424 to best available therapy as measured by laboratory assessments.[ Time Frame: Baseline through Week 32. ]"}],"start_date":"October 27, 2010","primary_completion_date":"January 15, 2014","completion_date":"February 9, 2018","first_posted":"November 19, 2010","results_first_posted":"March 6, 2015","last_update_posted":"March 6, 2019"},{"nctid":"NCT01243944","version_a":23,"version_b":24,"version_a_date":"2012-04-05","version_b_date":"2012-04-11","pom_a":[{"label":"1.","content":"Compare efficacy of INC424 to best available therapy as measured by spleen volume.[ Time Frame: Baseline through Week 24. ]"},{"label":"2.","content":"Compare efficacy of INC424 to best available therapy as measured by laboratory assessments.[ Time Frame: Baseline through Week 32. ]"}],"pom_b":[{"label":"1.","content":"Compare efficacy of INC424 to best available therapy as measured by spleen volume.[ Time Frame: Baseline through Week 32. ]"},{"label":"2.","content":"Compare efficacy of INC424 to best available therapy as measured by phlebotomy assessments.[ Time Frame: Baseline through Week 32. ]"}],"start_date":"October 27, 2010","primary_completion_date":"January 15, 2014","completion_date":"February 9, 2018","first_posted":"November 19, 2010","results_first_posted":"March 6, 2015","last_update_posted":"March 6, 2019"},{"nctid":"NCT01243944","version_a":24,"version_b":25,"version_a_date":"2012-04-11","version_b_date":"2012-04-16","pom_a":[{"label":"1.","content":"Compare efficacy of INC424 to best available therapy as measured by spleen volume.[ Time Frame: Baseline through Week 32. ]"},{"label":"2.","content":"Compare efficacy of INC424 to best available therapy as measured by phlebotomy assessments.[ Time Frame: Baseline through Week 32. ]"}],"pom_b":[{"label":"1.","content":"To compare the efficacy of INC424 to Best Available Therapy as assessed by both the absence of phlebotomy eligibility and reduction in spleen volume.[ Time Frame: 32 Weeks ]"}],"start_date":"October 27, 2010","primary_completion_date":"January 15, 2014","completion_date":"February 9, 2018","first_posted":"November 19, 2010","results_first_posted":"March 6, 2015","last_update_posted":"March 6, 2019"},{"nctid":"NCT01243944","version_a":34,"version_b":35,"version_a_date":"2014-03-12","version_b_date":"2015-02-19","pom_a":[{"label":"1.","content":"To compare the efficacy of INC424 to Best Available Therapy as assessed by both the absence of phlebotomy eligibility and reduction in spleen volume.[ Time Frame: 32 Weeks ]"}],"pom_b":[{"label":"1.","content":"The Percentage of Subjects Achieving a Primary Response at Week 32[ Time Frame: 32 Weeks ]Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32)."}],"start_date":"October 27, 2010","primary_completion_date":"January 15, 2014","completion_date":"February 9, 2018","first_posted":"November 19, 2010","results_first_posted":"March 6, 2015","last_update_posted":"March 6, 2019"},{"nctid":"NCT01243944","version_a":44,"version_b":45,"version_a_date":"2018-11-27","version_b_date":"2019-02-08","pom_a":[{"label":"1.","content":"The Percentage of Subjects Achieving a Primary Response at Week 32[ Time Frame: 32 Weeks ]Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32)."}],"pom_b":[{"label":"1.","content":"The Percentage of Participants Achieving a Primary Response at Week 32[ Time Frame: 32 Weeks ]Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32)."}],"start_date":"October 27, 2010","primary_completion_date":"January 15, 2014","completion_date":"February 9, 2018","first_posted":"November 19, 2010","results_first_posted":"March 6, 2015","last_update_posted":"March 6, 2019"},{"nctid":"NCT00339183","version_a":37,"version_b":38,"version_a_date":"2008-03-06","version_b_date":"2008-04-10","pom_a":[{"label":"1.","content":"Efficacy: Overall Survival (OS) and progression-free survival (PFS)"}],"pom_b":[{"label":"1.","content":"Efficacy: Overall Survival (OS) and progression-free survival (PFS)[ Time Frame: PFS results in Oct 2008, OS results Sep 2010 ]"}],"start_date":"June 30, 2006","primary_completion_date":"April 1, 2009","completion_date":"November 1, 2010","first_posted":"June 20, 2006","results_first_posted":"May 6, 2014","last_update_posted":"August 31, 2018"},{"nctid":"NCT00339183","version_a":61,"version_b":62,"version_a_date":"2010-07-01","version_b_date":"2010-07-15","pom_a":[{"label":"1.","content":"Efficacy: Overall Survival (OS) and progression-free survival (PFS)[ Time Frame: PFS results in Oct 2008, OS results Sep 2010 ]"}],"pom_b":[],"start_date":"June 30, 2006","primary_completion_date":"April 1, 2009","completion_date":"November 1, 2010","first_posted":"June 20, 2006","results_first_posted":"May 6, 2014","last_update_posted":"August 31, 2018"},{"nctid":"NCT00339183","version_a":79,"version_b":80,"version_a_date":"2013-06-13","version_b_date":"2014-04-03","pom_a":[],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months. ]Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.Progressive disease is defined as a \u2265 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions."},{"label":"2.","content":"Overall Survival[ Time Frame: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months ]Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date."}],"start_date":"June 30, 2006","primary_completion_date":"April 1, 2009","completion_date":"November 1, 2010","first_posted":"June 20, 2006","results_first_posted":"May 6, 2014","last_update_posted":"August 31, 2018"},{"nctid":"NCT00057343","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2005-09-12","pom_a":[],"pom_b":[{"label":"1.","content":"Event-free survival"}],"start_date":"March 2003","first_posted":"April 1, 2003","last_update_posted":"September 12, 2006"},{"nctid":"NCT00433589","version_a":20,"version_b":21,"version_a_date":"2011-11-08","version_b_date":"2013-01-10","pom_a":[{"label":"1.","content":"Distant metastasis-free survival at 5 years"},{"label":"2.","content":"Disease-free survival (DFS)"}],"pom_b":[{"label":"1.","content":"Distant metastasis-free survival at 5 years[ Time Frame: from enrollment/randomization ]"},{"label":"2.","content":"Disease-free survival (DFS)[ Time Frame: from enrollment/randomization ]"}],"start_date":"February 2007","primary_completion_date":"March 2020","completion_date":"October 2022","first_posted":"February 12, 2007","last_update_posted":"April 1, 2022"},{"nctid":"NCT00433589","version_a":25,"version_b":26,"version_a_date":"2019-06-14","version_b_date":"2022-03-21","pom_a":[{"label":"1.","content":"Distant metastasis-free survival at 5 years[ Time Frame: from enrollment/randomization ]"},{"label":"2.","content":"Disease-free survival (DFS)[ Time Frame: from enrollment/randomization ]"}],"pom_b":[{"label":"1.","content":"Distant metastasis-free survival at 5 years[ Time Frame: from enrollment/randomization ]o The primary endpoint for chemotherapy versus no chemotherapy (R-T) is that the 5-year distant metastasis free survival (DMFS) of 92% will be tested (a one-sided test)."},{"label":"2.","content":"Disease-free survival (DFS)[ Time Frame: from enrollment/randomization ]o The primary endpoint for the chemotherapy randomization (R-C) is disease free survival (DFS)."},{"label":"3.","content":"DFS[ Time Frame: from enrollment/randomization ]The primary test for the endocrine randomization (R-E) is DFS."}],"start_date":"February 2007","primary_completion_date":"March 2020","completion_date":"October 2022","first_posted":"February 12, 2007","last_update_posted":"April 1, 2022"},{"nctid":"NCT03686215","version_a":4,"version_b":5,"version_a_date":"2019-05-10","version_b_date":"2019-10-10","pom_a":[{"label":"1.","content":"Proportion of LUM Imaging System detection of cancer in the cavity in subjects with pathology-positive margins after standard of care breast-conserving surgery[ Time Frame: 10-14 days ]Positive Margin Population: Lumicell imaged subjects with positive margins by pathology of the outermost SOC specimen prior to any use of Lumicell imaging without any major protocol violations."}],"pom_b":[{"label":"1.","content":"Ratio of patients who have residual cancer found in at least one Lumicell guided shave among all patients.[ Time Frame: 10-14 days ]Residual cancer is defined as tumor found by pathology in a therapeutic shave after the SOC surgical procedure is completed; that is, tumor that current SOC surgery failed to remove."},{"label":"2.","content":"Sensitivity and specificity on a per-tissue basis[ Time Frame: 1 day ]Instrument diagnostic accuracy"}],"start_date":"November 4, 2019","primary_completion_date":"December 9, 2021","completion_date":"December 2022","first_posted":"September 26, 2018","last_update_posted":"August 16, 2022"},{"nctid":"NCT04221945","version_a":35,"version_b":36,"version_a_date":"2020-12-30","version_b_date":"2021-01-15","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)[ Time Frame: Up to approximately 38 months ]PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of disease progression, PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 46 months ]OS is the time from randomization to death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator[ Time Frame: Up to approximately 38 months ]PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of disease progression, PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 46 months ]OS is the time from randomization to death due to any cause."}],"start_date":"May 12, 2020","primary_completion_date":"February 7, 2024","completion_date":"December 7, 2024","first_posted":"January 9, 2020","last_update_posted":"September 16, 2022"},{"nctid":"NCT04221945","version_a":54,"version_b":55,"version_a_date":"2021-06-04","version_b_date":"2021-06-15","pom_a":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator[ Time Frame: Up to approximately 38 months ]PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of disease progression, PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 46 months ]OS is the time from randomization to death due to any cause."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator[ Time Frame: Up to approximately 38 months ]PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, or by histopathologic confirmation of suspected disease progression, PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. Unequivocal progression of non-target lesions is also considered PD."},{"label":"2.","content":"Overall Survival (OS)[ Time Frame: Up to approximately 46 months ]OS is the time from randomization to death due to any cause."}],"start_date":"May 12, 2020","primary_completion_date":"February 7, 2024","completion_date":"December 7, 2024","first_posted":"January 9, 2020","last_update_posted":"September 16, 2022"},{"nctid":"NCT00091169","version_a":35,"version_b":36,"version_a_date":"2006-12-20","version_b_date":"2006-12-27","pom_a":[],"pom_b":[{"label":"1.","content":"Change in average daily fatigue as assessed by the Brief Fatigue Inventory (BFI) from baseline to 4 weeks"}],"start_date":"November 2005","primary_completion_date":"March 2008","completion_date":"May 2011","first_posted":"September 8, 2004","results_first_posted":"May 30, 2016","last_update_posted":"May 30, 2016"},{"nctid":"NCT00091169","version_a":81,"version_b":82,"version_a_date":"2012-10-26","version_b_date":"2016-05-03","pom_a":[{"label":"1.","content":"Change in average daily fatigue as assessed by the Brief Fatigue Inventory (BFI) from baseline to 4 weeks"}],"pom_b":[{"label":"1.","content":"Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks[ Time Frame: assessed at baseline and 4 weeks after randomization ]Fatigue was measured using Brief Fatigue Inventory (BFI). The average of all 9 items included in the scale (range: 0-10) was used to measure fatigue level, and a higher average represented worse fatigue. Score change= BFI score at 4 weeks - BFI score at baseline."}],"start_date":"November 2005","primary_completion_date":"March 2008","completion_date":"May 2011","first_posted":"September 8, 2004","results_first_posted":"May 30, 2016","last_update_posted":"May 30, 2016"},{"nctid":"NCT00117286","version_a":5,"version_b":6,"version_a_date":"2008-07-10","version_b_date":"2009-05-25","pom_a":[{"label":"1.","content":"To demonstrate the efficacy of degarelix to evaluate safety and tolerability"}],"pom_b":[{"label":"1.","content":"Assessments of Safety and tolerability[ Time Frame: duration of study (study to continue until intervention is approved) ]"}],"start_date":"March 2005","primary_completion_date":"September 2009","completion_date":"November 2009","first_posted":"July 6, 2005","results_first_posted":"October 21, 2010","last_update_posted":"October 21, 2010"},{"nctid":"NCT00117286","version_a":8,"version_b":9,"version_a_date":"2010-02-09","version_b_date":"2010-09-29","pom_a":[{"label":"1.","content":"Assessments of Safety and tolerability[ Time Frame: duration of study (study to continue until intervention is approved) ]"}],"pom_b":[{"label":"1.","content":"Participants With Markedly Abnormal Change in Vital Signs and Body Weight[ Time Frame: 5 years ]This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline."},{"label":"2.","content":"Liver Function Tests[ Time Frame: 5 years ]The figures present the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases >3x ULN and ALT increases >3x ULN with concurrently increased bilirubin >1.5 ULN."}],"start_date":"March 2005","primary_completion_date":"September 2009","completion_date":"November 2009","first_posted":"July 6, 2005","results_first_posted":"October 21, 2010","last_update_posted":"October 21, 2010"},{"nctid":"NCT00060320","version_a":22,"version_b":23,"version_a_date":"2009-05-09","version_b_date":"2015-07-07","pom_a":[],"pom_b":[{"label":"1.","content":"Hot flash activity[ Time Frame: Up to 3.5 years ]"}],"start_date":"October 2003","primary_completion_date":"June 2006","completion_date":"June 2006","first_posted":"May 7, 2003","last_update_posted":"July 13, 2016"},{"nctid":"NCT01651000","version_a":16,"version_b":17,"version_a_date":"2016-06-08","version_b_date":"2016-07-08","pom_a":[{"label":"1.","content":"Changes of at least 30% in plasma iPTH from pretreatment baseline[ Time Frame: Approximately 6 months ]Primary Objectives:The primary objectives of this study are:To evaluate the efficacy of CTAP101 Capsules versus placebo in reducing plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline"},{"label":"2.","content":"Changes in safety and tolerability to CTAP101 capsules[ Time Frame: Approximately 6 months ]To investigate the safety and tolerability of CTAP101 Capsules through changes in adverse events, physical examinations,vital signs, clinical laboratory tests, vital signs, and 12-lead ECGs"}],"pom_b":[{"label":"1.","content":"Decrease in Plasma Intact Parathyroid Hormone (iPTH) From Pre-treatment Baseline of \u226530%[ Time Frame: Approximately 6 months ]Number and percent (n, %) of subjects attaining a mean decrease in plasma intact parathyroid hormone (iPTH) from pre-treatment baseline of \u226530% in the efficacy assessment phase (EAP), referred to as responders."}],"start_date":"September 2012","primary_completion_date":"July 2014","completion_date":"July 2014","first_posted":"July 26, 2012","results_first_posted":"August 17, 2016","last_update_posted":"December 18, 2019"},{"nctid":"NCT01651000","version_a":17,"version_b":18,"version_a_date":"2016-07-08","version_b_date":"2016-08-22","pom_a":[{"label":"1.","content":"Decrease in Plasma Intact Parathyroid Hormone (iPTH) From Pre-treatment Baseline of \u226530%[ Time Frame: Approximately 6 months ]Number and percent (n, %) of subjects attaining a mean decrease in plasma intact parathyroid hormone (iPTH) from pre-treatment baseline of \u226530% in the efficacy assessment phase (EAP), referred to as responders."}],"pom_b":[{"label":"1.","content":"Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of \u226530% From Pre-treatment Baseline Values[ Time Frame: Approximately 6 months ]Number of subjects in the intent to treat population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of \u226530% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders."}],"start_date":"September 2012","primary_completion_date":"July 2014","completion_date":"July 2014","first_posted":"July 26, 2012","results_first_posted":"August 17, 2016","last_update_posted":"December 18, 2019"},{"nctid":"NCT00123487","version_a":3,"version_b":4,"version_a_date":"2005-08-25","version_b_date":"2005-09-09","pom_a":[],"pom_b":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib"}],"start_date":"June 2005","primary_completion_date":"November 2006","completion_date":"June 2013","first_posted":"July 25, 2005","results_first_posted":"October 22, 2014","last_update_posted":"November 2, 2014"},{"nctid":"NCT00123487","version_a":19,"version_b":20,"version_a_date":"2007-11-26","version_b_date":"2007-12-11","pom_a":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib"}],"pom_b":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib[ Time Frame: throughout the study ]"}],"start_date":"June 2005","primary_completion_date":"November 2006","completion_date":"June 2013","first_posted":"July 25, 2005","results_first_posted":"October 22, 2014","last_update_posted":"November 2, 2014"},{"nctid":"NCT00123487","version_a":46,"version_b":47,"version_a_date":"2009-09-22","version_b_date":"2009-09-28","pom_a":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib[ Time Frame: throughout the study ]"}],"pom_b":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib[ Time Frame: 81 months ]"}],"start_date":"June 2005","primary_completion_date":"November 2006","completion_date":"June 2013","first_posted":"July 25, 2005","results_first_posted":"October 22, 2014","last_update_posted":"November 2, 2014"},{"nctid":"NCT00123487","version_a":110,"version_b":111,"version_a_date":"2014-01-22","version_b_date":"2014-10-16","pom_a":[{"label":"1.","content":"To estimate the Complete Hematological Response rate of 70 and 140 mg of BMS-354825 in patients who have primary or acquired resistance to imatinib[ Time Frame: 81 months ]"}],"pom_b":[{"label":"1.","content":"Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment[ Time Frame: Randomization up to 6 months ]MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) \u2264 upper limit of normal (ULN); absolute neutrophil count (ANC) \u2265 1,000/mm^3; platelets \u2265 100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts \u2264 5%; <5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets \u2265 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants."}],"start_date":"June 2005","primary_completion_date":"November 2006","completion_date":"June 2013","first_posted":"July 25, 2005","results_first_posted":"October 22, 2014","last_update_posted":"November 2, 2014"},{"nctid":"NCT00123487","version_a":111,"version_b":112,"version_a_date":"2014-10-16","version_b_date":"2014-10-30","pom_a":[{"label":"1.","content":"Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment[ Time Frame: Randomization up to 6 months ]MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) \u2264 upper limit of normal (ULN); absolute neutrophil count (ANC) \u2265 1,000/mm^3; platelets \u2265 100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts \u2264 5%; <5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets \u2265 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants."}],"pom_b":[{"label":"1.","content":"Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population[ Time Frame: Randomization up to 6 months ]MaHR defined by either complete hematologic response (CHR) or no evidence of leukemia (NEL). CHR defined as: white blood cells (WBC) \u2264 upper limit of normal (ULN); absolute neutrophil count (ANC) \u2265 1,000/mm^3; platelets \u2265 100,000/mm^3; no blasts or promyelocytes in peripheral blood (PB); bone marrow (BM) blasts \u2264 5%; <5% myelocytes plus metamyelocytes in PB; basophils in PB < 20%; no extra-medullar involvement (including no hepatomegaly or splenomegaly). NEL defined by same criteria as CHR except that platelets and ANC had to satisfy at least one of the following (note that both lower limits had to be satisfied): platelets \u2265 20,000/mm^3 and < 100,000/mm^3; ANC > 500/mm^3 and <1,000/mm^3. After Year 2, Amendment 3 allowed participants to switch from the BID to the QD dosing schedule. Percentage: number of participants with MaHR/number of randomized participants."}],"start_date":"June 2005","primary_completion_date":"November 2006","completion_date":"June 2013","first_posted":"July 25, 2005","results_first_posted":"October 22, 2014","last_update_posted":"November 2, 2014"},{"nctid":"NCT00674609","version_a":3,"version_b":4,"version_a_date":"2008-07-10","version_b_date":"2012-07-05","pom_a":[{"label":"1.","content":"Measure of treatment efficacy was the change in pain score from baseline to end of treatment (week 2) and the use of breakthrough medication during the last three days of test treatment use in the study.[ Time Frame: Pain - end of 2 weeks; Breakthrough Medication - last three days of test treatment ]"}],"pom_b":[{"label":"1.","content":"The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.[ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ]The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked \\"on a scale of \'0 to 10\', please indicate the number that best describes your pain or average pain in the last 24 hours\\" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline."},{"label":"2.","content":"The Consumption of Escape Analgesic Medication.[ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ]Subjects recorded their use of escape medication each day on their diary card."}],"start_date":"February 2002","primary_completion_date":"February 2004","completion_date":"March 2004","first_posted":"May 8, 2008","results_first_posted":"August 13, 2012","last_update_posted":"June 20, 2013"},{"nctid":"NCT00003906","version_a":16,"version_b":17,"version_a_date":"2009-08-10","version_b_date":"2010-04-16","pom_a":[],"pom_b":[{"label":"1.","content":"Incidence of invasive breast cancer; superiority of one of the therapies.[ Time Frame: Time from randomization to the occurance of invasive breast cancer. ]Determine which of the following is true:compared to tamoxifen, raloxifene significantly reduces the incidence rate of invasive breast cancer;compared to raloxifene, tamoxifen significantly reduces the incidence rate of invasive breast cancer; orthe statistical superiority of one of the treatments cannot be demonstrated and the choice of therapy should be based on benefit/risk considerations."}],"start_date":"May 1999","primary_completion_date":"December 2005","completion_date":"August 2012","first_posted":"January 27, 2003","last_update_posted":"October 6, 2015"},{"nctid":"NCT02453282","version_a":5,"version_b":6,"version_a_date":"2015-08-13","version_b_date":"2015-08-18","pom_a":[{"label":"1.","content":"The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS) in patients with NSCLC[ Time Frame: 12 months ]"}],"pom_b":[{"label":"1.","content":"The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS) in patients with NSCLC[ Time Frame: 3 years ]"}],"start_date":"July 21, 2015","primary_completion_date":"October 4, 2018","completion_date":"December 30, 2022","first_posted":"May 25, 2015","results_first_posted":"November 29, 2019","last_update_posted":"August 5, 2022"},{"nctid":"NCT02453282","version_a":13,"version_b":14,"version_a_date":"2016-02-23","version_b_date":"2016-05-25","pom_a":[{"label":"1.","content":"The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS) in patients with NSCLC[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS) and Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"}],"start_date":"July 21, 2015","primary_completion_date":"October 4, 2018","completion_date":"December 30, 2022","first_posted":"May 25, 2015","results_first_posted":"November 29, 2019","last_update_posted":"August 5, 2022"},{"nctid":"NCT02453282","version_a":17,"version_b":18,"version_a_date":"2016-12-14","version_b_date":"2017-01-31","pom_a":[{"label":"1.","content":"The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS) and Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"The efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Progression-Free Survival (PFS) and Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"},{"label":"2.","content":"The efficacy of durvalumab therapy compared to SoC in terms of Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"}],"start_date":"July 21, 2015","primary_completion_date":"October 4, 2018","completion_date":"December 30, 2022","first_posted":"May 25, 2015","results_first_posted":"November 29, 2019","last_update_posted":"August 5, 2022"},{"nctid":"NCT02453282","version_a":29,"version_b":30,"version_a_date":"2019-08-12","version_b_date":"2019-11-19","pom_a":[{"label":"1.","content":"The efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Progression-Free Survival (PFS) and Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"},{"label":"2.","content":"The efficacy of durvalumab therapy compared to SoC in terms of Overall Survival (OS) in patients with NSCLC[ Time Frame: 3 years ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy[ Time Frame: From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years). ]The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique."},{"label":"2.","content":"Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy[ Time Frame: Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years). ]The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique."}],"start_date":"July 21, 2015","primary_completion_date":"October 4, 2018","completion_date":"December 30, 2022","first_posted":"May 25, 2015","results_first_posted":"November 29, 2019","last_update_posted":"August 5, 2022"},{"nctid":"NCT00692770","version_a":33,"version_b":34,"version_a_date":"2012-05-02","version_b_date":"2012-07-26","pom_a":[{"label":"1.","content":"Recurrence Free Survival[ Time Frame: approximately 40 months from first patient first visit ]"}],"pom_b":[{"label":"1.","content":"Recurrence Free Survival[ Time Frame: approximately 70 months from first patient first visit ]"}],"start_date":"August 15, 2008","primary_completion_date":"November 29, 2013","completion_date":"November 28, 2014","first_posted":"June 6, 2008","results_first_posted":"December 1, 2014","last_update_posted":"August 8, 2018"},{"nctid":"NCT00692770","version_a":43,"version_b":44,"version_a_date":"2014-09-11","version_b_date":"2014-11-24","pom_a":[{"label":"1.","content":"Recurrence Free Survival[ Time Frame: approximately 70 months from first patient first visit ]"}],"pom_b":[{"label":"1.","content":"Recurrence Free Survival (RFS) by Independent Assessment[ Time Frame: From randomization up to 4 years or until disease recurrence whichever came first ]RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death."}],"start_date":"August 15, 2008","primary_completion_date":"November 29, 2013","completion_date":"November 28, 2014","first_posted":"June 6, 2008","results_first_posted":"December 1, 2014","last_update_posted":"August 8, 2018"},{"nctid":"NCT00692770","version_a":44,"version_b":45,"version_a_date":"2014-11-24","version_b_date":"2014-12-12","pom_a":[{"label":"1.","content":"Recurrence Free Survival (RFS) by Independent Assessment[ Time Frame: From randomization up to 4 years or until disease recurrence whichever came first ]RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death."}],"pom_b":[{"label":"1.","content":"Recurrence Free Survival (RFS) by Independent Assessment[ Time Frame: From randomization up to 4 years or until disease recurrence whichever came first ]Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans.RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death."}],"start_date":"August 15, 2008","primary_completion_date":"November 29, 2013","completion_date":"November 28, 2014","first_posted":"June 6, 2008","results_first_posted":"December 1, 2014","last_update_posted":"August 8, 2018"},{"nctid":"NCT00692770","version_a":48,"version_b":49,"version_a_date":"2016-03-21","version_b_date":"2017-09-13","pom_a":[{"label":"1.","content":"Recurrence Free Survival (RFS) by Independent Assessment[ Time Frame: From randomization up to 4 years or until disease recurrence whichever came first ]Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans.RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death."}],"pom_b":[{"label":"1.","content":"Recurrence Free Survival (RFS) by Independent Assessment[ Time Frame: From randomization up to 4 years or until disease recurrence whichever came first ]Disease recurrence of HCC (intra or extra hepatic) was defined as the appearance of a new intrahepatic lesions fulfilling the American Association for the Study of Liver Diseases (AASLD) criteria of diagnosis of HCC or a new extra-hepatic lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.0. In addition to investigator assessment, all images were reviewed by an independent panel of radiologists. The calculation of the RFS was based on the independent evaluation of the scans. RFS was defined as the time from randomization to the first documented disease recurrence by independent radiological assessment or death due to any cause whichever occurred first. For subjects who had not recurred or died at the time of analysis, RFS was censored at their last date of evaluable scan before drop-out for any other reason than recurrence or death."}],"start_date":"August 15, 2008","primary_completion_date":"November 29, 2013","completion_date":"November 28, 2014","first_posted":"June 6, 2008","results_first_posted":"December 1, 2014","last_update_posted":"August 8, 2018"},{"nctid":"NCT03008148","version_a":2,"version_b":3,"version_a_date":"2017-01-02","version_b_date":"2020-01-08","pom_a":[{"label":"1.","content":"Overall survival time.[ Time Frame: 120 weeks ]"}],"pom_b":[{"label":"1.","content":"Overall survival time.[ Time Frame: 120 weeks ]All subjects will be followed until study end (the date of last subject last visit; the last subject need to be followed at least 30 months) or death, whichever comes first; OS defined as the time from the date of Randomization to the date of death or last follow-up."}],"start_date":"October 11, 2018","primary_completion_date":"April 2025","completion_date":"April 2025","first_posted":"January 2, 2017","last_update_posted":"May 11, 2021"},{"nctid":"NCT03401229","version_a":23,"version_b":24,"version_a_date":"2020-07-21","version_b_date":"2020-08-27","pom_a":[{"label":"1.","content":"Effect of benralizumab on nasal polyp burden[ Time Frame: Week 56 (visit 11) ]Change from baseline in endoscopic total nasal polyp score (NPS). NPS (maximum 8) is the sum of the right and left nostril scores"},{"label":"2.","content":"Effect of benralizumab on patient reported nasal blockage (NB)[ Time Frame: Week 56 (visit 11) ]Change from baseline in mean nasal blockage score (NBS). NBS is assessed in daily diary by asking patients to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe"}],"pom_b":[{"label":"1.","content":"Effect of benralizumab on nasal polyp burden[ Time Frame: Week 40 (visit 9) ]Change from baseline in endoscopic total nasal polyp score (NPS). NPS (maximum 8) is the sum of the right and left nostril scores"},{"label":"2.","content":"Effect of benralizumab on patient-reported nasal blockage (NB)[ Time Frame: Week 40 (visit 9) ]Change from baseline in mean nasal blockage score (NBS). NBS is assessed using daily diary by asking patients to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe"}],"start_date":"January 15, 2018","primary_completion_date":"July 31, 2020","completion_date":"July 31, 2020","first_posted":"January 17, 2018","results_first_posted":"October 12, 2021","last_update_posted":"October 12, 2021"},{"nctid":"NCT03401229","version_a":24,"version_b":25,"version_a_date":"2020-08-27","version_b_date":"2021-07-27","pom_a":[{"label":"1.","content":"Effect of benralizumab on nasal polyp burden[ Time Frame: Week 40 (visit 9) ]Change from baseline in endoscopic total nasal polyp score (NPS). NPS (maximum 8) is the sum of the right and left nostril scores"},{"label":"2.","content":"Effect of benralizumab on patient-reported nasal blockage (NB)[ Time Frame: Week 40 (visit 9) ]Change from baseline in mean nasal blockage score (NBS). NBS is assessed using daily diary by asking patients to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe"}],"pom_b":[{"label":"1.","content":"Change From Baseline in Total NPS at Week 40[ Time Frame: Baseline to week 40 ]Change from baseline in total nasal polyps score (NPS) at week 40 was defined as the endpoint value at week 40 minus the baseline value. The total NPS was the sum of the right and left nostril scores and maximum total NPS is 8, as evaluated by nasal endoscopy and the left and right score were based on central read with scale from 0 to 4 where higher score reflects heavier bilateral nasal polyp burden. Baseline was the last valid value on or prior to the date of randomization. Data collected after nasal polyposis (NP) surgery and/or systemic corticosteroids for NP (SCS_NP) were set to missing. In calculation of summary statistics (mean and standard deviation), the worst-possible (WP) after NP surgery and worst-observation carried forward (WOCF) after SCS_NP were applied. In ANCOVA, a hybrid method of WP after NP surgery, WOCF after SCS_NP and multiple imputation (MI) assuming missing at random were used to build the complete imputation datasets for the analysis."},{"label":"2.","content":"Change From Baseline in NBS at Week 40[ Time Frame: Baseline to week 40 ]Change from baseline in nasal blockage score (NBS) at week 40 was defined as the endpoint value at week 40 minus the baseline value. The NBS was captured by an item in NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. The NBS and the changes from baseline were summarized every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Data collected after nasal polyposis (NP) surgery and/or systemic corticosteroids for NP (SCS_NP) were set to missing. In calculation of summary statistics (mean and standard deviation), the worst-possible (WP) after NP surgery and worst-observation carried forward (WOCF) after SCS_NP were applied. In ANCOVA, a hybrid method of the WP after NP surgery, WOCF after SCS_NP and multiple imputation (MI) assuming missing at random were used to build the complete imputation datasets for the analysis."}],"start_date":"January 15, 2018","primary_completion_date":"July 31, 2020","completion_date":"July 31, 2020","first_posted":"January 17, 2018","results_first_posted":"October 12, 2021","last_update_posted":"October 12, 2021"},{"nctid":"NCT02345850","version_a":14,"version_b":15,"version_a_date":"2021-08-30","version_b_date":"2021-11-22","pom_a":[{"label":"1.","content":"Chronic GVHD-free, relapse-free survival (CRFS) probability[ Time Frame: 2 years ]Intention-to-treating CRFS as a time to event variable."}],"pom_b":[{"label":"1.","content":"Chronic GVHD-free, Relapse-free Survival (CRFS) Probability[ Time Frame: 2 years ]The primary endpoint of the trial is Chronic GVHD/Relapse-Free Survival (CRFS), treated as a time to event variable. An event for this time to event outcome is defined as moderate to severe chronic GVHD, disease relapse, or death by any cause. Participant will be censored if lost to follow up prior to 2 years. Time is from randomization to the event of moderate to severe chronic GVHD, disease relapse, death, last follow up, or 2 years, whichever comes first. The primary analysis is performed using the intent-to-treat principle (ITT) so that all randomized patients are included in the analysis."}],"start_date":"August 2015","primary_completion_date":"October 5, 2020","completion_date":"October 5, 2020","first_posted":"January 26, 2015","results_first_posted":"December 21, 2021","last_update_posted":"December 21, 2021"},{"nctid":"NCT00424255","version_a":6,"version_b":7,"version_a_date":"2007-08-30","version_b_date":"2007-12-13","pom_a":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)"}],"pom_b":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)[ Time Frame: 1 Year ]"}],"start_date":"December 2006","primary_completion_date":"March 2013","completion_date":"November 2013","first_posted":"January 19, 2007","results_first_posted":"February 11, 2014","last_update_posted":"July 18, 2014"},{"nctid":"NCT00424255","version_a":8,"version_b":9,"version_a_date":"2008-02-12","version_b_date":"2008-02-14","pom_a":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)[ Time Frame: 1 Year ]"}],"pom_b":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)"}],"start_date":"December 2006","primary_completion_date":"March 2013","completion_date":"November 2013","first_posted":"January 19, 2007","results_first_posted":"February 11, 2014","last_update_posted":"July 18, 2014"},{"nctid":"NCT00424255","version_a":35,"version_b":36,"version_a_date":"2009-04-16","version_b_date":"2009-04-23","pom_a":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)"}],"pom_b":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)[ Time Frame: 1 Year ]"}],"start_date":"December 2006","primary_completion_date":"March 2013","completion_date":"November 2013","first_posted":"January 19, 2007","results_first_posted":"February 11, 2014","last_update_posted":"July 18, 2014"},{"nctid":"NCT00424255","version_a":63,"version_b":64,"version_a_date":"2013-07-30","version_b_date":"2013-12-19","pom_a":[{"label":"1.","content":"Disease-free survival measured by the time from the start of the study that a subject is free from disease (cancer recurrence or death from any cause)[ Time Frame: 1 Year ]"}],"pom_b":[{"label":"1.","content":"Disease Free Survival (DFS)[ Time Frame: From randomization until the earliest date of disease recurrence or death due to any cause (average of 101 study weeks) ]DFS is defined as the time from randomization until the earliest date of disease recurrence (evidence of local, regional, or distant disease progression, second primary tumor) or death due to any cause. Disease recurrence was based on the assessments from the blinded, independent reviewer (radiological and clinical). Participants who initiated alternative anti-cancer therapy prior to disease recurrence or death were treated as censored at the last assessment prior to the time of this initiation. For participants whose disease did not recur or who did not die, DFS was censored at the time of the last independently assessed radiological scan (where initiation of alternative anti-cancer therapy had not commenced). Participants who missed two or more consecutive disease assessments were censored at the last assessment prior to the missed assessments. Participants considered to have malignant disease at Baseline were censored at the time of randomization."}],"start_date":"December 2006","primary_completion_date":"March 2013","completion_date":"November 2013","first_posted":"January 19, 2007","results_first_posted":"February 11, 2014","last_update_posted":"July 18, 2014"},{"nctid":"NCT01193244","version_a":1,"version_b":2,"version_a_date":"2010-08-31","version_b_date":"2010-09-16","pom_a":[{"label":"1.","content":"To determine if orteronel plus prednisone improves radiographic progression-free survival (rPFS)[ Time Frame: Day 1 to radiographic disease progression or death ]Time from randomization to radiographic disease progression or death from any cause, whichever occurs first"},{"label":"2.","content":"To determine if orteronel plus prednisone improves overall survival (OS)[ Time Frame: Time from date of patient randomization to the date of patient death due to any cause ]Overall survival"}],"pom_b":[{"label":"1.","content":"Radiographic progression-free survival (rPFS)[ Time Frame: Day 1 to radiographic disease progression or death ]Time from randomization to radiographic disease progression or death from any cause, whichever occurs first"},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Time from date of patient randomization to the date of patient death due to any cause ]Overall survival"}],"start_date":"October 1, 2010","primary_completion_date":"January 1, 2014","completion_date":"April 7, 2016","first_posted":"September 1, 2010","results_first_posted":"May 17, 2017","last_update_posted":"May 17, 2017"},{"nctid":"NCT01193244","version_a":22,"version_b":23,"version_a_date":"2016-07-13","version_b_date":"2017-04-07","pom_a":[{"label":"1.","content":"Radiographic progression-free survival (rPFS)[ Time Frame: Day 1 to radiographic disease progression or death ]Time from randomization to radiographic disease progression or death from any cause, whichever occurs first"},{"label":"2.","content":"Overall survival (OS)[ Time Frame: Time from date of patient randomization to the date of patient death due to any cause ]Overall survival"}],"pom_b":[{"label":"1.","content":"Radiographic Progression-free Survival (rPFS)[ Time Frame: Baseline until radiographic disease progression or death, whichever occurred first (approximately up to 4.7 years) ]rPFS was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause, whichever occurred first. Radiographic disease progression was evaluated by computerized tomography (CT) scan or magnetic resonance imaging (MRI) and radionuclide bone scans at regularly scheduled visits. Radiographic disease progression in bone required a confirmatory scan. Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis. Radiographic disease progression was evaluated by independent central radiology review using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for soft tissue disease and Prostate Cancer Working Group (PCWG2) guidelines for bone disease. Participants who did not reach the endpoint were censored at their last assessment."},{"label":"2.","content":"Overall Survival[ Time Frame: Baseline until death (up to 4.7 years) ]Overall survival was calculated from the date of participant randomization to the date of participant death due to any cause. Participants without documentation of death at time of the analysis were censored as of the date the participant was last known to be alive, or the data cutoff date, whichever was earlier."}],"start_date":"October 1, 2010","primary_completion_date":"January 1, 2014","completion_date":"April 7, 2016","first_posted":"September 1, 2010","results_first_posted":"May 17, 2017","last_update_posted":"May 17, 2017"},{"nctid":"NCT02282020","version_a":31,"version_b":32,"version_a_date":"2017-11-24","version_b_date":"2018-04-20","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS) by blinded independent central review using Response Evaluation Criteria In Solid Tumours (RECIST) data[ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months ]To determine the efficacy of olaparib vs. physician\'s choice single agent chemotherapy by assessment of PFS using blinded independent central review"}],"pom_b":[{"label":"1.","content":"Objective Response Rate (ORR)[ Time Frame: Primary endpoint will be assessed at the time of the primary analysis: a minimum of 6 months after LSI, whichever is sooner ]To determine the efficacy of olaparib vs. physician\'s choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR)."}],"start_date":"February 6, 2015","primary_completion_date":"October 10, 2018","completion_date":"July 19, 2022","first_posted":"November 4, 2014","results_first_posted":"December 2, 2019","last_update_posted":"July 26, 2022"},{"nctid":"NCT02282020","version_a":38,"version_b":39,"version_a_date":"2019-06-21","version_b_date":"2019-11-27","pom_a":[{"label":"1.","content":"Objective Response Rate (ORR)[ Time Frame: Primary endpoint will be assessed at the time of the primary analysis: a minimum of 6 months after LSI, whichever is sooner ]To determine the efficacy of olaparib vs. physician\'s choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR)."}],"pom_b":[{"label":"1.","content":"Objective Response Rate (ORR)[ Time Frame: Maximum of 45 Months ]Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatmentObjective Response Rate (ORR) is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions \u2265 30%."}],"start_date":"February 6, 2015","primary_completion_date":"October 10, 2018","completion_date":"July 19, 2022","first_posted":"November 4, 2014","results_first_posted":"December 2, 2019","last_update_posted":"July 26, 2022"},{"nctid":"NCT02282020","version_a":47,"version_b":48,"version_a_date":"2022-03-17","version_b_date":"2022-07-25","pom_a":[{"label":"1.","content":"Objective Response Rate (ORR)[ Time Frame: Maximum of 45 Months ]Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatmentObjective Response Rate (ORR) is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions \u2265 30%."}],"pom_b":[{"label":"1.","content":"Objective Response Rate (ORR)[ Time Frame: RECIST follow-up assessments performed every 8 weeks (\xb11 week), up to 48 weeks, then every 12 weeks (\xb11 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months) ]To determine the efficacy of olaparib vs. physician\'s choice single agent chemotherapy by assessment of Objective Response Rate (ORR) using blinded independent central review (BICR)Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was used by a Blinded Independent Central Review (BICR) to assess participant response to treatmentORR is the number of participants with Complete Response (CR) or Partial Response (PR) in the Measurable Disease Analysis Set (MDAS). Complete response is declared when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. Partial response is declared when there is a decrease in sum of diameters of target lesions \u2265 30%."}],"start_date":"February 6, 2015","primary_completion_date":"October 10, 2018","completion_date":"July 19, 2022","first_posted":"November 4, 2014","results_first_posted":"December 2, 2019","last_update_posted":"July 26, 2022"},{"nctid":"NCT02352948","version_a":24,"version_b":25,"version_a_date":"2018-10-30","version_b_date":"2019-03-25","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: up to 3 years after first patient randomized ]"},{"label":"2.","content":"Progression Free Survival (PFS)[ Time Frame: up to 3 years after the first patient randomized ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: From randomization (Day 1) until death due to any cause, approximately 36 months ]The OS was defined as the time from the date of randomization until death due to any cause."},{"label":"2.","content":"Progression-Free Survival (PFS)[ Time Frame: Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years. ]The PFS was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression. The PFS was determined by Investigator assessments according to response evaluation criteria in solid tumours (RECIST) version 1.1. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 millimeter (mm) or progression of non-target lesions or the appearance of a new lesion"}],"start_date":"January 13, 2015","primary_completion_date":"February 9, 2018","completion_date":"June 30, 2023","first_posted":"February 2, 2015","results_first_posted":"April 16, 2019","last_update_posted":"July 19, 2022"},{"nctid":"NCT00404924","version_a":4,"version_b":5,"version_a_date":"2007-05-04","version_b_date":"2007-12-18","pom_a":[{"label":"1.","content":"Comparison of ZD6474 plus best supportive care (BSC) with placebo plus BSC for"},{"label":"2.","content":"Improvement in overall survival in patients with locally advanced or metastic non-small call lung cancer after prior therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor."}],"pom_b":[{"label":"1.","content":"Improvement in overall survival in patients with locally advanced or metastatic non-small call lung cancer after prior therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.[ Time Frame: time to death ]"}],"start_date":"November 2006","primary_completion_date":"October 2009","completion_date":"November 2014","first_posted":"November 29, 2006","results_first_posted":"March 26, 2012","last_update_posted":"September 30, 2016"},{"nctid":"NCT00404924","version_a":17,"version_b":18,"version_a_date":"2010-12-03","version_b_date":"2012-02-22","pom_a":[{"label":"1.","content":"Improvement in overall survival in patients with locally advanced or metastatic non-small call lung cancer after prior therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.[ Time Frame: time to death ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Time to death in months ]Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown)."}],"start_date":"November 2006","primary_completion_date":"October 2009","completion_date":"November 2014","first_posted":"November 29, 2006","results_first_posted":"March 26, 2012","last_update_posted":"September 30, 2016"},{"nctid":"NCT00404924","version_a":19,"version_b":20,"version_a_date":"2012-06-21","version_b_date":"2012-08-01","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Time to death in months ]Overall survival is defined as the time from date of randomization until death. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie their status must be known at the censored date and should not be lost to follow up or unknown)."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: Time to death in months ]Overall Survival (OS) is defined as the time from date of randomization until death. Any blinded/unknown patient which have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive (ie, their status must be known at the censored date and should not be lost to follow up or unknown)."}],"start_date":"November 2006","primary_completion_date":"October 2009","completion_date":"November 2014","first_posted":"November 29, 2006","results_first_posted":"March 26, 2012","last_update_posted":"September 30, 2016"},{"nctid":"NCT02766335","version_a":5,"version_b":6,"version_a_date":"2017-07-12","version_b_date":"2017-12-13","pom_a":[{"label":"1.","content":"Response rate (confirmed and unconfirmed, complete and partial), as defined by RECIST 1.1[ Time Frame: Up to 3 years ]Estimated by proportions, counting patients with unknown response status as non-responders."}],"pom_b":[{"label":"1.","content":"Response rate (confirmed and unconfirmed, complete and partial), as defined by Response Evaluation Criteria in Solid Tumors 1.1[ Time Frame: Up to 3 years ]Estimated by proportions, counting patients with unknown response status as non-responders."}],"start_date":"July 2014","primary_completion_date":"September 2018","completion_date":"September 2020","first_posted":"May 9, 2016","results_first_posted":"December 30, 2021","last_update_posted":"December 30, 2021"},{"nctid":"NCT02766335","version_a":8,"version_b":9,"version_a_date":"2020-02-07","version_b_date":"2021-12-01","pom_a":[{"label":"1.","content":"Response rate (confirmed and unconfirmed, complete and partial), as defined by Response Evaluation Criteria in Solid Tumors 1.1[ Time Frame: Up to 3 years ]Estimated by proportions, counting patients with unknown response status as non-responders."}],"pom_b":[{"label":"1.","content":"Response Rate in MEDI4736-treated Participants[ Time Frame: Up to 3 years post registration ]The percentage of participants with confirmed and unconfirmed, partial response and complete response to treatment with MEDI4736 per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1).Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR"},{"label":"2.","content":"Overall Response Rate Among PD-L1 Positive Participants Treated With MEDI4736[ Time Frame: Up to 3 years post registration ]The percentage of PD-L1 positive participants with confirmed and unconfirmed, partial response and complete response to treatment with MEDI4736 per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1).Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR"}],"start_date":"July 2014","primary_completion_date":"September 2018","completion_date":"September 2020","first_posted":"May 9, 2016","results_first_posted":"December 30, 2021","last_update_posted":"December 30, 2021"},{"nctid":"NCT00134056","version_a":35,"version_b":36,"version_a_date":"2007-05-23","version_b_date":"2007-06-04","pom_a":[],"pom_b":[{"label":"1.","content":"Survival"},{"label":"2.","content":"Progression-free survival"}],"start_date":"August 2006","primary_completion_date":"February 2016","completion_date":"February 2016","first_posted":"August 24, 2005","results_first_posted":"May 2, 2017","last_update_posted":"October 27, 2021"},{"nctid":"NCT00134056","version_a":466,"version_b":467,"version_a_date":"2012-06-19","version_b_date":"2014-02-24","pom_a":[{"label":"1.","content":"Survival"},{"label":"2.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Compare survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of death due to any cause. Patient last known to be alive are censored at date of last contact."},{"label":"2.","content":"Compare progression-free survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients without progression are censored at date of last contact. Disease progression is defined by confirmed bone disease progression, soft tissue or pain progression."}],"start_date":"August 2006","primary_completion_date":"February 2016","completion_date":"February 2016","first_posted":"August 24, 2005","results_first_posted":"May 2, 2017","last_update_posted":"October 27, 2021"},{"nctid":"NCT00134056","version_a":469,"version_b":470,"version_a_date":"2016-10-13","version_b_date":"2017-03-21","pom_a":[{"label":"1.","content":"Compare survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of death due to any cause. Patient last known to be alive are censored at date of last contact."},{"label":"2.","content":"Compare progression-free survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients without progression are censored at date of last contact. Disease progression is defined by confirmed bone disease progression, soft tissue or pain progression."}],"pom_b":[{"label":"1.","content":"Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of death due to any cause. Patient last known to be alive are censored at date of last contact."},{"label":"2.","content":"Compare Progression-free Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone Refractory Prostate Cancer.[ Time Frame: Up to 7 years after study opens ]Measured from date of registration to date of first observation of progressive disease, or death due to any cause. Patients without progression are censored at date of last contact. Disease progression is defined by confirmed bone disease progression, soft tissue or pain progression."}],"start_date":"August 2006","primary_completion_date":"February 2016","completion_date":"February 2016","first_posted":"August 24, 2005","results_first_posted":"May 2, 2017","last_update_posted":"October 27, 2021"},{"nctid":"NCT01808573","version_a":43,"version_b":44,"version_a_date":"2019-08-30","version_b_date":"2019-12-09","pom_a":[{"label":"1.","content":"Independently assessed Progression Free Survival[ Time Frame: Estimated 10 months ]"},{"label":"2.","content":"Overall Survival[ Time Frame: Estimated 28 months ]"}],"pom_b":[{"label":"1.","content":"Centrally Assessed Progression Free Survival[ Time Frame: From randomization date to recurrence, progression or death, assessed up to 38 months ]Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months."},{"label":"2.","content":"Overall Survival[ Time Frame: From randomization date to death, assessed up to 59 months. ]Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 48 months."}],"start_date":"March 29, 2013","primary_completion_date":"September 28, 2018","completion_date":"December 9, 2019","first_posted":"March 11, 2013","results_first_posted":"December 11, 2019","last_update_posted":"June 11, 2021"},{"nctid":"NCT01808573","version_a":44,"version_b":45,"version_a_date":"2019-12-09","version_b_date":"2020-03-03","pom_a":[{"label":"1.","content":"Centrally Assessed Progression Free Survival[ Time Frame: From randomization date to recurrence, progression or death, assessed up to 38 months ]Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months."},{"label":"2.","content":"Overall Survival[ Time Frame: From randomization date to death, assessed up to 59 months. ]Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 48 months."}],"pom_b":[{"label":"1.","content":"Centrally Assessed Progression Free Survival[ Time Frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut. ]Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months."},{"label":"2.","content":"Overall Survival[ Time Frame: From randomization date to death, assessed up to 59 months.The result is based on primary analysis data cut. ]Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 48 months."}],"start_date":"March 29, 2013","primary_completion_date":"September 28, 2018","completion_date":"December 9, 2019","first_posted":"March 11, 2013","results_first_posted":"December 11, 2019","last_update_posted":"June 11, 2021"},{"nctid":"NCT00085124","version_a":51,"version_b":52,"version_a_date":"2007-01-18","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival"}],"start_date":"December 2003","primary_completion_date":"June 2007","first_posted":"June 11, 2004","last_update_posted":"June 5, 2013"},{"nctid":"NCT00085124","version_a":66,"version_b":67,"version_a_date":"2010-02-06","version_b_date":"2011-04-11","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: eight months post treatment ]"}],"start_date":"December 2003","primary_completion_date":"June 2007","first_posted":"June 11, 2004","last_update_posted":"June 5, 2013"},{"nctid":"NCT00085124","version_a":69,"version_b":70,"version_a_date":"2012-11-29","version_b_date":"2012-12-19","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: eight months post treatment ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Up to 10 years ]"},{"label":"2.","content":"Complete response (CR) rate[ Time Frame: Up to 10 years ]"},{"label":"3.","content":"Median disease-free survival (DFS)[ Time Frame: Up to 10 years ]"}],"start_date":"December 2003","primary_completion_date":"June 2007","first_posted":"June 11, 2004","last_update_posted":"June 5, 2013"},{"nctid":"NCT00902330","version_a":3,"version_b":4,"version_a_date":"2011-02-09","version_b_date":"2013-03-20","pom_a":[{"label":"1.","content":"Changes in symptoms of depression, anxiety, fatigue, pain, and sleep disturbances over time"}],"pom_b":[],"start_date":"April 2009","primary_completion_date":"May 2013","completion_date":"May 2014","first_posted":"May 15, 2009","results_first_posted":"April 2, 2015","last_update_posted":"November 23, 2015"},{"nctid":"NCT00902330","version_a":4,"version_b":5,"version_a_date":"2013-03-20","version_b_date":"2013-04-23","pom_a":[],"pom_b":[{"label":"1.","content":"Effects of CES as compared to sham CES on symptoms of depression, anxiety, fatigue, pain and sleep disturbances in women receiving adjuvant chemotherapy for early-stage breast cancer[ Time Frame: Up to 2 weeks afer completion of study treatment ]Measured using the Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory (BPI) short-form, the Brief Fatigue Inventory (BFI), and the General Sleep Disturbance Scale (GSDS)."}],"start_date":"April 2009","primary_completion_date":"May 2013","completion_date":"May 2014","first_posted":"May 15, 2009","results_first_posted":"April 2, 2015","last_update_posted":"November 23, 2015"},{"nctid":"NCT00902330","version_a":7,"version_b":8,"version_a_date":"2013-12-17","version_b_date":"2015-03-19","pom_a":[{"label":"1.","content":"Effects of CES as compared to sham CES on symptoms of depression, anxiety, fatigue, pain and sleep disturbances in women receiving adjuvant chemotherapy for early-stage breast cancer[ Time Frame: Up to 2 weeks afer completion of study treatment ]Measured using the Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory (BPI) short-form, the Brief Fatigue Inventory (BFI), and the General Sleep Disturbance Scale (GSDS)."}],"pom_b":[{"label":"1.","content":"Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage Breast Cancer[ Time Frame: Up to 2 weeks afer completion of study treatment, for up to 8 months ]Using Hospital Anxiety and Depression Scale (HADS) a 14 item scale, 7 relate to anxiety, 7 to depression; each item is scored from 0-3, a person can score 0 to 21 for either anxiety or depression (0 is best and 21 is worst), Brief Pain Inventory (BPI) short-form measures the intensity and interference of pain in the patient\'s life; 12 questions with 0 (does not interfere) to 10 (completely interferes); mean will be used as the measure of pain; Brief Fatigue Inventory (BFI) assess the severity and impact of cancer-related fatigue. Has 9 questions with 0 (does not interfere) to 10 (completely interferes), the total mean score is the mean of the 9 questions; severe fatigue can be defined as a score of 7 or higher, General Sleep Disturbance Scale (GSDS) 21 items to evaluate sleep issues (0=never to 7=every day); the 21 items are summed to produce a total score of 9=no sleep disturbance to 137=extreme sleep disturbance . Used standard questionnaire"}],"start_date":"April 2009","primary_completion_date":"May 2013","completion_date":"May 2014","first_posted":"May 15, 2009","results_first_posted":"April 2, 2015","last_update_posted":"November 23, 2015"},{"nctid":"NCT00102973","version_a":30,"version_b":31,"version_a_date":"2008-08-11","version_b_date":"2011-07-21","pom_a":[],"pom_b":[{"label":"1.","content":"Study Objectives[ Time Frame: Every 8 Weeks ]To demonstrate superiority in the objective response rate (ORR) of TLK286 in combination with carboplatin as compared to active control therapy with liposomal doxorubicin"}],"start_date":"December 2004","primary_completion_date":"July 2008","completion_date":"July 2008","first_posted":"February 7, 2005","last_update_posted":"May 31, 2012"},{"nctid":"NCT05317416","version_a":5,"version_b":6,"version_a_date":"2022-06-07","version_b_date":"2022-06-14","pom_a":[{"label":"1.","content":"Minimal Residual Disease negativity rate[ Time Frame: 12 months after randomization ]Minimal Residual Disease negativity rate per IMWG criteria as assessed via New Generation Sequencing"},{"label":"2.","content":"Progression Free Survival[ Time Frame: Assessed for up to approximately 5 years ]Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria"}],"pom_b":[{"label":"1.","content":"Minimal Residual Disease negativity rate[ Time Frame: 12 months after randomization ]Minimal Residual Disease negativity rate per IMWG criteria as assessed via Next Generation Sequencing"},{"label":"2.","content":"Progression Free Survival[ Time Frame: Assessed for up to approximately 5 years ]Progression Free Survival assessed by Blinded Independent Central review per IMWG response criteria"}],"start_date":"March 25, 2022","primary_completion_date":"June 14, 2027","completion_date":"June 14, 2027","first_posted":"April 7, 2022","last_update_posted":"September 13, 2022"},{"nctid":"NCT04209114","version_a":8,"version_b":9,"version_a_date":"2020-03-19","version_b_date":"2020-07-28","pom_a":[{"label":"1.","content":"Pathologic complete response (pCR) rate of neoadjuvant nivolumab + NKTR-214 to Standard of Care (SOC) in all randomized participants[ Time Frame: Approximately 36 months ]"},{"label":"2.","content":"Event-free survival (EFS) of neoadjuvant nivolumab + NKTR-214 followed by adjuvant nivolumab + NKTR-214 after RC vs. SOC[ Time Frame: Approximately 54 months ]"}],"pom_b":[{"label":"1.","content":"Pathologic complete response (pCR) rate of neoadjuvant nivolumab + bempeg to Standard of Care (SOC) in all randomized participants[ Time Frame: Approximately 36 months ]"},{"label":"2.","content":"Event-free survival (EFS) of neoadjuvant nivolumab + bempeg followed by adjuvant nivolumab + bempeg after RC vs. SOC[ Time Frame: Approximately 54 months ]"}],"start_date":"February 17, 2020","primary_completion_date":"December 28, 2026","completion_date":"June 28, 2029","first_posted":"December 23, 2019","last_update_posted":"August 1, 2022"},{"nctid":"NCT04209114","version_a":20,"version_b":21,"version_a_date":"2021-12-01","version_b_date":"2022-02-07","pom_a":[{"label":"1.","content":"Pathologic complete response (pCR) rate of neoadjuvant nivolumab + bempeg to Standard of Care (SOC) in all randomized participants[ Time Frame: Approximately 36 months ]"},{"label":"2.","content":"Event-free survival (EFS) of neoadjuvant nivolumab + bempeg followed by adjuvant nivolumab + bempeg after RC vs. SOC[ Time Frame: Approximately 54 months ]"}],"pom_b":[{"label":"1.","content":"Pathologic Complete Response (pCR) rate of Arm A to Arm C[ Time Frame: Approximately 47 months ]"},{"label":"2.","content":"Event-Free Survival (EFS) of Arm A vs Arm C[ Time Frame: Approximately 65 months ]"}],"start_date":"February 17, 2020","primary_completion_date":"December 28, 2026","completion_date":"June 28, 2029","first_posted":"December 23, 2019","last_update_posted":"August 1, 2022"},{"nctid":"NCT01035229","version_a":1,"version_b":2,"version_a_date":"2009-12-17","version_b_date":"2009-12-18","pom_a":[{"label":"1.","content":"Overall Survival"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ]"}],"start_date":"April 2010","primary_completion_date":"October 2013","completion_date":"October 2013","first_posted":"December 18, 2009","results_first_posted":"October 27, 2014","last_update_posted":"September 22, 2016"},{"nctid":"NCT01035229","version_a":32,"version_b":33,"version_a_date":"2014-02-13","version_b_date":"2014-10-23","pom_a":[{"label":"1.","content":"Overall Survival[ Time Frame: Until all patients have disease progression or leave study due to intolerable advese events- Estimate of 1 year for each patient. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: When 454 OS events were observed ]OS was defined as the time from the date of randomization to the date of death from any cause. The comparison of OS between the 2 arms was done using a stratified log-rank test at one-sided 2.5% level of significance."}],"start_date":"April 2010","primary_completion_date":"October 2013","completion_date":"October 2013","first_posted":"December 18, 2009","results_first_posted":"October 27, 2014","last_update_posted":"September 22, 2016"},{"nctid":"NCT00761280","version_a":25,"version_b":26,"version_a_date":"2013-10-22","version_b_date":"2014-08-07","pom_a":[{"label":"1.","content":"Survival rate[ Time Frame: 24 months ]"}],"pom_b":[{"label":"1.","content":"Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)[ Time Frame: 24 months ]Survival rate was defined as the proportion of participants known to be alive at 24 months from randomization. If a participant\'s status was unknown and there was no follow-up information available, they were categorized as \'Died\' for the purposes of the analysis."},{"label":"2.","content":"Survival at 24 Months in the Intent-to-treat Population - Number of Participants[ Time Frame: 24 months ]Survival status was assessed at 24 months from randomization. Participants with unknown or missing status were considered treatment failures, i.e., assumed to be dead. The category \\"Lost to / insufficient follow-up\\" includes participants who were alive at last data collection point but did not yet have enough follow-up time to reach the 24 month time point."}],"start_date":"December 2008","primary_completion_date":"February 2012","completion_date":"June 2012","first_posted":"September 29, 2008","results_first_posted":"August 22, 2014","last_update_posted":"November 14, 2014"},{"nctid":"NCT01416181","version_a":23,"version_b":24,"version_a_date":"2013-04-20","version_b_date":"2013-07-12","pom_a":[{"label":"1.","content":"To investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in subjects with SPMS.[ Time Frame: 96 weeks ]"}],"pom_b":[{"label":"1.","content":"Part 1: percentage of subjects experiencing confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]"},{"label":"2.","content":"Part 2: The number of patients with Adverse Events and Serious Adverse Events[ Time Frame: 218 weeks ]"}],"start_date":"September 13, 2011","primary_completion_date":"July 28, 2015","completion_date":"April 13, 2016","first_posted":"August 12, 2011","results_first_posted":"June 27, 2017","last_update_posted":"September 11, 2017"},{"nctid":"NCT01416181","version_a":25,"version_b":26,"version_a_date":"2013-09-12","version_b_date":"2014-08-18","pom_a":[{"label":"1.","content":"Part 1: percentage of subjects experiencing confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]"},{"label":"2.","content":"Part 2: The number of patients with Adverse Events and Serious Adverse Events[ Time Frame: 218 weeks ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of participants with confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]Confirmed disability progression is defined as one or more of the following criteria, confirmed at a second visit at least 6 months later and at Week 96: \u2022 Confirmed progression in EDSS: EDSS score increased from baseline by at least 1 point if baseline EDSS \u22645.5 or by at least 0.5 points if baseline EDSS \u22656; \u2022 Confirmed progression in T25FW: T25FW increased by at least 20% of the baseline walk; \u2022 Confirmed progression in 9HPT: 9HPT increased by at least 20% of the time taken at baseline. The progression in 9HPT can occur on either hand, but will have to be confirmed on the same hand. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs."},{"label":"2.","content":"The number of participants with Adverse Events and Serious Adverse Events[ Time Frame: 218 weeks ]"}],"start_date":"September 13, 2011","primary_completion_date":"July 28, 2015","completion_date":"April 13, 2016","first_posted":"August 12, 2011","results_first_posted":"June 27, 2017","last_update_posted":"September 11, 2017"},{"nctid":"NCT01416181","version_a":28,"version_b":29,"version_a_date":"2015-05-23","version_b_date":"2015-08-20","pom_a":[{"label":"1.","content":"Part 1: Percentage of participants with confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]Confirmed disability progression is defined as one or more of the following criteria, confirmed at a second visit at least 6 months later and at Week 96: \u2022 Confirmed progression in EDSS: EDSS score increased from baseline by at least 1 point if baseline EDSS \u22645.5 or by at least 0.5 points if baseline EDSS \u22656; \u2022 Confirmed progression in T25FW: T25FW increased by at least 20% of the baseline walk; \u2022 Confirmed progression in 9HPT: 9HPT increased by at least 20% of the time taken at baseline. The progression in 9HPT can occur on either hand, but will have to be confirmed on the same hand. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs."},{"label":"2.","content":"The number of participants with Adverse Events and Serious Adverse Events[ Time Frame: 218 weeks ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of participants with confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]Confirmed disability progression is defined as one or more of the following criteria, confirmed at a second visit at least 6 months later and at Week 96: \u2022 Confirmed progression in EDSS: EDSS score increased from baseline by at least 1 point if baseline EDSS \u22645.5 or by at least 0.5 points if baseline EDSS \u22656; \u2022 Confirmed progression in T25FW: T25FW increased by at least 20% of the baseline walk; \u2022 Confirmed progression in 9HPT: 9HPT increased by at least 20% of the time taken at baseline. The progression in 9HPT can occur on either hand, but will have to be confirmed on the same hand. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs."},{"label":"2.","content":"The number of participants with Adverse Events (AE) and Serious Adverse Events (SAE)[ Time Frame: 218 weeks ]"}],"start_date":"September 13, 2011","primary_completion_date":"July 28, 2015","completion_date":"April 13, 2016","first_posted":"August 12, 2011","results_first_posted":"June 27, 2017","last_update_posted":"September 11, 2017"},{"nctid":"NCT01416181","version_a":32,"version_b":33,"version_a_date":"2016-07-15","version_b_date":"2017-05-24","pom_a":[{"label":"1.","content":"Part 1: Percentage of participants with confirmed progression of disability in one or more of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks ]Confirmed disability progression is defined as one or more of the following criteria, confirmed at a second visit at least 6 months later and at Week 96: \u2022 Confirmed progression in EDSS: EDSS score increased from baseline by at least 1 point if baseline EDSS \u22645.5 or by at least 0.5 points if baseline EDSS \u22656; \u2022 Confirmed progression in T25FW: T25FW increased by at least 20% of the baseline walk; \u2022 Confirmed progression in 9HPT: 9HPT increased by at least 20% of the time taken at baseline. The progression in 9HPT can occur on either hand, but will have to be confirmed on the same hand. The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs."},{"label":"2.","content":"The number of participants with Adverse Events (AE) and Serious Adverse Events (SAE)[ Time Frame: 218 weeks ]"}],"pom_b":[{"label":"1.","content":"Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)[ Time Frame: Up to 96 weeks (2 years) ]Confirmed disability progression, defined as \u22651 of the following criteria (confirmed at a second visit \u22656 months later and at Week 96):Confirmed progression in EDSS (EDSS score increased from baseline [BL] by \u22651 point if BL EDSS \u22645.5 or by \u22650.5 points if BL EDSS \u22656);Confirmed progression in T25FW (T25FW increased by \u226520% of the BL walk);Confirmed progression in 9HPT (9HPT increased by \u226520% of the time taken at BL on either hand and confirmed on the same hand).The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation."},{"label":"2.","content":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)[ Time Frame: 218 weeks ]AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator."}],"start_date":"September 13, 2011","primary_completion_date":"July 28, 2015","completion_date":"April 13, 2016","first_posted":"August 12, 2011","results_first_posted":"June 27, 2017","last_update_posted":"September 11, 2017"},{"nctid":"NCT01015833","version_a":154,"version_b":155,"version_a_date":"2011-09-21","version_b_date":"2012-11-19","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 3 years ]The confidence bound estimates for futility will also be adjusted according to the Lan-DeMets analogue of the O\'Brien-Fleming boundaries."}],"start_date":"February 15, 2010","primary_completion_date":"May 21, 2015","completion_date":"August 15, 2018","first_posted":"November 18, 2009","results_first_posted":"May 2, 2018","last_update_posted":"August 4, 2022"},{"nctid":"NCT01015833","version_a":505,"version_b":506,"version_a_date":"2017-08-22","version_b_date":"2018-04-03","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 3 years ]The confidence bound estimates for futility will also be adjusted according to the Lan-DeMets analogue of the O\'Brien-Fleming boundaries."}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Up to 3 years ]Overall survival is defined as the time from study entry to death from any cause. The median OS was estimated using the Kaplan-Meier method."}],"start_date":"February 15, 2010","primary_completion_date":"May 21, 2015","completion_date":"August 15, 2018","first_posted":"November 18, 2009","results_first_posted":"May 2, 2018","last_update_posted":"August 4, 2022"},{"nctid":"NCT01635764","version_a":8,"version_b":9,"version_a_date":"2013-07-31","version_b_date":"2013-10-21","pom_a":[{"label":"1.","content":"Proportion of subjects achieving clinical response.[ Time Frame: Baseline (Week 0) up to Week 60. ]Subjects achieving improvement in hidradenitis suppurativa severity."}],"pom_b":[{"label":"1.","content":"Proportion of subjects achieving clinical response[ Time Frame: Baseline (Week 0) up to Week 60 ]Subjects achieving improvement in hidradenitis suppurativa severity"}],"start_date":"April 2012","primary_completion_date":"August 2016","completion_date":"August 2016","first_posted":"July 10, 2012","results_first_posted":"September 5, 2017","last_update_posted":"January 24, 2018"},{"nctid":"NCT01635764","version_a":21,"version_b":22,"version_a_date":"2016-09-26","version_b_date":"2017-08-03","pom_a":[{"label":"1.","content":"Proportion of subjects achieving clinical response[ Time Frame: Baseline (Week 0) up to Week 60 ]Subjects achieving improvement in hidradenitis suppurativa severity"}],"pom_b":[{"label":"1.","content":"Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"2.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"3.","content":"Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"4.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 201, and 216 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"5.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"6.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"7.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"8.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations[ Time Frame: Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"9.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"10.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Patient\'s Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient\'s Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"11.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"12.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"13.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"14.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"15.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."}],"start_date":"April 2012","primary_completion_date":"August 2016","completion_date":"August 2016","first_posted":"July 10, 2012","results_first_posted":"September 5, 2017","last_update_posted":"January 24, 2018"},{"nctid":"NCT01635764","version_a":22,"version_b":23,"version_a_date":"2017-08-03","version_b_date":"2017-09-05","pom_a":[{"label":"1.","content":"Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"2.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"3.","content":"Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"4.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 201, and 216 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"5.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"6.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"7.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"8.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations[ Time Frame: Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"9.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"10.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Patient\'s Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient\'s Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"11.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"12.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"13.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"14.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"15.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."}],"pom_b":[{"label":"1.","content":"Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"2.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"3.","content":"Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule \u2265 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"4.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"5.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"6.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"7.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"8.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations[ Time Frame: Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"9.","content":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population[ Time Frame: Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"10.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The Patient\'s Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient\'s Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"11.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"12.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"13.","content":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"14.","content":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."},{"label":"15.","content":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average \u2265 3[ Time Frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204 ]The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \\"last 24 hours.\\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average \u2265 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits."}],"start_date":"April 2012","primary_completion_date":"August 2016","completion_date":"August 2016","first_posted":"July 10, 2012","results_first_posted":"September 5, 2017","last_update_posted":"January 24, 2018"},{"nctid":"NCT00674739","version_a":8,"version_b":9,"version_a_date":"2010-01-26","version_b_date":"2011-04-24","pom_a":[{"label":"1.","content":"The primary efficacy endpoint is the proportion of subjects achieving complete clearance of all warts (baseline and new) at the EOS.[ Time Frame: Up to 16 weeks ]"}],"pom_b":[{"label":"1.","content":"Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study[ Time Frame: Up to 16 weeks ]Proportion of subjects with complete clearance of all warts (both presented at Baseline and newly emerged warts) at End of Study. Primary analysis performed on the Intent to Treat population with imputation (Last Observation Carried Forward)for missing data points."}],"start_date":"May 2008","primary_completion_date":"July 2009","completion_date":"July 2009","first_posted":"May 8, 2008","results_first_posted":"May 18, 2011","last_update_posted":"May 24, 2011"},{"nctid":"NCT00565851","version_a":204,"version_b":205,"version_a_date":"2009-08-26","version_b_date":"2009-08-28","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":205,"version_b":206,"version_a_date":"2009-08-28","version_b_date":"2009-09-01","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival"}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":359,"version_b":360,"version_a_date":"2011-04-02","version_b_date":"2012-08-24","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]"}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":516,"version_b":517,"version_a_date":"2015-06-02","version_b_date":"2015-06-03","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]"}],"pom_b":[],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":517,"version_b":518,"version_a_date":"2015-06-03","version_b_date":"2015-06-05","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]"}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":590,"version_b":591,"version_a_date":"2015-10-09","version_b_date":"2015-10-27","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":1073,"version_b":1074,"version_a_date":"2018-01-31","version_b_date":"2018-02-01","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"pom_b":[{"label":"1.","content":"To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."},{"label":"2.","content":"To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or Fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":1076,"version_b":1077,"version_a_date":"2018-02-06","version_b_date":"2018-02-07","pom_a":[{"label":"1.","content":"To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."},{"label":"2.","content":"To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or Fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"pom_b":[{"label":"1.","content":"To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."},{"label":"2.","content":"To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT00565851","version_a":1145,"version_b":1146,"version_a_date":"2020-03-06","version_b_date":"2020-11-13","pom_a":[{"label":"1.","content":"To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."},{"label":"2.","content":"To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or fallopian tube cancer[ Time Frame: Up to 10 years ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months)."}],"pom_b":[{"label":"1.","content":"To Determine if Surgical Secondary Cytoreduction in Addition to Adjuvant Chemotherapy Increases the Duration of Overall Survival in Patients With Recurrent Platinum Sensitive Epithelial Ovarian Cancer, Peritoneal Primary or Fallopian Tube Cancer[ Time Frame: The time frame is 82.5 months (median duration of follow-up) ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months). The median duration of follow-up is calculated by the reverse Kaplan-Meier method."},{"label":"2.","content":"To Determine if the Addition of Bevacizumab Increases the Duration of Overall Survival Relative to Second-line Paclitaxel and Carboplatin Alone in Patients With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Primary or Fallopian Tube Cancer[ Time Frame: The time frame is 82.5 months (median duration of follow-up). ]The treatment regimens will be compared with a logrank procedure which includes all of the patients categorized by their randomly assigned treatment. The logrank test will be stratified by the secondary surgical debulking status (randomized to undergo cytoreduction, vs randomized to not undergo secondary cytoreduction vs not a candidate or did not consent to secondary surgical cytoreduction) and the duration of treatment free-interval prior to enrolling onto this study (6-12 months vs > 12 months). The median duration of follow-up is calculated by the reverse Kaplan-Meier method."}],"start_date":"December 6, 2007","primary_completion_date":"April 30, 2019","first_posted":"November 30, 2007","results_first_posted":"December 14, 2020","last_update_posted":"September 10, 2022"},{"nctid":"NCT03551626","version_a":18,"version_b":19,"version_a_date":"2020-04-18","version_b_date":"2020-09-02","pom_a":[{"label":"1.","content":"Change from baseline in composite rate of pyrexia related events[ Time Frame: Baseline up to 12 months ]The composite rate of grade 3/4 pyrexia, ospitalization due to pyrexia, or permanent treatment discontinuation due to pyrexia by 12 months in overall treated subjects"}],"pom_b":[{"label":"1.","content":"Change from baseline in composite rate of pyrexia related events[ Time Frame: Baseline up to 12 months ]The composite rate of grade 3/4 pyrexia, hospitalization due to pyrexia, or permanent treatment discontinuation due to pyrexia by 12 months in overall treated subjects"}],"start_date":"August 29, 2018","primary_completion_date":"October 5, 2020","completion_date":"September 16, 2021","first_posted":"June 11, 2018","last_update_posted":"October 15, 2021"},{"nctid":"NCT05329545","version_a":2,"version_b":3,"version_a_date":"2022-04-14","version_b_date":"2022-07-29","pom_a":[{"label":"1.","content":"PFS assessed by BICR[ Time Frame: Every 6 weeks and then every 12 weeks until disease progression or start of a new therapy, assessed up to an average of 12 months. ]Demonstrate superiority in Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 of upifitamab rilsodotin versus placebo as maintenance therapy"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1[ Time Frame: Up to 12 months after the last dose for the last participant. ]PFS is defined as the time from randomization to the earliest date of progressive disease as assessed by BICR per RECIST Version 1.1 or death due to any cause."}],"start_date":"June 23, 2022","primary_completion_date":"September 29, 2024","completion_date":"March 4, 2025","first_posted":"April 15, 2022","last_update_posted":"September 14, 2022"},{"nctid":"NCT01242748","version_a":7,"version_b":8,"version_a_date":"2012-12-20","version_b_date":"2015-05-13","pom_a":[{"label":"1.","content":"PSA level[ Time Frame: Every 3 months during 27 months of treatment ]"}],"pom_b":[{"label":"1.","content":"Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years\' Treatment Between Degarelix and Goserelin[ Time Frame: From baseline to 3 years ]PSA PFS failure is defined as either PSA failure (defined as increase in serum PSA of 50%, and at least 5 ng/mL, compared to nadir, measured on two consecutive occasions at least 2 weeks apart) or death, whichever is first. The number below present the unadjusted rates (estimated using the Kaplan-Meier method) of no PSA-PFS."}],"start_date":"October 2010","primary_completion_date":"December 2011","completion_date":"January 2012","first_posted":"November 17, 2010","results_first_posted":"June 3, 2015","last_update_posted":"June 3, 2015"},{"nctid":"NCT03985423","version_a":6,"version_b":7,"version_a_date":"2022-05-03","version_b_date":"2022-06-07","pom_a":[{"label":"1.","content":"Overall Response[ Time Frame: Week 4 ]Achievement of either a Complete or Partial Response"}],"pom_b":[{"label":"1.","content":"Overall Response[ Time Frame: Week 4 ]Achievement of either a Complete or Partial ResponseComplete Response is adjudicated if the following are observed:No fever = body temperature <37.5\xb0CNormal spleen sizeNo cytopenia = Absolute Neutrophil Counts >=1.0x109/L and platelet count >=100x109/L [absence of G-CSF and transfusion support must be documented for at least 4 days to report no cytopenia]No hyperferritinemia = serum level is <2000 \xb5g/LNo evidence of coagulopathy, i.e., normal D-Dimer and/or normal (>150 mg/dL) fibrinogen levelsNo neurological and CSF abnormalities attributed to HLHNo sustained worsening of sCD25 (as indicated by at least two consecutive measurements that are > 2-fold higher than baseline)Partial Response is adjudicated if there is an improvement (>50% change from baseline or normalization) of at least 3 HLH clinical and laboratory criteria (including Central Nervous System abnormalities)"}],"start_date":"June 2, 2020","primary_completion_date":"November 2021","completion_date":"November 2021","first_posted":"June 13, 2019","last_update_posted":"May 10, 2021"},{"nctid":"NCT01095003","version_a":7,"version_b":8,"version_a_date":"2015-10-30","version_b_date":"2019-08-07","pom_a":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Every 6 weeks ]"}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Baseline up to 2 years 7 months ]PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last."}],"start_date":"May 2009","primary_completion_date":"December 2011","completion_date":"October 2015","first_posted":"March 29, 2010","results_first_posted":"September 13, 2019","last_update_posted":"April 28, 2022"},{"nctid":"NCT00557817","version_a":3,"version_b":4,"version_a_date":"2008-08-29","version_b_date":"2008-09-11","pom_a":[{"label":"1.","content":"Median time to achieve Hb level > 13 g/dL in each arm.[ Time Frame: 126 days after HCT ]"},{"label":"2.","content":"Proportion of complete correctors (i.e. patients reaching Hb > 13 g/dL) before day 126 in each arm.[ Time Frame: 126 days after HCT ]"}],"pom_b":[{"label":"1.","content":"Median time to achieve hemoglobin (Hb) level > 13 g/dL in each arm.[ Time Frame: 126 days after hematocrit (HCT) ]"},{"label":"2.","content":"Proportion of complete correctors (i.e. patients reaching Hb > 13 g/dL) before day 126 in each arm.[ Time Frame: 126 days after HCT ]"}],"start_date":"March 2004","primary_completion_date":"August 2008","completion_date":"August 2008","first_posted":"November 14, 2007","last_update_posted":"January 11, 2010"},{"nctid":"NCT00694382","version_a":43,"version_b":44,"version_a_date":"2011-08-05","version_b_date":"2011-12-14","pom_a":[{"label":"1.","content":"Time-to-first occurrence of symptomatic Deep Venous Thrombosis of lower or upper limbs, non fatal Pulmonary embolism, and VTE-related deaths[ Time Frame: From randomization up to 3 calendar days after last study drug injection ]"}],"pom_b":[{"label":"1.","content":"Time-to-first occurrence of symptomatic Deep Venous Thrombosis of lower or upper limbs, non fatal Pulmonary embolism, and VTE-related deaths as confirmed by the Central Independent Adjudication Committee (CIAC)[ Time Frame: From randomization up to 3 days after last study drug injection ]"}],"start_date":"June 2008","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2008","last_update_posted":"January 23, 2013"},{"nctid":"NCT00694382","version_a":44,"version_b":45,"version_a_date":"2011-12-14","version_b_date":"2013-01-14","pom_a":[{"label":"1.","content":"Time-to-first occurrence of symptomatic Deep Venous Thrombosis of lower or upper limbs, non fatal Pulmonary embolism, and VTE-related deaths as confirmed by the Central Independent Adjudication Committee (CIAC)[ Time Frame: From randomization up to 3 days after last study drug injection ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or VTE-related Death[ Time Frame: From randomization up to 3 days after last study drug injection ]VTE included any symptomatic Deep Vein Thrombosis [DVT] of lower or upper limbs and any non-fatal Pulmonary Embolism [PE] as confirmed by a Central Independent Adjudication Committee [CIAC] after review of compression ultrasound or venography for DVT, ventilation/perfusion lung scan, pulmonary angiogram or spiral computer tomography lung scan for PE.VTE-related death included fatal PE and unexplained deaths without confirmatory autopsy. Any sudden death could be classified as fatal PE by the CIAC unless diagnostic test results strongly indicated an alternative diagnosis\\"."},{"label":"2.","content":"Time-to-first Occurrence of VTE or VTE-related Death (Cumulative Incidence Function)[ Time Frame: From randomization up to 3 days after last study drug injection ]Participants alive and not having experienced VTE were right censored at last study drug injection plus 3 days. In order to correct for competing risks (Deaths other than VTE-related death), a model of cause-specific hazards was used to estimate the Cumulative incidence Function with Prentice non-parametric estimator."}],"start_date":"June 2008","primary_completion_date":"November 2010","completion_date":"November 2010","first_posted":"June 10, 2008","last_update_posted":"January 23, 2013"},{"nctid":"NCT02055781","version_a":79,"version_b":80,"version_a_date":"2016-12-15","version_b_date":"2018-10-18","pom_a":[{"label":"1.","content":"Efficacy[ Time Frame: Baseline to Week 24 ]To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a \u2265 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0."}],"pom_b":[{"label":"1.","content":"To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy[ Time Frame: Baseline to Week 24 ]To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a \u2265 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0."}],"start_date":"February 2014","primary_completion_date":"April 2016","completion_date":"April 2016","first_posted":"February 5, 2014","results_first_posted":"November 18, 2021","last_update_posted":"November 18, 2021"},{"nctid":"NCT02055781","version_a":80,"version_b":81,"version_a_date":"2018-10-18","version_b_date":"2021-10-21","pom_a":[{"label":"1.","content":"To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy[ Time Frame: Baseline to Week 24 ]To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a \u2265 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0."}],"pom_b":[{"label":"1.","content":"Spleen Volume Reduction[ Time Frame: Baseline to Week 24 ]Proportion of patients achieving a \u2265 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT)."},{"label":"2.","content":"Total Symptom Score (TSS) Reduction[ Time Frame: Baseline to Week 24 ]Proportion of patients achieving a \u2265 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 [absent] to 10 [worst imaginable]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS."}],"start_date":"February 2014","primary_completion_date":"April 2016","completion_date":"April 2016","first_posted":"February 5, 2014","results_first_posted":"November 18, 2021","last_update_posted":"November 18, 2021"},{"nctid":"NCT00004931","version_a":18,"version_b":19,"version_a_date":"2012-11-09","version_b_date":"2013-01-10","pom_a":[],"pom_b":[{"label":"1.","content":"DFS rate[ Time Frame: Time to first documented evidence of colon cancer recurrence, second primary cancer, or death from any cause without prior evidence of colon cancer recurrence or second primary cancer, assessed up to 3 years ]"}],"start_date":"February 2000","primary_completion_date":"September 2005","first_posted":"May 14, 2003","last_update_posted":"January 14, 2013"},{"nctid":"NCT02920008","version_a":1,"version_b":2,"version_a_date":"2016-09-28","version_b_date":"2017-03-20","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: 24 months ]"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: 24 months ]Number of days from day subject was randomized to date of death, regardless of cause."}],"start_date":"March 16, 2017","primary_completion_date":"January 20, 2020","completion_date":"June 1, 2020","first_posted":"September 30, 2016","last_update_posted":"September 9, 2021"},{"nctid":"NCT01305200","version_a":45,"version_b":46,"version_a_date":"2012-11-21","version_b_date":"2014-02-12","pom_a":[{"label":"1.","content":"Duration of severe oral mucositis (WHO Grade 3 or 4)"}],"pom_b":[{"label":"1.","content":"Duration of severe oral mucositis (WHO grade 3 or 4)[ Time Frame: Up to day 20 ]Will be compared between the groups in a 2 sample t-test. Descriptive statistics will be used to summarize the duration of severe mucositis in each arm."}],"start_date":"March 2011","primary_completion_date":"June 2015","completion_date":"June 30, 2015","first_posted":"February 28, 2011","results_first_posted":"May 9, 2017","last_update_posted":"September 17, 2019"},{"nctid":"NCT01305200","version_a":50,"version_b":51,"version_a_date":"2016-10-21","version_b_date":"2017-03-28","pom_a":[{"label":"1.","content":"Duration of severe oral mucositis (WHO grade 3 or 4)[ Time Frame: Up to day 20 ]Will be compared between the groups in a 2 sample t-test. Descriptive statistics will be used to summarize the duration of severe mucositis in each arm."}],"pom_b":[{"label":"1.","content":"Duration of Severe Oral Mucositis (WHO Grade 3 or 4)[ Time Frame: Day -1 (day prior to stem cell infusion) to Day 20 following transplantation. ]Mean days of severe (WHO Grade 3 or 4) Mucositis."}],"start_date":"March 2011","primary_completion_date":"June 2015","completion_date":"June 30, 2015","first_posted":"February 28, 2011","results_first_posted":"May 9, 2017","last_update_posted":"September 17, 2019"},{"nctid":"NCT01302834","version_a":142,"version_b":143,"version_a_date":"2012-09-27","version_b_date":"2013-06-28","pom_a":[{"label":"1.","content":"5-year overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: From randomization to date of failure (death) or last follow-up. Analysis occurs after 219 failures have been reported. ]"}],"start_date":"June 2011","primary_completion_date":"July 12, 2018","first_posted":"February 24, 2011","results_first_posted":"January 9, 2020","last_update_posted":"June 28, 2022"},{"nctid":"NCT01302834","version_a":150,"version_b":151,"version_a_date":"2019-05-16","version_b_date":"2019-12-19","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: From randomization to date of failure (death) or last follow-up. Analysis occurs after 219 failures have been reported. ]"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From randomization to last follow-up. Analysis was to occur after 180 deaths were reported. Analysis occurred after 133 deaths were reported. Maximum follow-up at time of analysis was 6.5 years. ]An event for overall survival is death due to any cause. Survival time is defined as time from randomization to the date of death or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. The protocol endpoint is hazard ratio, which is reported in the statistical analysis results. Five-year rate is reported simply as summary data; it is not the outcome measure."}],"start_date":"June 2011","primary_completion_date":"July 12, 2018","first_posted":"February 24, 2011","results_first_posted":"January 9, 2020","last_update_posted":"June 28, 2022"},{"nctid":"NCT00292279","version_a":2,"version_b":3,"version_a_date":"2006-02-15","version_b_date":"2008-05-08","pom_a":[{"label":"1.","content":"Infectious complication"},{"label":"2.","content":"Systemic inflammatory response syndrome (SIRS)"}],"pom_b":[{"label":"1.","content":"Infectious complication[ Time Frame: POD+1 to POD+14 ]"},{"label":"2.","content":"Systemic inflammatory response syndrome (SIRS)[ Time Frame: POD+1 to POD +8 ]"}],"start_date":"June 2002","primary_completion_date":"November 2003","completion_date":"February 2004","first_posted":"February 15, 2006","last_update_posted":"May 14, 2008"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,T.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,B.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,B.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,B.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,B.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,B.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,B.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,B.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,B.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,D.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,B.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var p="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:p,maxWidth:p}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,B.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,C.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,U.Z)(m.Z).breakpoints,s=V(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,f=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,b=s.direction,y=void 0===b?"row":b,g=s.item,_=void 0!==g&&g,k=s.rowSpacing,T=s.spacing,C=void 0===T?0:T,P=s.wrap,x=void 0===P?"wrap":P,E=s.zeroMinWidth,F=void 0!==E&&E,N=(0,w.Z)(s,oe),A=k||C,R=c||C,O=e.useContext(X),M=v?u||12:O,D={},z=(0,r.Z)({},N);i.keys.forEach((function(e){null!=N[e]&&(D[e]=N[e],delete z[e])}));var W=(0,r.Z)({},s,{columns:M,container:v,direction:y,item:_,rowSpacing:A,columnSpacing:R,wrap:x,zeroMinWidth:F,spacing:C},D,{breakpoints:i.keys}),L=ue(W);return(0,p.jsx)(X.Provider,{value:M,children:(0,p.jsx)(le,(0,r.Z)({ownerState:W,className:(0,S.Z)(L.root,l),as:f,ref:n},z))})})),de=ce,pe=n(2065);function fe(e){return(0,T.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,D.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,pe.Fq)("#fff",he(a.elevation)),", ").concat((0,pe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),be=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,f=n.variant,m=void 0===f?"elevation":f,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),b=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,C.Z)(o,fe,a)}(v);return(0,p.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(b.root,o),ref:t},h))}));function ye(e){return(0,T.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,D.ZP)(be,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,C.Z)({root:["root"]},ye,t)}(u);return(0,p.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,T.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var ke=["className","component"],Te=(0,D.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Ce=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,ke),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,C.Z)({root:["root"]},Se,t)}(u);return(0,p.jsx)(Te,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function Pe(e){return(0,T.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var xe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Ee=(0,D.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,M.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Fe={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Ne={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Ae=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Ne[e]||e}(n.color),i=V((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,f=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,b=void 0!==v&&v,y=i.variant,g=void 0===y?"body1":y,_=i.variantMapping,k=void 0===_?Fe:_,T=(0,w.Z)(i,xe),P=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:f,noWrap:h,paragraph:b,variant:g,variantMapping:k}),x=c||(b?"p":k[g]||Fe[g])||"span",E=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,M.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,C.Z)(s,Pe,i)}(P);return(0,p.jsx)(Ee,(0,r.Z)({as:x,ref:t,ownerState:P,className:(0,S.Z)(E.root,u)},T))})),Re=n(5682),Oe=["component","direction","spacing","divider","children"];function Me(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var De=(0,D.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Re.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,j.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Re.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),ze=e.forwardRef((function(e,t){var n=V((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,f=n.children,m=(0,w.Z)(n,Oe),h={direction:l,spacing:c};return(0,p.jsx)(De,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?Me(f,d):f}))})),We=ze,Le=n(1774),Ie=n.n(Le);var Be=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,p.jsx)(we,{children:(0,p.jsx)(Ce,{children:(0,p.jsxs)(Ae,{children:[(0,p.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,p.jsxs)(de,{container:!0,spacing:2,children:[(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsx)(Ce,{children:(0,p.jsxs)(de,{container:!0,children:[(0,p.jsxs)(de,{item:!0,xs:4,children:[(0,p.jsxs)(Ae,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,p.jsxs)(Ae,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,p.jsxs)(Ae,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,p.jsxs)(Ae,{children:["Start Date: ",t.start_date]}):null]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,p.jsxs)(Ae,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,p.jsxs)(Ae,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Ce,{children:[(0,p.jsxs)(Ae,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,p.jsx)(Ae,{variant:"caption"}),(0,p.jsx)(We,{spacing:1,children:l(t.pom_a)})]})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Ce,{children:[(0,p.jsxs)(Ae,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,p.jsx)(We,{spacing:1,children:l(t.pom_b)})]})})}),(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Ce,{children:[(0,p.jsx)(Ae,{variant:"h6",children:"Compare the Raw Text"}),(0,p.jsx)(Ie(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function je(e){return(0,T.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var Ze=["className","color","enableColorOnDark","position"],He=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ve=(0,D.ZP)(be,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,M.Z)(n.position))],t["color".concat((0,M.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:He(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:He(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:He(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:He(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ue=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,f=(0,w.Z)(n,Ze),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,M.Z)(t)),"position".concat((0,M.Z)(n))]};return(0,C.Z)(a,je,r)}(m);return(0,p.jsx)(Ve,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},f))}));function Je(e){return(0,T.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var $e=["className","component","disableGutters","variant"],Ge=(0,D.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,f=(0,w.Z)(n,$e),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,C.Z)(n,Je,t)}(m);return(0,p.jsx)(Ge,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},f))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,f=e.useState(!1),m=(0,g.Z)(f,2),h=m[0],v=m[1],b=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),y={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,p.jsx)("span",{className:b,style:y,children:(0,p.jsx)("span",{className:_})})};var ut,ct,dt,pt,ft,mt,ht,vt,bt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),yt=["center","classes","className"],gt=d(ft||(ft=ut||(ut=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,D.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),kt=(0,D.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=pt||(pt=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),bt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),bt.child,bt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),bt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Tt=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,yt),f=e.useState([]),m=(0,g.Z)(f,2),h=m[0],v=m[1],b=e.useRef(0),y=e.useRef(null);e.useEffect((function(){y.current&&(y.current(),y.current=null)}),[h]);var _=e.useRef(!1),k=e.useRef(null),T=e.useRef(null),C=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(k.current)}}),[]);var P=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,B.Z)(e),[(0,p.jsx)(kt,{classes:{ripple:(0,S.Z)(u.ripple,bt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,bt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,bt.ripplePulsate),child:(0,S.Z)(u.child,bt.child),childLeaving:(0,S.Z)(u.childLeaving,bt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,bt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},b.current)])})),b.current+=1,y.current=o}),[u]),x=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,p,f=u?null:C.current,m=f?f.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,b=h.clientY;c=Math.round(v-m.left),d=Math.round(b-m.top)}if(i)(p=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(p+=1);else{var y=2*Math.max(Math.abs((f?f.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((f?f.clientHeight:0)-d),d)+2;p=Math.sqrt(Math.pow(y,2)+Math.pow(g,2))}null!=e&&e.touches?null===T.current&&(T.current=function(){P({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})},k.current=setTimeout((function(){T.current&&(T.current(),T.current=null)}),80)):P({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})}}),[s,P]),E=e.useCallback((function(){x({},{pulsate:!0})}),[x]),F=e.useCallback((function(e,t){if(clearTimeout(k.current),"touchend"===(null==e?void 0:e.type)&&T.current)return T.current(),T.current=null,void(k.current=setTimeout((function(){F(e,t)})));T.current=null,v((function(e){return e.length>0?e.slice(1):e})),y.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:E,start:x,stop:F}}),[E,x,F]),(0,p.jsx)(St,(0,r.Z)({className:(0,S.Z)(bt.root,u.root,c),ref:C},d,{children:(0,p.jsx)(st,{component:null,exit:!0,children:h})}))})),Ct=Tt;function Pt(e){return(0,T.Z)("MuiButtonBase",e)}var xt,Et=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),Ft=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Nt=(0,D.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((xt={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(xt,"&.".concat(Et.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(xt,"@media print",{colorAdjust:"exact"}),xt)),At=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,f=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,b=void 0!==v&&v,y=o.disableTouchRipple,_=void 0!==y&&y,k=o.focusRipple,T=void 0!==k&&k,P=o.LinkComponent,x=void 0===P?"a":P,E=o.onBlur,F=o.onClick,N=o.onContextMenu,A=o.onDragLeave,R=o.onFocus,O=o.onFocusVisible,M=o.onKeyDown,D=o.onKeyUp,z=o.onMouseDown,W=o.onMouseLeave,L=o.onMouseUp,I=o.onTouchEnd,B=o.onTouchMove,j=o.onTouchStart,Z=o.tabIndex,H=void 0===Z?0:Z,V=o.TouchRippleProps,U=o.touchRippleRef,J=o.type,$=(0,w.Z)(o,Ft),G=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,U),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),G.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!b&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&T&&!b&&le&&q.current.pulsate()}),[b,T,ae,le]);var pe=de("start",z),fe=de("stop",N),me=de("stop",A),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),W&&W(e)})),be=de("start",j),ye=de("stop",I),ge=de("stop",B),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),E&&E(e)}),!1),we=(0,Qe.Z)((function(e){G.current||(G.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),O&&O(e)),R&&R(e)})),Se=function(){var e=G.current;return f&&"button"!==f&&!("A"===e.tagName&&e.href)},ke=e.useRef(!1),Te=(0,Qe.Z)((function(e){T&&!ke.current&&ae&&q.current&&" "===e.key&&(ke.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),M&&M(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),F&&F(e))})),Ce=(0,Qe.Z)((function(e){T&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(ke.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),D&&D(e),F&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&F(e)})),Pe=f;"button"===Pe&&($.href||$.to)&&(Pe=x);var xe={};"button"===Pe?(xe.type=void 0===J?"button":J,xe.disabled=h):($.href||$.to||(xe.role="button"),h&&(xe["aria-disabled"]=h));var Ee=(0,Ke.Z)(te,G),Fe=(0,Ke.Z)(n,Ee);var Ne=(0,r.Z)({},o,{centerRipple:l,component:f,disabled:h,disableRipple:b,disableTouchRipple:_,focusRipple:T,tabIndex:H,focusVisible:ae}),Ae=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,C.Z)(o,Pt,a);return n&&r&&(i.root+=" ".concat(r)),i}(Ne);return(0,p.jsxs)(Nt,(0,r.Z)({as:Pe,className:(0,S.Z)(Ae.root,c),ownerState:Ne,onBlur:_e,onClick:F,onContextMenu:fe,onFocus:we,onKeyDown:Te,onKeyUp:Ce,onMouseDown:pe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:ye,onTouchMove:ge,onTouchStart:be,ref:Fe,tabIndex:h?-1:H,type:J},xe,$,{children:[u,ce?(0,p.jsx)(Ct,(0,r.Z)({ref:K,center:l},V)):null]}))})),Rt=At;function Ot(e){return(0,T.Z)("MuiIconButton",e)}var Mt=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Dt=["edge","children","className","color","disabled","disableFocusRipple","size"],zt=(0,D.ZP)(Rt,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,M.Z)(n.color))],n.edge&&t["edge".concat((0,M.Z)(n.edge))],t["size".concat((0,M.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Mt.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),Wt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,f=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,b=void 0===v?"medium":v,y=(0,w.Z)(n,Dt),g=(0,r.Z)({},n,{edge:i,color:c,disabled:f,disableFocusRipple:h,size:b}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,M.Z)(r)),a&&"edge".concat((0,M.Z)(a)),"size".concat((0,M.Z)(o))]};return(0,C.Z)(i,Ot,t)}(g);return(0,p.jsx)(zt,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:f,ref:t,ownerState:g},y,{children:s}))})),Lt=n(2156),It=n(5129);n(8472),(0,G.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function Bt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,p.jsx)(K,{sx:{flexGrow:1},children:(0,p.jsx)(Ue,{position:"static",children:(0,p.jsxs)(qe,{children:[(0,p.jsxs)(Ae,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,p.jsxs)(Ae,{component:"div",children:[t>0?(0,p.jsx)(Wt,{color:"inherit",variant:"text",onClick:o,children:(0,p.jsx)(Lt.Z,{})}):null,t<r-1?(0,p.jsx)(Wt,{color:"inherit",variant:"text",onClick:i,children:(0,p.jsx)(It.Z,{})}):null]})]})})})}for(var jt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Zt=[],Ht=Q.e,Vt=Q.C,Ut=Vt.length,Jt=0;Jt<Ut;Jt++)Zt.push("");var $t=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Vt[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Zt),c=(0,g.Z)(u,2),d=c[0],f=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],b=h[1];return(0,e.useEffect)((function(){l(Vt[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Ut;t++){var n={};n.nctid=Vt[t].nctid,n.version_a=Vt[t].version_a,n.version_b=Vt[t].version_b,n.classification_number=d[t],n.classification_meaning=jt[d[t]],e.push(n)}b(e)}),[d]),(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(Bt,{datumNumber:r,setDatumNumber:a,numComparisons:Ut,outputData:v,batchNum:Ht}),(0,p.jsx)(W,{children:(0,p.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,p.jsx)(Be,{datum:s,datumNumber:r,results:d,setResults:f})})})]})};t.createRoot(document.getElementById("root")).render((0,p.jsxs)(e.StrictMode,{children:[(0,p.jsx)(y,{}),(0,p.jsx)($t,{})]}))}()}();
//# sourceMappingURL=main.89eb8bce.js.map